FDA schválila společnosti AbbVie podkožní zahajovací režim přípravku SKYRIZI pro dospělé se středně až těžce aktivní Crohnovou nemocí, který umožňuje zahájit léčbu doma.
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiii The safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identified FDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.
"People living with Crohn's disease need treatments that can deliver meaningful disease control from the start," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "With the approval of subcutaneous induction, we are building on the strong efficacy of SKYRIZI while giving patients and physicians greater flexibility in how treatment is initiated. This is one more example of how AbbVie continues to advance treatment to better meet the needs of people living with Crohn's disease."
Subcutaneous SKYRIZI Shows High Rates of Clinical Remission and Endoscopic Response by Week 12iii
This FDA approval is supported by positive results from the Phase 3 AFFIRM trial evaluating the efficacy and safety of SC SKYRIZI versus placebo in patients with moderately to severely active CD.iii SKYRIZI achieved superiority of the co-primary endpoints of clinical remission and endoscopic response at week 12.iii Although the study enrolled a primarily treatment-refractory population, these Phase 3 results were particularly strong within patients without prior advanced therapy failure (advanced therapy-naïve).iii By week 12, nearly three-quarters (74%) of advanced therapy (AT)-naïve patients were in clinical remission (vs. 27% placebo) and these AT-naïve patients achieved endoscopic response at four times the rate of placebo (60% vs. 15%, respectively).iii SC SKYRIZI also had a higher efficacy response in patients who had previously failed advanced therapy.iii
SC SKYRIZI also met secondary endpoints including endoscopic remission and FACIT fatigue scores at week 12 vs. placebo.iii The safety profile of SC SKYRIZI for induction was generally consistent with its known profile in CD, with no new safety risks observed.iii
Together, these results demonstrate market-leading clinical and endoscopic outcomes in advanced therapy-naïve patients that set a high bar in CD. Furthermore, the strength of these subcutaneous results provides a compelling foundation for future clinical trials.
AFFIRM Phase 3 Proportion of Patients Meeting Efficacy Endpoints at Week 12iii
Total Population
Prior Advanced Therapy
Failurea
Without Prior Advanced
Therapy Failureb
(Advanced Therapy-Naïve)
Proportion of
Patients
Placebo
N=94
Skyrizi SCc
N=180
Placebo
N=61
Skyrizi SCc
N=115
Placebo
N=33
Skyrizi SCc
N=65
Clinical
Remissiond,e
30 %
56 %h
31 %
45 %
27 %
74 %
Endoscopic
Responsed,f
15 %
43 %h
15 %
33 %
15 %
60 %
Endoscopic
Remissiong
11 %
26 %h
11 %
17 %
9 %
43 %
a. Prior advanced therapy failure includes inadequate response, loss of response, or intolerance to one or more biologic or Janus Kinase inhibitor (JAKi) treatments for CD
b. Without prior advanced therapy failure includes patients who were naïve to biologics or JAKi, or patients who had never failed or demonstrated intolerance to biologics or JAKi
c. SKYRIZI 720 mg as a subcutaneous injection at Week 0, Week 2, Week 4, and Week 8
d. Co-primary endpoints
e. Defined as Crohn's disease activity index (CDAI) < 150
f. Defined as a decrease in Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) > 50% from baseline, or a decrease of at least 2 points for subjects with a baseline
score of 4 and isolated ileal disease, based on central reading
g. SES-CD ≤ 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading
h. p <0.001 compared to placebo in total population.
Subcutaneous Treatment With SKYRIZI Offers Fully Self-Administered Therapy From the Start
The induction dosing regimen with SC SKYRIZI is 720 mg delivered by OBI induction pack at weeks 0, 2, 4 and 8.iii Patients also have the option to start treatment intravenously with 600 mg delivered at weeks 0, 4 and 8.iii Patients can then continue with maintenance dosing starting at week 12 administered by OBI every eight weeks.iii
"When patients and I discuss treatment, they want to know two things: will it work? And how will it fit into their lives?" said Millie D. Long, M.D., MPH, chief, division of gastroenterology and hepatology, University of North Carolina at Chapel Hill, and lead investigator of AFFIRM. "AFFIRM answered the first question, with superior rates of clinical remission and endoscopic response versus placebo during induction with subcutaneous SKYRIZI, particularly in patients new to advanced therapy. This approval answers the second. As a physician who has used the SKYRIZI OBI, I've seen firsthand the convenience it can offer patients. Now with this approval, patients can start treatment at home and continue the same way through maintenance."
Patients Report Satisfaction and Ease of Use in Real World Experience With SKYRIZI OBI
First introduced in 2022 for CD maintenance treatment, the SKYRIZI OBI has demonstrated strong user experience. In a real-world survey of 186 people living with CD, 88% reported AbbVie's OBI easy to use.v In evaluating alternative routes of administration, a patient-reported survey of 352 adults living with IBD found 87% were satisfied or highly satisfied with OBI compared to 71% with an autoinjectorvi, demonstrating patient preference for OBI.
FDA Also Approved Update to Tuberculosis (TB) Language in U.S. Prescribing Information
Additionally, the FDA approved an update to the SKYRIZI prescribing information's warning and precautions language across all approved indications.iii The revised label advises healthcare providers to consider TB evaluation prior to treatment initiation based on clinical judgment.iii This change gives healthcare providers greater flexibility in patient assessment before starting SKYRIZI treatment. There is no mandatory TB test prior to initiating SKYRIZI.
About Crohn's Disease
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.vii,viii It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.ix,x Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.xi
About the AFFIRM Studyxii
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of risankizumab subcutaneous (SC) as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12. A total of 274 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% had failed advanced therapies for the treatment of CD before. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients receive blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C where all patients receive the approved risankizumab maintenance treatment.xii More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).xii
Patient Access and Support
AbbVie is committed to helping people access SKYRIZI and other medicines, including offering a patient support program and co-pay card that may reduce out-of-pocket costs to as little as $0 per month for eligible, commercially insured patients. For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides SKYRIZI at no charge to those who qualify. More information about this assistance program can be found at www.AbbVie.com/myAbbVieAssist.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.iii SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.iii
SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationiii
SKYRIZI is a prescription medicine used to treat:
moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis in adults and children 6 years of age and older. moderately to severely active Crohn's disease in adults. moderately to severely active ulcerative colitis in adults. IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medicine that may cause serious side effects, including:
Serious allergic reactions:
Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded (low blood pressure) swelling of your face, eyelids, lips, mouth, tongue, or throat trouble breathing or throat tightness chest tightness skin rash, hives itching Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your mucus (phlegm) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 or visit http://glowpregnancyregistry.com to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/PatientAccessSupport to learn more.
Please click here for the Full Prescribing Information and Medication Guide.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
i. Co-primary endpoint defined as Crohn's Disease Activity Index (CDAI) score <150.
ii. Co-primary endpoint defined as decrease in SES-CD > 50% from baseline (or for patients with isolated ileal disease and a baseline SES-CD of 4, at least a 2-point reduction from baseline), as scored by a central reviewer.
iii. SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.
iv. Defined as CDAI of 220 to 450 and SES-CD ≥ 6 (or ≥ 4 for isolated ileal disease).
v. Keefer L, Griffith JM, Yang M, et al. Treatment satisfaction and patients' experiences with risankizumab on-body injector among adults with Crohn's disease in clinical practice: initial results from the ASPIRE-CD study. Poster P5425. Presented at: American College of Gastroenterology Annual Scientific Meeting; October 24-29, 2025; Phoenix, AZ.
vi. Data on file, AbbVie Inc. Source: ZS Associates; December 2024-February 2025.
vii. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed October 13, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf.
viii. Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Accessed February 23, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304.
ix. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60.
x. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
xi. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.
xii. ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Risankizumab Subcutaneous Induction in Participants With Moderately to Severely Active Crohn's Disease (AFFIRM). NCT06063967. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed October 13, 2026.
Společnost AbbVie má za čtvrtletí končící v září 2026 vykázat EPS ve výši 3,79 USD, což představuje meziroční nárůst o 103,8 %, a tržby ve výši 17,37 miliardy USD, meziročně o 10,1 % vyšší.
The market expects AbbVie (ABBV - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on October 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis drugmaker is expected to post quarterly earnings of $3.79 per share in its upcoming report, which represents a year-over-year change of +103.8%.
Revenues are expected to be $17.37 billion, up 10.1% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.35% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for AbbVie?For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.26%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that AbbVie would post earnings of $3.64 per share when it actually produced earnings of $3.65, delivering a surprise of +0.27%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
AbbVie doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAnother stock from the Zacks Large Cap Pharmaceuticals industry, Eli Lilly (LLY - Free Report) , is soon expected to post earnings of $5.38 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of -23.4%. Revenues for the quarter are expected to be $22.11 billion, up 25.6% from the year-ago quarter.
The consensus EPS estimate for Lilly has been revised 0.1% higher over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0.00%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Lilly will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
AbbVie oznámila povzbudivé výsledky studie fáze 2a přípravku ABBV-466, který u Crohnovy choroby dosáhl vyšší míry remise než samotný Skyrizi i trosunilimab.
AbbVie (ABBV +0.14%) is performing well this year. The company's shares have climbed 26% on the back of a strong financial performance. Further, the pharmaceutical giant's medium-term outlook appears bright. AbbVie has no significant loss of patent exclusivity remaining this decade, and its two growth pillars, Skyrizi and Rinvoq, are firing on all cylinders.
Still, AbbVie is already thinking about succession plans for its most important medicines, and recent developments suggest the company is well on its way to finding new drugs to pass the torch to.
Image source: The Motley Fool.
Better than Skyrizi?First, a little background on Skyrizi. It is currently approved for several immunology disorders, including plaque psoriasis and Crohn's disease. Skyrizi is AbbVie's single biggest growth driver right now. In the first half of the year, the medicine generated almost $10 billion in sales, up 27% year over year and significantly more than any other product in the company's lineup.
However, Skyrizi's web of patents may begin to expire in the U.S. by 2033, potentially inviting cheaper biosimilar competition. That still seems far away, but considering Skyrizi's current sales trajectory, AbbVie will have to launch a next-gen drug years before 2033 to avoid a catastrophic decline in sales once (if) biosimilars enter the market by then.
Thankfully, the drugmaker is making progress on that project. On Oct. 19, the company announced encouraging Phase 2a results for a next-gen immunology drug, ABBV-466. This medicine combines risankizumab, the active ingredient in Skyrizi, with trosunilimab, another drug AbbVie is developing.
In the Phase 2a study, ABBV-466 achieved higher rates of remission among patients with Crohn's disease than Skyrizi and trosunilimab monotherapy. What's even more encouraging is that ABBV-466's advantage over Skyrizi and trosunilimab increased substantially by week 24 compared to week 12.
The combo treatment still has to confirm these results in Phase 3 studies. If it does, it may prove to be a strong successor to Skyrizi, at least for Crohn's disease and perhaps for ulcerative colitis.
ABBV AbbVie$285.19+$0.39 (+0.14%)
NYSE · As of 4:00 PM ET 10/22/26
An important acquisitionAbbVie's attempts to strengthen its immunology portfolio also received a boost earlier this year with its $10.9 billion cash acquisition of Apogee Therapeutics. The key asset from that transaction was zumilokibart, a medicine being developed to treat several conditions, including eczema, asthma, and COPD. AbbVie is looking to challenge the massive Dupixent empire.
Dupixent is approved across all those indications and generates over $15 billion in annual sales. It is one of the top-selling drugs in the world. But AbbVie's zumilokibart could have an advantage. It may need maintenance injections only every three months, or possibly even every six months, while maintaining competitive efficacy. Dupixent is typically administered every other week.
Zumilokibart’s more convenient dosing schedule could help make it a blockbuster. AbbVie will have to run Phase 3 studies before it can request approval, but it's yet another medicine that could help the company perform well long after biosimilars for Skyrizi enter the market.
Why the stock is a buyAbbVie's other main growth driver, Rinvoq, should not face generics in the U.S. (its most important market) until 2037. The company has other important drugs contributing to sales growth, including Qulipta, a migraine treatment, Vraylar, a schizophrenia therapy, its Botox franchise, and the cancer drug Venclexta.
Further, AbbVie boasts attractive pipeline candidates in other areas. One of the more promising ones it is working on is an investigational long-acting weight-loss therapy called ABBV-295. And that's just the tip of the iceberg.
Finally, AbbVie is an excellent dividend stock. Counting the time it spent under the wing of its former parent company, Abbott Laboratories, AbbVie is a Dividend King, or a corporation with at least 50 consecutive years of dividend increases. It also offers a forward yield of 2.5%, much higher than the S&P 500's average of 1.1%. In short, AbbVie can deliver competitive returns over the long run, especially when dividends are reinvested.
Capstone Capital Management Ltd bought a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,772 shares of the company’s stock, valued at approximately $987,000.
Several other hedge funds have also bought and sold shares of the company. Range Financial Group LLC raised its stake in AbbVie by 2.4% in the 3rd quarter. Range Financial Group LLC now owns 5,565 shares of the company’s stock valued at $1,456,000 after acquiring an additional 130 shares during the period. Newman Dignan & Sheerar Inc. boosted its position in AbbVie by 57.9% during the third quarter. Newman Dignan & Sheerar Inc. now owns 6,547 shares of the company’s stock worth $1,713,000 after purchasing an additional 2,400 shares during the period. Benchmark Financial Wealth Advisors LLC boosted its position in AbbVie by 11.0% during the third quarter. Benchmark Financial Wealth Advisors LLC now owns 4,309 shares of the company’s stock worth $1,127,000 after purchasing an additional 428 shares during the period. Cushing Capital Partners LLC bought a new position in AbbVie during the third quarter worth $242,000. Finally, Physician Wealth Advisors Inc. increased its holdings in shares of AbbVie by 11.3% in the third quarter. Physician Wealth Advisors Inc. now owns 1,531 shares of the company’s stock valued at $401,000 after purchasing an additional 155 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.
AbbVie Trading Down 1.5% NYSE:ABBV opened at $284.63 on Thursday. The stock has a market cap of $502.89 billion, a P/E ratio of 80.41, a PEG ratio of 1.32 and a beta of 0.24. The stock has a 50 day simple moving average of $264.93 and a 200 day simple moving average of $240.92. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the company posted $2.97 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 EPS for the current year.
AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment. Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald increased their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Argus raised their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Rothschild & Co Redburn upped their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 price target on shares of AbbVie in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $278.07.
Read Our Latest Stock Analysis on AbbVie
About AbbVie (Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
See Also Five stocks we like better than AbbVie GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall? Intercepting Growth: Karman Secures $218M Lockheed Martin Deal Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Lutikizumab společnosti AbbVie ve studii fáze 3 INTREPID po 16 týdnech významně zlepšil příznaky středně těžké až těžké hnisavé hidradenitidy oproti placebu.
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physicians Lutikizumab was generally well tolerated, with no new safety concerns identified1 INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).
Axxcess Wealth Management ve třetím čtvrtletí snížila svůj podíl ve společnosti AbbVie o 45,1 % prodejem 39 607 akcií; na konci období držela 48 309 akcií v hodnotě 12,637 mil. USD.
Axxcess Wealth Management LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 45.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,309 shares of the company’s stock after selling 39,607 shares during the period. Axxcess Wealth Management LLC’s holdings in AbbVie were worth $12,637,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Ranch Capital Advisors Inc. increased its stake in shares of AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after acquiring an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK increased its position in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after purchasing an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of AbbVie during the 2nd quarter worth about $23,557,000. Wedge Capital Management L L P NC raised its stake in shares of AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares in the last quarter. Finally, State Street Corp raised its stake in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth ABBV has been the subject of several recent research reports. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. BNP Paribas Exane raised their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. UBS Group raised their price objective on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research report on Tuesday, October 6th. Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, Canaccord Genuity Group boosted their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $278.07.
Get Our Latest Stock Analysis on ABBV AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment. Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial Insider Activity at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
AbbVie Stock Performance Shares of NYSE ABBV opened at $284.63 on Thursday. The firm has a market cap of $502.89 billion, a price-to-earnings ratio of 80.41, a P/E/G ratio of 1.32 and a beta of 0.24. The business’s 50-day simple moving average is $264.93 and its 200-day simple moving average is $240.92. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current year.
AbbVie Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
About AbbVie (Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Featured Stories Five stocks we like better than AbbVie GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall? Intercepting Growth: Karman Secures $218M Lockheed Martin Deal Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Allergan Aesthetics představí v Dubaji data, podle nichž všech osm pacientů užívajících léky typu GLP-1 na hubnutí zaznamenalo po třech měsících používání HArmonyCa™ viditelné zlepšení střední části obličeje.
Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM®, SKINVIVE™ and BOTOX® Cosmetic
The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss
The company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™
, /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supporting its expanding global aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Dubai, taking place October 21-23, 2026.
The program includes an expert-led symposium hosted by the Allergan Medical Institute (AMI), a global medical affairs symposium and multiple Meet the Expert sessions. Global and regional faculty will discuss the clinical evidence informing the AA Signature™ approach, which integrates treatments from across the Allergan Aesthetics portfolio into personalized treatment planning. The program will focus particularly on AA Signature™ Lift-Up and the introduction of HArmonyCa™ in the United Arab Emirates (UAE).
Following its recent launch in the UAE, HArmonyCa™, a hybrid facial injectable combining hyaluronic acid (HA) and calcium hydroxyapatite (CaHA), will be featured at AMWC Dubai. Developed by Allergan Aesthetics, HArmonyCa™ is a regenerative biostimulator powered by DART® (Dual Action Rejuvenating Technology), combining the immediate lifting effect of HA with the longer-term biostimulatory activity of CaHA.1
"This meeting brings together the science, clinical expertise and education that continue to shape the aesthetics field in the Middle East and beyond," said Darin Messina, Ph.D., senior vice president, head of aesthetics research and development, AbbVie. "The breadth of data to be presented at AMWC reflects Allergan Aesthetics' commitment to developing evidence-based portfolio approaches to treatment as the industry continues to evolve alongside patient needs. We are excited to introduce HArmonyCa™ and its Dual Action Rejuvenating Technology as part of the continued expansion of our aesthetics portfolio."
Data being presented at AMWC Dubai add to the clinical and scientific evidence supporting the Allergan Aesthetics portfolio and the products that form the AA Signature™ multimodal approach, including SKINVIVE™, HArmonyCa™ and BOTOX® Cosmetic (onabotulinumtoxinA).
As patients' aesthetic needs evolve over time, changes associated with medical weight loss can span facial volume, structure and skin quality, reinforcing the importance of personalized assessment and treatment planning that considers the patient more holistically. This research adds to the growing body of evidence investigating the use of the Allergan Aesthetics portfolio in patients navigating the effects of medical weight loss.
In a subgroup analysis of patients using glucagon-like peptide-1 (GLP-1) weight-loss medications, all eight participants treated with HArmonyCa™ showed visible midface improvement at three months, providing an early clinical signal for addressing facial volume changes in this emerging patient population. These findings offer preliminary evidence on the use of HArmonyCa™ in patients experiencing facial volume changes while undergoing GLP-1 medical weight loss.2
Additional clinical data being presented include patient-reported outcomes showing improvement in neck appearance and satisfaction after SKINVIVE™ treatment, alongside new original research examining patient-reported satisfaction, treatment benefits and motivations for retreatment among Middle Eastern patients receiving long-term, repeated BOTOX® Cosmetic treatment for upper facial lines. The majority of patients were satisfied with the effects of long-term repeated treatment upper forehead lines and reported feeling younger as a result of the treatment.4
On October 22, Allergan Aesthetics' global medical affairs team will bring together experts for the "Breakthrough Science in Aesthetics: New Frontiers in Clinical Outcomes and Care" symposium. Together, Dr. Mariola Galazka, Dr. Koenraad De Boulle and Dr. Mansi Mukherjee will discuss advances in neurotoxin science and innovation, long-term BOTOX® Cosmetic evidence and natural-looking outcomes of the portfolio, while highlighting the value of multimodal aesthetic approaches. They will also explore how emerging science can unlock new possibilities for key patient segments and shape the future of aesthetics.
Showcasing educational science
On October 21, AMI will host the "AA Signature™ Lift-Up Multimodal Approach with Regenerative Biostimulation" symposium. Dr. Raafat Lakis, Dr. Reha Yavuzer and Dr. Mariola Galazka will explore the AA Signature™ Lift-Up approach, HArmonyCa™ and DART® Technology as part of longer-term multimodal treatment planning. The program will also feature a live technique showcase and an expert panel discussion.
Practitioners can engage directly with faculty during Meet the Expert sessions at Allergan Aesthetics booth B16, covering the AA Signature™ Lift-Up approach, clinical considerations in facial neurotoxin treatment and the importance of building trust through clinical expertise.
Collectively, the program underscores Allergan Aesthetics' commitment to advancing personalized, evidence-led aesthetics.
Type
Title
Authors
BOTOX® Cosmetic
Original
Patient-Perceived Satisfaction and Benefits of
Long-Term OnabotulinumtoxinA for Upper
Facial Lines: A Sub-Analysis of Patients From
Middle Eastern Sites From a Global
Retrospective Chart Review and Cross-
Sectional Study
Mukherjee M, Aleisa
AM, Raza A,
Musumeci M
HArmonyCa™
Encore
Complete Analysis of a 24-Month Multicenter,
Evaluator-Blinded, Randomized, Parallel-
Group Study to Evaluate the Safety and
Effectiveness of a Hybrid Hyaluronic Acid and
Calcium Hydroxyapatite Injectable for Midface
Soft Tissue Augmentation
Humphrey S,
Demosthenous N,
Nikolis A, Urdiales
Gálvez F, Salomon M,
Schumacher A
Encore
Treatment of Midface Volume Deficits with a
Hybrid Hyaluronic Acid and Calcium
Hydroxyapatite Injectable in Participants
Undergoing GLP-1 Medical Weight Loss: A
Safety and Efficacy Subgroup Analysis from a
Pivotal Study
Humphrey S, Nikolis
A, Urdiales Gálvez F,
Demosthenous N,
Kus S, Kerson G,
Salomon M,
Schumacher A
Encore
An Evaluation of the Mechanism of Action of a
Hyaluronic Acid and Calcium Hydroxyapatite
Hybrid Injectable
Braz A, Chang N,
Urdiales Gálvez F,
Hariri S, Malkah N,
Nakab L
JUVÉDERM®/HA fillers
Encore
Patient Reported Satisfaction and Improvement
of Neck Appearance with VYC-12L: Results
From a Multicenter, Evaluator-Blinded,
Randomized, Controlled Study
Cox SE, Palm M,
Burgess C, Kazin R,
Nguyen T, Garcia JK,
Chawla S
Encore
Cross-linked Hyaluronic Acid Gel's Secondary
Effects on Dermal ECM Structure and Stability:
A Spatial Proteomics Study
Kutikov A, Pierce A,
Malkah N, Nakab L
Encore
Assessing the Potential for Injectable HA Gel
Displacement: A 3D Imaging Study in a Rat
Model
Pierce A, Ly J, Nakab
L, Kutikov A
Encore
Evaluation of Degradation Kinetics and
Biocompatibility of VYC-20L HA Dermal Filler in
a Rodent Model Using MRI and Histological
Analysis
Kutikov A, Nakab L
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
Braz A, Eduardo CC de P, Pierce A, et al. A Novel Hybrid Injectable for Soft-tissue Augmentation: Analysis of Data and Practical Experience. Plast Reconstr Surg Glob Open. 2024;12(9):e6190.
Humphrey S, Nikolis A, Urdiales Gálvez F, et al. Treatment of Midface Volume Deficits with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Injectable in Participants Undergoing GLP-1 Medical Weight Loss: A Safety and Efficacy Subgroup Analysis from a Pivotal Study. To be presented at AMWC Dubai 2026; Dubai, UAE.
Humphrey S, Demosthenous N, Nikolis A, et al. Complete Analysis of a 24-Month Multicenter, Evaluator-Blinded, Randomized, Parallel-Group Study to Evaluate the Safety and Effectiveness of a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Injectable for Midface Soft Tissue Augmentation. To be presented at AMWC Dubai 2026; Dubai, UAE.
Mukherjee M, Aleisa AM, Raza A, Musumeci M. Patient-Perceived Satisfaction and Benefits of Long-Term OnabotulinumtoxinA for Upper Facial Lines: A Sub-Analysis of Patients From Middle Eastern Sites From a Global Retrospective Chart Review and Cross-Sectional Study. To be presented at AMWC Dubai 2026; Dubai, UAE.
Focused Alpha LLC increased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 109.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,657 shares of the company’s stock after purchasing an additional 2,429 shares during the period. Focused Alpha LLC’s holdings in AbbVie were worth $1,218,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the business. Corient Private Wealth LP purchased a new stake in AbbVie during the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new position in AbbVie during the 2nd quarter valued at about $2,905,952,000. Jupiter Topco LLC bought a new stake in AbbVie in the second quarter worth about $1,560,354,000. Diamant Asset Management Inc. grew its stake in shares of AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after buying an additional 3,654,351 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $817,473,000. Institutional investors own 70.23% of the company’s stock.
Insider Transactions at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.
AbbVie Trading Up 2.1% ABBV stock opened at $288.66 on Wednesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The business’s 50-day moving average is $264.22 and its 200 day moving average is $240.39. The stock has a market cap of $510.01 billion, a price-to-earnings ratio of 81.54, a PEG ratio of 1.29 and a beta of 0.24. AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.
AbbVie Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
More AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Promising Crohn’s disease results strengthen AbbVie’s pipeline. In a Phase 2a study, investigational ABBV-466, a dual-targeting therapy against IL-23 and integrin α4β7, produced higher endoscopic remission rates than either monotherapy at Week 12, with the treatment advantage widening by Week 24. The results suggest a potential future combination option in inflammatory bowel disease and helped reinforce AbbVie’s immunology strategy. AbbVie Presents Data for ABBV-466 Positive Sentiment: Analysts see continued growth in neuroscience. AbbVie’s neuroscience franchise is projected to deliver nearly 16% revenue growth in the third quarter, supported by established products and newer Parkinson’s disease therapies. This offers another source of expansion as the company manages the loss of exclusivity for Humira. AbbVie’s Neuroscience Franchise Positive Sentiment: Strong cash generation supports the investment case. A comparison with Vertex highlighted AbbVie’s substantial free cash flow and its ability to navigate Humira’s patent expiration, factors that may support dividends, business development and pipeline investment. AbbVie vs. Vertex Pharmaceuticals Neutral Sentiment: McLaren Formula 1 partnership raises AbbVie’s visibility. The multiyear sponsorship and “Race to Innovate” campaign will promote awareness of immune-mediated diseases and provide charitable donations tied to McLaren’s championship points. The initiative is strategically positive for brand recognition but is unlikely to materially affect near-term earnings. AbbVie Named Official Pharmaceutical Partner of McLaren Negative Sentiment: Competitive risk remains in immunology. Reports that Rapport Therapeutics may enter a market estimated at $4.3 billion—and positive commentary surrounding Spyre Therapeutics’ ulcerative-colitis combination approach—highlight potential future competition. However, these programs remain developmental and do not appear to change AbbVie’s near-term results. Rapport Enters AbbVie Market Analyst Upgrades and Downgrades A number of research firms have recently commented on ABBV. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Rothschild & Co Redburn increased their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Scotiabank boosted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Oppenheimer boosted their target price on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Wells Fargo & Company increased their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $277.18.
View Our Latest Stock Report on AbbVie
AbbVie Company Profile (Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Featured Stories Five stocks we like better than AbbVie Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
K 17. říjnu FedWatch odhadoval pravděpodobnost prosincového zvýšení sazeb na 89 %. AbbVie má dluh ve výši 70,8 mld. USD, z větší části v dluhopisech s pevnou úrokovou sazbou.
Kevin Warsh's Federal Open Market Committee (FOMC) has its next meeting on Oct. 28 to decide on a course of action for interest rates. It looks as if they aren't coming down anytime soon.
According to the CME Group's proprietary FedWatch tool, which tracks the chances of future changes in the effective federal funds rate, the Fed probably won't hike rates on Oct. 28. But as of Oct. 17, the FedWatch tool predicted an 89% chance of a rate hike for the Fed's December meeting.
We might not be at the start of a prolonged Fed rate hike cycle. Warsh and the FOMC might only raise rates by another 0.25% or 0.5% by the end of the year. But in recent months, longer-term bond yields have been rising. If you're concerned about the effects of higher rates on your stock portfolio, now might be a good time to look at stocks that tend to hold up better in a rising rate environment.
One of the best dividend stocks to consider is AbbVie (ABBV +2.80%). This leading pharma stock has a long-term track record of raising its dividend and delivering strong growth for investors. Let's look at why AbbVie could be a good stock to buy now to protect your portfolio from rising interest rates.
Fed chair Kevin Warsh. Image source: Federal Reserve.
ABBV: a Dividend King with 18.8% annualized returns over 10 years
AbbVie develops and sells well-known pharmaceuticals like Skyrizi, Rinvoq, Humira, and Botox. Over the past 10 years, ABBV stock has delivered annualized returns of about 18.8%, strongly outperforming the S&P 500 index. This pharma stock has done even better in the past few years, with average annual returns of 23.7% over the past five years and 28.9% over the past year.
The drugmaker also pays strong, steady dividends. The stock is a Dividend King, with more than 50 years of history of increasing its payout to investors. AbbVie became an independent company in 2013 after a spinoff from Abbott Laboratories, but AbbVie retained (and has continued) the former parent company's long-term dividend streak. In 2026, AbbVie paid total dividends of $6.92 ($1.73 per quarter). Its forward annual dividend yield is 2.42%.
ABBV AbbVie$290.60+$7.92 (+2.80%)
NYSE · As of 1:53 PM ET 10/20/26
Why ABBV is a good stock when rates are rising
There are a few reasons why AbbVie could be a great choice for your portfolio if interest rates remain high or continue rising.
First, higher interest rates tend to be worse for stocks of companies with a lot of floating-rate debt. When interest rates go up, those companies often struggle to refinance their debts. AbbVie investors shouldn't worry about this risk; this company has a strong balance sheet, and AbbVie's debt of $70.8 billion is only 14% of the company's $504 billion market cap. And most of AbbVie's debt is in fixed-rate senior notes.
Another reason AbbVie stock could be resilient in a higher-rate environment is the nature of the pharmaceutical industry. When people need medical treatment, they tend to go get it -- whether interest rates are high or not. Successful pharmaceuticals are not rate-sensitive in the way that consumer discretionary purchases might be. Past performance doesn't guarantee future results. But here's how ABBV performed in 2022 during the most recent Fed rate hike cycle:
ABBV Total Return Level data by YCharts
And perhaps here's a simple but underrated reason why now is a good time to buy ABBV: It's not connected to the artificial intelligence (AI) trade. Some investors are getting nervous about AI stocks and the large amounts of debt that companies are issuing to build AI data centers. AbbVie is in an industry sector that is totally separate from AI. If you want to diversify against a possible sell-off in AI stocks, ABBV and other healthcare stocks could put your money to work in a different part of the economy.
Ben Gran has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and CME Group. The Motley Fool has a disclosure policy.
Key Takeaways AbbVie's neuroscience revenues are expected to grow roughly 16% to $3.29 billion in Q3 2026.Vraylar sales are projected at $1.08 billion, while Botox Therapeutic sales are expected to be 1.07 billion.Vyalev sales are expected to reach $283 million, while Juvmo's launch could draw investor attention. Although immunology remains AbbVie’s (ABBV - Free Report) largest revenue-generating franchise, neuroscience is emerging as another important growth driver. Spanning psychiatry, migraine and Parkinson’s disease (PD), the franchise offers multiple avenues for expansion through established treatments and newer products. Investors will be keen to know how the segment performed in the third quarter when the company announces results on Oct. 30.
The Zacks Consensus Estimate for AbbVie’s neuroscience revenues in the third quarter of 2026 is pegged at $3.29 billion. The figure implies year-over-year growth of nearly 16%, with growth expected across most marketed products.
A Closer Look at ABBV’s Neuroscience DrugsAbbVie’s established brands, Vraylar and Botox Therapeutic, are expected to remain significant contributors to neuroscience revenues. Vraylar is used to treat several psychiatric conditions, while Botox Therapeutic has multiple approved uses, including chronic migraine prevention, spasticity and cervical dystonia. The Zacks Consensus Estimate for Vraylar sales is pegged at $1.08 billion, while the same for Botox stands at $1.07 billion.
Turning to the oral migraine portfolio, the Zacks Consensus Estimate for Ubrelvy sales is pinned at $393 million, while that for Qulipta is pegged at $364 million. Ubrelvy is used for the acute treatment of migraine attacks, whereas Qulipta is indicated for migraine prevention.
Among the newer products, Vyalev is projected to generate $283 million in revenues, up from $256 million generated in the previous quarter. AbbVie expects the PD therapy to achieve blockbuster status in 2026 as domestic uptake accelerates.
Meanwhile, AbbVie received FDA approval for Juvmo, a once-daily oral treatment for PD, in late September. Given the timing of the approval — just days before the end of the third quarter — the drug is unlikely to make a meaningful contribution to revenues during the period. Investors will likely look for management commentary on the initial launch and early uptake.
Other Players in the Neuroscience SpaceAbbVie faces competition from large-cap biotech/pharmaceutical companies in the market, which include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
AbbVie na kongresu ESMO 2026 představí data ze sedmi onkologických programů; Temab-A v kombinaci s bevacizumabem dosáhl u kolorektálního karcinomu 30% míry objektivní odpovědi.
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine AbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of development Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere®(mirvetuximab soravtansine-gynx) , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.
Collectively, the findings across Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Elahere® (mirvetuximab soravtansine-gynx) and Emrelis™ (telisotuzumab vedotin-tllv) demonstrate how AbbVie is leveraging its deep expertise in cancer biology to advance differentiated approaches that address the complexity and heterogeneity of solid tumors and help meet the diverse needs of cancer patients worldwide.
"The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation," said Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie. "Across multiple tumor types and stages of development, we are seeing encouraging evidence of longer-term clinical benefit, promising outcomes in biomarker-defined patient populations, and the potential of novel combinations and next-generation platforms. Together, these findings reinforce our strategy of translating scientific insights into differentiated treatment approaches with the potential to meaningfully improve outcomes for patients living with cancer."
Selected findings from AbbVie's investigational solid tumor portfolio include updated clinical, survival and translational biomarker data across multiple antibody-drug conjugates (ADCs) and bispecific antibody programs, supporting continued development across a range of solid tumors:
Temab-A Updated data continue to demonstrate encouraging clinical activity for Temab-A, an investigational, next-generation, c-Met-directed ADC with a novel topoisomerase 1 inhibitor (Top1i), across multiple solid tumor types. In a Phase 1 study of patients with previously treated advanced colorectal cancer (CRC), pooled data from the safety lead-in and dose-optimization cohorts showed that Temab-A (2.4 mg/kg) in combination with bevacizumab demonstrated a 30% overall response rate (ORR) and encouraging overall survival (OS) outcomes after a median follow-up of 18.2 months. Median OS reached 14.7 months with the combination (n=30), compared with 10.2 months for standard of care (n=20), regardless of c-Met protein expression level. No new safety signals were observed.1 This combination is being further evaluated in the ongoing global Phase 3 AndroMETa-CRC-560 study (NCT07525206). In an updated analysis from the ongoing Phase 1 study of Temab-A in non-squamous non-small cell lung cancer (NSCLC), the ORR was 50% with a median OS of 13.8 months in unselected patients with epidermal growth factor receptor (EGFR) wild-type disease (n=48). Among patients with EGFR-mutant disease (n=41), ORR was observed at 63% with a median OS of 16.2 months. In patients with EGFR wild-type disease, at the c-Met 3+, ≥25% expression threshold, median OS was approximately 19.2 months. As a monotherapy, Temab-A is being further evaluated, compared to the standard of care, in the global Phase 3 AndroMETa-Lung-167 study for previously treated patients with EGFR wild-type, non-squamous NSCLC (NCT07821684). In a separate post-hoc pooled exploratory analysis of 19 patients with EGFR-mutant NSCLC and baseline brain metastases, Temab-A achieved a 37% intracranial ORR, with a median duration of intracranial response of 19.8 months. No new safety signals were observed. AbbVie recently announced that Temab-A received two U.S. FDA Breakthrough Therapy Designations in CRC and NSCLC based, in part, on the data highlighted above. These designations further underscore the potential of Temab-A in addressing patient needs in these disease areas. ABBV-706: Updated Phase 1 findings reinforce the potential of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC), while new biomarker and translational findings further support SEZ6 as a promising therapeutic target. At the selected Phase 3 dose of 1.8 mg/kg (n=41), in a heavily pre-treated population, ABBV-706 achieved a 56% ORR and 12.4-month median OS in 2L+ SCLC patients; in the 2L-only subset (n=17), ORR increased to 82% and a 14.4-month median OS was observed. Safety was comparable to previously reported data. ABBV-706 is being further evaluated in an ongoing, randomized, open-label, multicenter Phase 3 trial versus standard of care in patients with R/R SCLC (NCT07365241). ABBV-969: Biomarker findings from a Phase 1 dose escalation study (NCT06318273) of ABBV-969 demonstrated robust molecular responses in heavily pretreated (median 5 prior lines of therapy) metastatic castration-resistant prostate cancer (mCRPC) patients (n=49). By cycle 3, 90% of patients achieved a ≥50% reduction in circulating tumor DNA (ctDNA) and 78% experienced circulating tumor cell conversion from unfavorable to favorable levels (≥5 to <5 cells). Among 27 patients with baseline PSMA PET assessments receiving ABBV-969 at doses ≥3 mg/kg, two were PSMA PET-negative per VISION criteria; both achieved a PSA50 response, including one patient with stable disease and one with a confirmed partial response.4 Together, these data further support the continued clinical development of ABBV-969, AbbVie's dual-targeting ADC approach to address tumor heterogeneity by simultaneously targeting two highly prevalent targets associated with mCRPC, prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), while delivering a Top1i payload. ABBV-1480 New data continue to support the development potential of ABBV-1480, a PD-1 × VEGF bispecific antibody, in lung cancer and other solid tumors. In a Phase 1 study of patients with first-line PD-L1-positive NSCLC, ABBV-1480 monotherapy (n=22) achieved a 61.9% ORR and a median progression-free survival (PFS) of 15.2 months.5 In previously treated NSCLC, ABBV-1480 combined with docetaxel at the 20 mg/kg dose (n=21) delivered a 66.7% ORR and 8.5-month median PFS.5 The most common grade ≥3 treatment-related adverse events for monotherapy were hypertension and proteinuria; for combination therapy, they were decreased neutrophil count, decreased white blood cell count and decreased lymphocyte count.5 ABBV-1480 continues to advance in clinical development, including the global Phase 3 AMUR-Lung-01 trial (NCT07756645) and a newly initiated combination study with Temab-A in NSCLC (NCT07874282). Details on key presentations at ESMO 2026 are available below and the full abstracts are available through the congress online program.
Approved medicines and investigational assets referenced are being evaluated in ongoing clinical trials across multiple stages of development and disease areas, both as standalone therapies and in combination regimens. For more information on AbbVie's ongoing clinical trial programs, please visit ClinicalTrials.gov.
Note: All presentation times are listed in local Madrid time.
Abstract Title
Date/Time
Session
Abstract Number
Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer
Friday, October 23, 2026
3:15—4:00 PM
Poster
Metastatic prostate cancer; Poster Area – Hall 5
2224P
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
Saturday, October 24, 2026
09:27—09:32 AM
Rapid Oral
NSCLC, metastatic; Almeria Auditorium – Hall 9
2658RO
Long-term follow-up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
Saturday, October 24, 2026
3:20—3:25 PM
Rapid Oral
Gastrointestinal Tumours, lower digestive; Alicante Auditorium – Hall 6
791RO
RC118 combined with RC148 (ABBV-1480) for advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): updated results from a randomized Phase 2 trial
Sunday, October 25, 2026
12:00—12:45 PM
Poster
Oesophagogastric cancer; Poster Area – Hall 5
2910P
Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): Post hoc analysis from a phase 1 first-in-human (FIH) study in patients (pts) with brain metastases (BMs)
Monday, October 26, 2026
12:00—12:45 PM
Poster
NSCLC, metastatic; Poster Area – Hall 5
2635P
Real world (RW) uptake and characteristics of patients (Pts) receiving telisotuzumab vedotin-tllv (Teliso-V) in non-small cell lung cancer (NSCLC) from a US Claims Database
Monday, October 26, 2026
12:00—12:45 PM
Poster
NSCLC, locally advanced; Poster Area – Hall 5
2583P
ABBV-706: A first-in-class SEZ6-targeted topoisomerase 1 inhibitor (Top1i)-antibody-drug conjugate (ADC) with robust antitumour activity in relapsed/refractory small cell lung cancer (R/R SCLC)
Monday, October 26, 2026
10:15—10:20AM
Rapid Oral
Non-metastatic NSCLC and other thoracic malignancies; Burgos Auditorium – Hall 3
3837RO
Characterization of responder outcomes in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC): Phase 3 MIRASOL (GOG 3045/ENGOT-ov55)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1268P
Assessment of mirvetuximab soravtansine (MIRV) vs investigator's choice chemotherapy (ICC) as first line of therapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) in MIRASOL (GOG 3045/ENGOT-ov55)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1308P
Time to improvement in fatigue patient-reported outcomes (PRO) with mirvetuximab soravtansine (MIRV) vs investigator-choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1332P
Hematologic safety of carboplatin (Carbo) plus mirvetuximab soravtansine (MIRV) in patients (pts) with folate receptor alpha (FRα)-expressing platinum-sensitive ovarian cancer (PSOC)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1330P
FLORENZA: A phase 2, open-label, randomized study to evaluate safety, efficacy, and dose optimization of mirvetuximab soravtansine (MIRV) combination therapies for epithelial ovarian cancer (EOC)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers: Poster Area – Hall 5
1342TiP
Updated overall survival results from the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma with longer follow up
Monday, October 26, 2026
12:00—12:45 PM
Poster
SCLC; Poster Area – Hall 5
3826P
RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): Updated results from a phase 1/2 study
Monday, October 26, 2026
12:00—12:45 PM
Poster
NSCLC, Metastatic; Poster Area – Hall 5
2669P
Temab-A, ABBV-706 and ABBV-969 are investigational medicines and are not approved by any health authority worldwide. Their safety and efficacy have not been established and are being evaluated in ongoing clinical studies.
AbbVie holds exclusive rights from RemeGen to develop, manufacture and commercialize ABBV-1480 outside of Greater China. ABBV-1480 is an investigational medicine and is being evaluated in ongoing clinical studies.
Alveltamig (ZG006) is an investigational medicine being developed by Suzhou Zelgen Biopharmaceuticals and has not been approved by any health authority worldwide.
U.S. Prescribing Information for AbbVie Medicines
Please see full Prescribing Information for ELAHERE® (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv)
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
1 Cecchini M, Cruz-Correa M, Han S, et al. "Long-term follow up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study." Abstract presented at European Society for Medical Oncology Congress, 2026. Madrid, Spain.
2 Raimbourg J, Camidge R, Kim T, et al. " Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): post hoc analysis from a Phase 1 first-in-human (FIH) study in patients (pts) with brain metastases." Abstract presented at Europoean Society for Medical Oncology Congress, 2026. Madrid, Spain.
3 Chiang A, Jahchan N, Faivre E, et al. "ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumour Activity in Relapsed/Refractory Small Cell Lung Cancer (R/R SCLC)." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain.
4 Peer A, Tolcher A, Joshua A, et al. "Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain
5 Yu J, Sun Y, Wen Q, et al. "RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): updated results from a Phase 1/2 study." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain.
AbbVie zvýšila dividendu již 54. rok po sobě; přípravky Skyrizi a Rinvoq ve 2. čtvrtletí 2026 vygenerovaly tržby přes 7,5 mld. USD a společnost vyplatila na dividendách více než 6,1 mld. USD.
Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest rates on the rise, makes it more difficult to differentiate the good from the bad.
AbbVie (ABBV +0.71%) is by no means a high-yield trap. This pharma stock is well-positioned to succeed in any rate cycle.
Image source: Getty Images.
The exact opposite of a high-yield trap What makes a stock a high-yield trap? Different investors can have different criteria, but there's one tell-tale sign. A stock with a high dividend yield but a payout ratio consistently above its free cash flow is almost always a trap. If a company doesn't generate sufficient free cash flow, it will be forced to cut its dividend sooner or later.
Rising interest rates make it especially difficult for companies with balance sheets loaded to the gills with floating-rate debt. They frequently must shift funds from the dividend program to cover their higher interest expenses.
Similarly, a company with a business model whose revenue is highly sensitive to consumer spending can experience problems when rates increase. When consumers have to spend more of their money on car and home loans and credit card debt, they have less money to buy these companies' products.
AbbVie doesn't have issues on any of these fronts. The drugmaker generates more than enough free cash flow to cover its quarterly dividend payment of $1.73 per share. While AbbVie's debt totals $70.8 billion, much of it is in fixed-rate senior notes that aren't sensitive to interest rate fluctuations. Patients don't quit taking AbbVie's medications because interest rates go up, either.
ABBV AbbVie$285.42+$2.02 (+0.71%)
NYSE · As of 4:00 PM ET 10/16/26
The numbers add up for AbbVie Importantly, AbbVie has increased its dividend for 54 consecutive years (including the period when it was part of Abbott Laboratories (ABT +0.20%)). This achievement qualifies the company to be part of the Dividend Kings, a group of stocks that have increased their dividends for at least 50 consecutive years.
As you might imagine, Dividend Kings are loath to break their dividend-hike streaks and lose their status in the elite group. Both Abbott and AbbVie have ensured their dividends keep flowing and growing regardless of what the Federal Reserve does with rates.
AbbVie shouldn't have much trouble holding onto its Dividend King membership for two key reasons: Skyrizi and Rinvoq. These two autoimmune disease drugs together raked in over $7.5 billion in the second quarter of 2026 alone. That's more than the $6.1 billion the company paid in dividends during the quarter.
Another important number to know is 90. That's roughly how many programs the company has in clinical development. Around 60 of them are in mid- or late-stage clinical studies. This robust pipeline should help ensure that AbbVie continues to generate plenty of revenue in the future to grow its dividend.
A Dividend King to own for the long run To be sure, AbbVie's dividend yield of 2.5% isn't nearly as high as it's been in the past. However, that isn't a poor reflection on the company's ability to pay dividends. Instead, it's a testament to how great AbbVie's stock has performed in recent years. Its share price has risen so much that the solid dividend growth hasn't kept pace, causing this yield to slide.
Like all biotech and pharmaceutical companies, AbbVie faces the risk of pipeline setbacks. The good news, though, is that the company has enough therapies in development to remain successful even if some don't fulfill their potential.
In a market where investors can easily get stuck with high-yield traps, AbbVie offers a solution. It's an ideal Dividend King to own for the long run.
AbbVie představí data, podle nichž RINVOQ po 144 týdnech navodil klinickou remisi u 78,9 % pacientů s Crohnovou nemocí při dávce 15 mg a až u 86,6 % pacientů při dávce 30 mg.
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis
New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented
, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.
"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."
Key data to be presented include:
Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib
Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.
Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.
Upadacitinib in the Real World: New Insights from Clinical Practice
Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.
A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.
Additional Findings on Risankizumab Subcutaneous Induction in CD
Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.
aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.
bDefined as endoscopic subscore = 0.
cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.
dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.
eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.
The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:
Presentation Title
Session Details
Efficacy of Risankizumab by Crohn's Disease
Location: Results From 144 Weeks of the
FORTIFY Open-Label Extension Study
Oral
Monday, 19 October
16:00 – 17:00
OP165: Teaching an old dog new tricks:
New implementations of current IBD drug
Efficacy and Safety of Risankizumab
Subcutaneous Induction in Patients With
Moderately to Severely Active Crohn's Disease:
Week 12 Results From the Phase 3 AFFIRM Study
Oral
Monday, 19 October
16:00 – 17:00
OP166: Teaching an old dog new tricks:
New implementations of current IBD drug
Efficacy and Safety of Subcutaneous
Risankizumab Maintenance Therapy Among
Patients With Moderately to Severely Active
Crohn's Disease Who Responded to
Subcutaneous Risankizumab Induction Therapy:
24-Week Results From the AFFIRM Trial
Moderated poster
Monday, 19 October
16:00 – 17:00
MP0087: The IBD exposome: Diet,
environment, and sustainability
Sustained Clinical and Endoscopic Improvements With
up to 3 Years of Risankizumab Maintenance
Treatment in Patients with Moderate to Severe
Ulcerative Colitis Regardless of the Number of Prior
Advanced Therapy Exposures
E-Poster
17-20 October
PP1176
Efficacy and Safety of Upadacitinib Maintenance
Therapy in Moderately to Severely Active
Crohn's Disease: 144-Week Results From the U-
ENDURE Long-Term Extension Study
Oral
Monday, 19 October
11:30 – 12:30
OP108: Long term outcomes
of interventional trials in IBD
Effectiveness of Upadacitinib Treatment in
Moderate to Severe Crohn's Disease in Real-
World Clinical Practice: 6-Month Results From
the UPlift Study
Moderated poster
Sunday, 18 October
09:00 – 10:00
MP0015: Therapeutics in IBD - Real
world experience (3)
Comparative Health Care Resource Use and
Treatment Patterns Following Tumor Necrosis
Factor Inhibitor Cycling Versus Switching to
Upadacitinib: A Propensity Score Matched
Analysis
Oral
Tuesday, 20 October
14:30 – 15:30
OP292: Real world observations in IBD:
Things we don't see in clinical trials
ABBV-466, A Novel Dual-targeting Therapy,
Leads to Endoscopic Remission in Moderate-to-
severe Crohn's Disease: Primary Results and
Molecular Profiling from the Phase 2a TARGET-
CD study
Oral
Monday, 19 October
10:00 – 11:00
LB08: Late-Breaking IBD Trials
SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2
On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.
EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1
Indications
Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Important Safety Information
Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).
Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.
Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.
Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.
The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).
Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.
This is not a complete summary of all safety information.
See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu
Globally, prescribing information varies; refer to the individual country product label for complete information.
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.3,4 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.3
Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.
EU Indications and Important Safety Information about RINVOQ® (upadacitinib)3
Indications
Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA)
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.
Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Important Safety Information
Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.
Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:
- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy).
Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.
Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.
Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.
Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.
Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.
Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.
Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.
Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.
Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.
Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.
Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.
Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.
Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.
Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.
Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.
Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.
Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.
Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.
Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.
The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.
The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.
The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.
The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.
The most common serious adverse reactions were serious infections.
The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.
RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.
This is not a complete summary of all safety information.
See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu
Globally, prescribing information varies; refer to the individual country product label for complete information.
About TARGET-CD:
TARGET-CD (M24-885) is a global Phase 2a, multicenter, randomized platform study designed to evaluate multiple investigational targeted therapies, including monotherapy and combination approaches, in adults with moderately to severely active Crohn's disease. The innovative platform design enables evaluation of the efficacy, safety, and mechanistic profiles of different therapeutic strategies using a common comparator, with the goal of rapidly advancing new treatment approaches for patients with Crohn's disease. More information on the TARGET-CD trial can be found at www.clinicaltrials.gov (NCT06548542).
About ABBV-466:
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.
ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
SKYRIZI. Summary of product characteristics. AbbVie; 2026.
SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
RINVOQ. Summary of product characteristics. AbbVie; 2026.
Pipeline. AbbVie. 2026. Accessed September 24, 2026. https://www.abbvie.com/our-science/pipeline.html
AbbVie (ABBV +0.71%), which accounts for 6.2% of my portfolio, is one of my favorite long-term dividend stocks. The pharmaceutical giant has raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years.
I'm sitting on an unrealized gain of nearly 200% on my original position in AbbVie, which I started in early 2020, and I've consistently reinvested my dividends. Its forward yield of 2.4% might seem low compared to the 10-Year Treasury's 5.1% yield. Still, its low forward price-to-earnings ratio of 16 and its massive portfolio of billion-dollar drugs (including the blockbusters Skyrizi and Rinvoq) should limit its downside potential in this choppy market.
Image source: Getty Images.
How many shares of AbbVie should you own for $5,000 in annual income?
To earn $5,000 in annual dividends from AbbVie, you would need to own 723 shares for about $206,358 as of this writing. That might not seem like a great deal, especially when the same investment in Pfizer (PFE +0.48%) would generate nearly $12,000 in annual dividends.
ABBV AbbVie$285.42+$2.02 (+0.71%)
NYSE · As of 4:00 PM ET 10/16/26
But over the past three years, AbbVie's stock rallied 93% as it overcame its loss of U.S. exclusivity for Humira (its blockbuster autoimmune drug) and expanded its new drugs to offset that pressure. Pfizer's stock sank 8% as its sales of COVID-19 vaccines evaporated and its other major drugs faced patent cliffs. Therefore, AbbVie could still be a solid investment for long-term income investors, even though its yield seems unimpressive.
Leo Sun has positions in AbbVie and Pfizer. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool has a disclosure policy.
CliftonLarsonAllen Wealth Advisors ve třetím čtvrtletí snížila svůj podíl ve společnosti AbbVie o 9,1 % prodejem 2 439 akcií; nyní drží 24 277 akcií v hodnotě 6,351 milionu USD.
Cliftonlarsonallen Wealth Advisors LLC decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 9.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 24,277 shares of the company’s stock after selling 2,439 shares during the quarter. Cliftonlarsonallen Wealth Advisors LLC’s holdings in AbbVie were worth $6,351,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Ranch Capital Advisors Inc. lifted its holdings in AbbVie by 37.0% in the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after purchasing an additional 45,132 shares during the period. Danica Pension Livsforsikringsaktieselskab bought a new position in AbbVie in the 2nd quarter worth approximately $23,557,000. Wedge Capital Management L L P NC grew its holdings in AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after buying an additional 9,380 shares in the last quarter. Finally, Mission Wealth Management LP grew its holdings in AbbVie by 119.1% during the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock valued at $17,376,000 after buying an additional 37,531 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Positive SKYRIZI Crohn’s disease data: Phase 3 AFFIRM results showed that subcutaneous SKYRIZI produced meaningful clinical and endoscopic benefits versus placebo, with a safety profile consistent with the established treatment. The data could support regulatory review of a more convenient induction option and strengthen AbbVie’s post-Humira growth franchise. Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s Investment Narrative? Positive Sentiment: Analyst and earnings optimism: RBC reaffirmed an “outperform” rating and cited potential third-quarter strength from RINVOQ, SKYRIZI, and Vraylar. Erste Group also raised its FY2027 EPS estimate to $16.34 from $16.19 while maintaining a “Buy” rating. Investors are looking ahead to AbbVie’s October 30 earnings report. AbbVie Poised for Q3 Top-Line Beat Positive Sentiment: Broad healthcare rally and options activity: Pharmaceutical stocks rallied broadly, supporting ABBV. Investors also purchased 86,296 AbbVie call options, approximately 445% above typical call volume, indicating elevated bullish positioning, although options activity alone does not guarantee further gains. Lilly, Merck, AbbVie Stocks Surge Neutral Sentiment: Mixed comparative view: A Zacks analysis argued that Sanofi currently offers a more attractive combination of valuation, outlook, and Dupixent growth, suggesting AbbVie’s strong recent performance has left less valuation upside relative to some peers. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? Negative Sentiment: Valuation and conflicting market reaction: One report characterized ABBV as trading above estimated fair value, while another described an initial decline following the new SKYRIZI data. The conflicting reactions highlight execution, regulatory, and valuation risks despite the data’s long-term potential. A Look at AbbVie After a Decline AbbVie Price Performance NYSE:ABBV opened at $283.58 on Thursday. The firm has a market capitalization of $501.03 billion, a price-to-earnings ratio of 25.24, a PEG ratio of 1.25 and a beta of 0.24. The business has a 50 day simple moving average of $261.16 and a 200-day simple moving average of $238.38. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $285.40. AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the company posted $2.97 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
Wall Street Analyst Weigh In Several equities research analysts have recently issued reports on ABBV shares. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein restated a “market perform” rating and set a $225.00 target price (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. Argus upped their target price on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. BMO Capital Markets raised their target price on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $277.18.
View Our Latest Stock Report on ABBV
Insider Activity In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
AbbVie Profile (Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
Further Reading Five stocks we like better than AbbVie Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday. The stock traded as high as $281.30 and last traded at $280.8740, with a volume of 5,593,125 shares changing hands. The stock had previously closed at $276.47.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Skyrizi and Rinvoq remain the central growth drivers. Analysts expect the two medicines to deliver strong Q3 revenue growth and help counter Humira’s continuing sales erosion. However, increasing competition in immunology remains a consideration. Will Skyrizi & Rinvoq Drive AbbVie’s Top-Line Growth in Q3?
Positive Sentiment: Long-term clinical data for SKYRIZI and RINVOQ provided additional pipeline support. AbbVie highlighted findings at the ACG 2026 conference, helping support confidence in the therapies’ durability and commercial potential. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026
Positive Sentiment: Analyst backing remains supportive. Guggenheim reaffirmed a Buy rating, while a separate report cited an analyst upgrade. These actions suggest that some analysts see further upside despite ABBV’s substantial recent gains. AbbVie Stock Rating Reaffirmed as Buy by Guggenheim
Positive Sentiment: Investors continue to view AbbVie as a durable income and growth holding. Although the dividend yield has fallen because the share price has risen faster than the dividend, the company’s payout record and expanding product portfolio remain attractive to income investors. AbbVie’s Dividend Yield Is at Its Lowest Level Since 2018
Neutral Sentiment: Broader biotech sentiment is improving as pharmaceutical companies pursue acquisitions to replenish pipelines ahead of patent expirations. This could benefit AbbVie’s sector valuation, but it also underscores the industry’s broader patent-cliff pressures. Biotech’s Rebound Reality
Negative Sentiment: Humira’s decline and rising competition could limit near-term growth if Skyrizi and Rinvoq do not continue gaining market share. Valuation is also a risk, with Wall Street price targets showing a wide gap between bullish and bearish expectations. AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape
Analyst Ratings Changes
Several brokerages have issued reports on ABBV. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. HSBC boosted their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Morgan Stanley upped their target price on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Leerink Partners increased their price target on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $277.18.
View Our Latest Report on AbbVie
AbbVie Stock Performance
The business’s fifty day moving average is $259.79 and its two-hundred day moving average is $237.39. The company has a market cap of $496.25 billion, a P/E ratio of 79.34, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the company earned $2.97 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 13.94 EPS for the current fiscal year.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie’s payout ratio is 195.48%.
Insider Buying and Selling at AbbVie
In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.
Institutional Trading of AbbVie
A number of hedge funds have recently added to or reduced their stakes in ABBV. State Street Corp increased its stake in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP purchased a new position in AbbVie in the 2nd quarter valued at about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new stake in AbbVie in the 2nd quarter worth about $2,905,952,000. Finally, Deutsche Bank AG boosted its holdings in AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.
AbbVie Company Profile
(Get Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
Featured Articles
Five stocks we like better than AbbVie
Salesforce Just Got a Rare Double Upgrade—What Changed?
OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
AbbVie ve třetím čtvrtletí očekává tržby Skyrizi ve výši 5,71 mld. USD (+21 % meziročně) a Rinvoq ve výši 2,73 mld. USD (+25 % meziročně), které mají kompenzovat 31% pokles tržeb Humiry.
Key Takeaways AbbVie's Skyrizi and Rinvoq are expected to sustain growth despite Humira's ongoing sales erosion.Skyrizi sales are estimated at $5.71 billion, up 21%, while Rinvoq is expected to rise 25% to $2.73 billion.J&J's Tremfya and Icotyde, along with Lilly's Omvoh, intensify competition in immunology. AbbVie (ABBV - Free Report) is scheduled to report its third-quarter 2026 results on Oct. 30, before the opening bell. Investors will likely focus on the sales growth of its immunology franchise, which is led by two blockbuster medications, Skyrizi and Rinvoq.
Strong demand for both drugs has helped AbbVie sustain top-line growth despite the U.S. loss of exclusivity for its legacy drug Humira in 2023. Skyrizi and Rinvoq collectively overlap with Humira across several major inflammatory conditions, plus a distinct new indication, atopic dermatitis. Both products have delivered strong growth across approved indications, particularly in the inflammatory bowel disease (IBD) market, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Continued growth in the immunology market, market-share gains and uptake across newer indications are expected to support sales. In July 2026, the European Commission approved Rinvoq for vitiligo and severe alopecia areata, expanding its potential growth opportunities. Applications for both indications are under review in the United States.
The Zacks Consensus Estimate for Skyrizi sales is pegged at $5.71 billion, while the same for Rinvoq stands at $2.73 billion. These figures imply year-over-year growth of approximately 21% and 25%, respectively, based on third-quarter 2025 sales. Continued demand across approved indications and further market-share gains are expected to support their performance.
Sales of both drugs are also expected to offset the decline in Humira, which is expected to continue its downward trajectory due to generic erosion. The Zacks Consensus Estimate for the drug’s sales is pegged at $688 million, indicating a decline of about 31% year over year.
Beyond immunology, AbbVie has expanded its presence in neuroscience and oncology. Over the past few years, the company’s neuroscience franchise spans migraine and Parkinson’s disease treatments, while its oncology portfolio has expanded beyond blood cancers into solid tumors. Nevertheless, the performance of Skyrizi and Rinvoq will remain central to assessing whether growth in AbbVie’s newer immunology drugs can continue to offset Humira’s erosion.
ABBV’s Competition in the Immunology SpaceThe immunology market is highly competitive, with major pharmaceutical companies vying for market share across several indications. A key competitor is Johnson & Johnson (JNJ - Free Report) , which markets two major immunology drugs, Stelara and Tremfya. Both drugs are approved for multiple inflammatory conditions, including UC and CD. Following the entry of Stelara biosimilars in the United States in 2025, J&J is increasingly relying on Tremfya’s growth to offset declining Stelara sales and support its immunology franchise.
J&J is also expanding its immunology portfolio. Earlier in March, it secured approval for Icotyde, a once-daily oral drug for moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi.
Eli Lilly (LLY - Free Report) is another competitor expanding its presence in immunology through Omvoh. The drug received FDA approval for UC in October 2023 and for CD in January 2025. These approvals established the LLY drug as a competitor in both the major forms of IBD, where AbbVie’s Skyrizi has been gaining traction.
ABBV’s Price Performance, Valuation and EstimatesThis year so far, shares of AbbVie have risen 21% compared with the industry’s 12.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 17.75 times forward earnings, lower than its industry’s average of 18.18 times.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.05 to $13.98, while the 2027 estimate has fallen from $16.15 to $16.04 over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided between a $297 bull case and…
AbbVie (NYSE:ABBV | ABBV Price Prediction) trades at $277.15 midday Friday. Our 24/7 Wall St. price target is $279.12 over 12 months, representing 2.46% upside from the model price.
Our high confidence reflects broad growth: Skyrizi, Rinvoq and neuroscience each delivered growth above 20% last quarter. AbbVie completed its Apogee Therapeutics acquisition on September 3, 2026. The stock sits near the $280.79 consensus target, limiting upside.
A Breakout Above the 52-Week High Shows Momentum Building Shares rose 6.62% over the past week, 11.4% over the past month and 24.16% year to date, breaking above the prior 52-week high of $274.94.
Second-quarter revenue of $16.99 billion rose 10.2%, ahead of the $16.76 billion consensus. Adjusted EPS of $3.65 met the $3.64 estimate. Management raised revenue guidance by $300 million to about $67.6 billion. The FDA approved JUVMO (tavapadon) for Parkinson’s disease, and Temab-A received two Breakthrough Therapy Designations.
Why Bulls See $297 Within Reach Skyrizi sales reached $5.51 billion last quarter, up 24.4%, with management expecting $21.7 billion for the full year. Rinvoq peak sales in vitiligo and alopecia areata alone could approach $2 billion. Apogee’s zumilokibart posted positive Phase 2 results in atopic dermatitis, positioning it as a credible billion-dollar candidate.
A new under-the-skin Skyrizi dose for Crohn’s disease could accelerate growth starting “really early in 27”. Wall Street gives 8 Strong Buy and 16 Buy ratings to the stock. The bull case reaches $297.77.
Humira Erosion and Debt Keep Risks on the Table Humira sales fell 35.9% to $756 million, and Imbruvica dropped 29.4%. Net debt stands at 2.26x EBITDA. The trailing P/E of 114 reflects $5 billion in acquired R&D charges in 2025.
On forward earnings, the stock trades at 16x. Management targets two times net leverage within two to three years. Our bear case is $246.52.
How AbbVie Compares to Merck and Eli Lilly Company Forward P/E Quarterly Revenue Growth (YoY) AbbVie 16x 10.2% Merck 15x 5.1% Eli Lilly 24x 47.7% Merck (NYSE:MRK) faces a similar patent cliff. Keytruda sales of $7.904 billion declined 1%. Merck trades at a discount to AbbVie, which makes sense given AbbVie’s faster growth.
Eli Lilly (NYSE:LLY) competes in immunology through Ebglyss, whose sales rose 131%. Lilly’s premium multiple reflects much faster growth. AbbVie sits between both peers.
AbbVie Price Prediction 2026-2030 Our 24/7 Wall St. price target of $279.12 carries a hold rating and 90% confidence. After the rally, valuation has caught up with fundamentals. Approval of the Skyrizi Crohn’s dose or strong Rinvoq dermatology launches could turn positive.
Accelerating Humira declines or higher Apogee integration costs would call for caution. For now, AbbVie looks fairly valued.
The 24/7 Wall St. price target model projects where AbbVie could trade if current growth trends hold.
Year Price Target from 24/7 Wall St. 2026 $274.36 2027 $279.12 2028 $289.22 2029 $300.38 2030 $314.29 These estimates assume AbbVie executes its immunology strategy. Key swing factors: Skyrizi’s patent defense ahead of 2033 expiration and how quickly Apogee drugs reach market.
Contact [email protected] for any questions or corrections.
Studie AFFIRM fáze 3 ukázala, že podkožně podávaný přípravek SKYRIZI dosáhl po 12 týdnech významně vyšší míry klinické remise a endoskopické odpovědi u pacientů s Crohnovou nemocí než placebo.
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care , /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14. Data presented will include newly unveiled AFFIRM results showing efficacy for SKYRIZI® (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with SKYRIZI in difficult-to-treat IBD and growing real-world evidence supporting RINVOQ® (upadacitinib) in advanced CD.
"People living with IBD want treatments that meaningfully reduce the burden of their disease," said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. "Our presence at ACG reflects AbbVie's drive, as a leader in IBD, to provide what matters most to patients — therapies that perform over time and against the most complicated drivers of disease."
The ACG conference agenda is available here. Select AbbVie oral and poster presentations are highlighted below:
Clinical Remission and Endoscopic Outcomes With Subcutaneous SKYRIZI
Title
Description
Session Details
Efficacy and Safety of
Risankizumab
Subcutaneous Induction and
Maintenance in Patients
With Moderately to Severely
Active Crohn's Disease:
Results From the Phase 3
AFFIRM Study
Results from the Phase 3 AFFIRM trial
showed subcutaneous risankizumab
achieved significantly higher rates of clinical
remission and endoscopic response versus
placebo at Week 12, with rates of all
endpoints remaining numerically higher
through Week 24 among clinical
responders.
Tuesday,
October 13
2:15 PM – 2:25 PM CDT
Oral Presentation 37
Comparative Efficacy of
Subcutaneous
Risankizumab Versus
Guselkumab as Induction
Therapy in Patients With
Moderately to Severely
Active Crohn's Disease: An
Anchored Matching-Adjusted
Indirect Comparison
New indirect comparative analyses showed
subcutaneous risankizumab achieved
significantly higher rates of endoscopic
response versus guselkumab during
induction in patients with moderately to
severely active Crohn's disease.
Tuesday,
October 13
10:30 AM – 4:00 PM CDT
Poster P5748
Multiyear Endoscopic Healing With SKYRIZI in Patients With Complex Disease Characteristics and Prior Treatment Exposure
Title
Description
Session Details
Efficacy of Risankizumab by
Crohn's Disease Location:
Results From 144 Weeks of
the FORTIFY Open-Label
Extension Study
New analyses from the Phase 3 FORTIFY
open-label extension study demonstrated
sustained clinical and endoscopic outcomes
with risankizumab through 144 weeks of
treatment across ileal, colonic and
ileocolonic Crohn's disease. Clinical and
endoscopic remission rates were generally
maintained or improved over time across
disease locations.
Sunday,
October 11
3:30 PM – 7:00 PM CDT
Poster P1061
Risankizumab for Fistulizing
Crohn's Disease: Post Hoc
Analysis of Up to 5 Years of
Treatment From the
FORTIFY Open-Label
Extension
Data from the Phase 3 FORTIFY open-
label extension study showed that 74.5% of
patients with fistulizing Crohn's disease
achieved no draining fistulas after five years
of treatment with risankizumab.
Sunday,
October 11
3:30 PM – 7:00 PM CDT
Poster P1058
Efficacy of Risankizumab by
Crohn's Disease Location
Through 148 Weeks of
Treatment: Results from the
SEQUENCE Open-Label
Extension Study
New analyses from the ongoing
SEQUENCE study demonstrated durable
clinical and endoscopic efficacy with
risankizumab through nearly three years of
treatment in patients with moderately to
severely active Crohn's disease following
anti-TNF failure. Endoscopic outcomes
among patients with ileal disease continued
to improve over time and became
comparable to outcomes observed across
other disease locations by Week 148.
Sunday,
October 11
3:30 PM – 7:00 PM CDT
Poster P1060
Sustained Clinical and
Endoscopic Improvements
With up to 3 Years of
Risankizumab Maintenance
Treatment in Patients With
Moderate to Severe
Ulcerative Colitis Regardless
of the Number of Prior
Advanced Therapy
Exposures
New analyses from the ongoing
COMMAND open-label extension study
demonstrated sustained clinical and
endoscopic improvements with
risankizumab through three years of
treatment in patients with moderately to
severely active ulcerative colitis. Benefits
were observed regardless of prior
advanced therapy exposure, including
among patients with experience across
multiple advanced therapies.
Tuesday,
October 13
10:30 AM – 4:00 PM CDT
Poster P5727
Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease
Title
Description
Session Details
Real-World Outcomes of
Upadacitinib in Fistulizing
and Stricturing Crohn's
Disease Among Patients in
the Veterans Affairs Health
System
Real-world data from the Veterans Affairs
health system showed that 93.3% of
patients with fistulizing disease and 76.9%
of patients with stricturing disease who
remained on treatment achieved clinical
remission and corticosteroid-free remission
with upadacitinib.
Monday, October 12
10:30 AM – 4:15 PM CDT
Poster P3482
Real-World Outcomes of
Upadacitinib in Isolated Ileal
Crohn's Disease Among
Patients in the Department
of Defense Healthcare
System
New real-world data from the Department of
Defense healthcare system demonstrated
clinical and endoscopic outcomes with
upadacitinib in patients with isolated ileal
Crohn's disease. At six months, 57% of
patients achieved clinical remission, 58%
achieved endoscopic response and 53.6%
achieved endoscopic remission.
Tuesday, October 13
2:35 PM – 2:45 PM CDT
Oral Presentation 39
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.i SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.i
On April 27, 2026, AbbVie announced submission of an application to the FDA seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.
SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationi
SKYRIZI is a prescription medicine used to treat:
moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis in adults and children 6 years of age and older. moderate to severe Crohn's disease in adults. moderate to severe ulcerative colitis in adults. IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medicine that may cause serious side effects, including:
Serious allergic reactions:
Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded
(low blood pressure) swelling of your face, eyelids, lips,
mouth, tongue, or throat trouble breathing or throat tightness chest tightness skin rash, hives itching Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your mucus
(phlegm) muscle aches warm, red, or painful
skin or sores on your
body different from
your psoriasis weight loss diarrhea or stomach
pain burning when you
urinate or urinating
more often than normal Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Before using SKYRIZI, tell your healthcare provider about all of your medical conditions,
including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
Please click here for the Full Prescribing Information and Medication Guide.
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3 and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.
Upadacitinib is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus and vitiligo. The use of upadacitinib for these diseases is not FDA approved, and its safety and efficacy have not been established for these diseases.
RINVOQ® (upadacitinib) U.S. Uses and Important Safety Informationii
RINVOQ is a prescription medicine used to treat:
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. Adults with giant cell arteritis (GCA). Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers. Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers. It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.
RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)
What is the most important information I should know about RINVOQ<*>?
RINVOQ may cause serious side effects, including:
Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster). Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor. Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen. Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker. Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor. Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away. Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting. Low blood sugar (hypoglycemia) in people with diabetes. If you have diabetes, your HCP may tell you to check your blood sugar (glucose) more often during treatment with RINVOQ. Call your HCP if you have any problems with low blood sugar. Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results. Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as: Fever, sweating, or
chills
Shortness of breath
Warm, red, or
painful skin or
sores on your body Muscle aches
Feeling tired
Blood in phlegm
Diarrhea or
stomach pain Cough
Weight loss
Burning when
urinating or
urinating more
often than normal Have TB or have been in close contact with someone with TB. Are a current or past smoker. Have had a heart attack, other heart problems, or stroke. Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines. Have other medical conditions, including liver problems, diabetes, low blood cell counts, chronic lung disease, HIV, or a weak immune system. Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP. Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines. Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose. There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110. Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
Medicines for fungal or bacterial infections Rifampicin or phenytoin Medicines that affect your immune system If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw Pain or discomfort in your arms, back, neck, jaw, or stomach Shortness of breath with or without chest discomfort Breaking out in a cold sweat Nausea or vomiting Feeling lightheaded Weakness in one part or on one side of your body Slurred speech Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including: Swelling Pain or tenderness in one or
both legs Sudden unexplained chest or
upper back pain Shortness of breath or difficulty
breathing Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits. What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, swelling of the feet and hands (peripheral edema), increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your HCP.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ/RINVOQ LQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your HCP.
<*>Unless otherwise stated, "RINVOQ" in the IMPORTANT SAFETY INFORMATION refers to RINVOQ and RINVOQ LQ.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.
Please click here for the Full Prescribing Information and Medication Guide.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
i SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.
ii RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.
Dividendový výnos společnosti AbbVie klesl na 2,6 %, tedy na nejnižší úroveň od začátku roku 2018, protože cena akcií rostla rychleji než dividenda. Společnost dividendu zvyšuje již 54 let v řadě.
AbbVie (ABBV +1.49%) has been a favorite for income investors since spinning off from Abbott Labs (ABT +1.13%) in 2013. For much of the past 13 years, the big drugmaker offered one of the more attractive dividend yields in the healthcare sector.
However, AbbVie's dividend yield today hovers around 2.6% -- the lowest level since early 2018. For investors accustomed to collecting yields of 3.5% or more, this relatively smaller amount might not seem appealing. But there's a good case to be made that AbbVie is still a great pick for income investors anyway.
Image source: Getty Images.
What's behind AbbVie's declining dividend yield? There are three ways that a dividend yield can decline. First, a company can cut the dividend while its share price either remains flat or rises. Second, the company's share price can rise while its dividend doesn't change. Third, both the company's share price and dividend can increase, with the share price rising faster than the dividend.
AbbVie is a clear example of the third scenario. The company inherited a long streak of dividend hikes from Abbott and has kept it going. AbbVie is a member of the Dividend Kings, an elite group of stocks with at least 50 consecutive dividend increases. It has grown its dividend (including the period when it was part of Abbott) for 54 consecutive years.
The company's dividend increases haven't been paltry, either. Since 2013, AbbVie's dividend payout has soared by almost 333%. Over the last five years, its dividend has risen 33%.
But AbbVie's share price has grown much more rapidly. The big biotech stock is up roughly 676% since 2013 and has gained 148% over the last five years, handily beating the S&P 500's (^GSPC +0.59%) during the period. Therefore, AbbVie's yield compression is entirely price-driven.
Premium Feature
Moneyball Superscore
79/100
Today's Change
(
1.49
%) $
4.05
Current Price
$
276.47
Blue skies ahead There's more growth ahead for AbbVie. The drugmaker no longer has to worry about the Humira patent cliff. Humira's two successors, Skyrizi and Rinvoq, are on track for combined sales of over $29 billion in 2026. At its peak in 2021, Humira's annual sales were around $22 billion.
Even better, the sales growth for Skyrizi and Rinvoq remains strong. In the second quarter of 2026, sales for both immunology drugs jumped by more than 24% year over year.
AbbVie's lineup also includes other blockbuster growth drivers. Sales for the antipsychotic Vraylar, the migraine therapies Qulipta and Ubrelvy, and the cancer drug Venclexta continue to grow in the double digits.
The company's pipeline features around 90 programs in clinical development, with two-thirds of them in mid- or late-stage testing. That number doesn't include the assets acquired in AbbVie's recent acquisition of Apogee Therapeutics.
Granted, Wall Street doesn't expect huge near-term gains for AbbVie. The consensus 12-month price target reflects only around 5% upside. Some analysts are more optimistic, though. For example, Morgan Stanley's (MS +1.38%) Terence Flynn thinks AbbVie's shares can rise by 14% over the next 12 months, while Scotiabank's (NYSE: BNS) Louise Chen projects a gain of nearly 18%.
AbbVie is still a good pick for income investors for one simple reason: Its dividend is likely to continue growing robustly. A yield of 2.6% isn't all that shabby. However, if AbbVie increases its dividend payouts by its average growth rate over the last five years, investors' yield on cost could easily top 4.6% within the next 10 years.
Don't overlook the peace-of-mind factor, either. AbbVie's dividend yield might not be as high as it once was, but the reliability of the dividends is as strong as ever.
GAMMA Investing LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 10.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,060 shares of the company’s stock after acquiring an additional 7,058 shares during the period. AbbVie makes up 0.6% of GAMMA Investing LLC’s holdings, making the stock its 24th largest position. GAMMA Investing LLC’s holdings in AbbVie were worth $19,635,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of ABBV. Galvin Gaustad & Stein LLC raised its stake in shares of AbbVie by 0.7% during the third quarter. Galvin Gaustad & Stein LLC now owns 6,941 shares of the company’s stock valued at $1,816,000 after purchasing an additional 46 shares in the last quarter. Grove Bank & Trust lifted its holdings in AbbVie by 0.7% in the third quarter. Grove Bank & Trust now owns 15,465 shares of the company’s stock worth $4,045,000 after purchasing an additional 112 shares during the period. Factor Wealth Management LTD grew its position in AbbVie by 1.1% in the 3rd quarter. Factor Wealth Management LTD now owns 19,240 shares of the company’s stock valued at $5,033,000 after buying an additional 207 shares in the last quarter. Conrad Siegel Investment Advisors Inc. bought a new position in AbbVie in the 3rd quarter valued at about $201,000. Finally, Farther Finance Advisors LLC increased its stake in AbbVie by 10.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 132,821 shares of the company’s stock valued at $34,745,000 after buying an additional 12,862 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes A number of analysts have recently weighed in on the stock. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Bank of America reissued a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Argus upped their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $276.64.
Check Out Our Latest Research Report on AbbVie Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.
AbbVie Stock Performance AbbVie stock opened at $272.20 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $274.94. The firm has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a P/E/G ratio of 1.23 and a beta of 0.24. The company has a 50 day moving average price of $258.56 and a 200 day moving average price of $236.35.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts forecast that AbbVie Inc. will post 14.01 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook. Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns AbbVie Company Profile (Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
Further Reading Five stocks we like better than AbbVie Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Bell Asset Management ve třetím čtvrtletí snížila svůj podíl ve společnosti AbbVie o 48,2 % prodejem 10 062 akcií; na konci čtvrtletí držela 10 833 akcií v hodnotě 2,834 milionu USD.
Bell Asset Management Ltd cut its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 48.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,833 shares of the company’s stock after selling 10,062 shares during the quarter. AbbVie makes up approximately 1.0% of Bell Asset Management Ltd’s portfolio, making the stock its 23rd largest holding. Bell Asset Management Ltd’s holdings in AbbVie were worth $2,834,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter worth approximately $30,000. Abound Financial LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $32,000. Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie in the first quarter worth $34,000. Marquette Asset Management LLC grew its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Finally, Phillip James Consulting Co. bought a new stake in shares of AbbVie during the 4th quarter valued at $36,000. Institutional investors own 70.23% of the company’s stock.
Insider Activity at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes ABBV has been the subject of a number of recent analyst reports. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley lifted their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $276.64. Read Our Latest Stock Analysis on AbbVie
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook. Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns AbbVie Price Performance NYSE:ABBV opened at $272.20 on Friday. The company has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a PEG ratio of 1.23 and a beta of 0.24. The business has a 50 day moving average of $258.56 and a 200 day moving average of $236.35. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $274.94.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.01 EPS for the current year.
AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.
AbbVie Company Profile (Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
See Also Five stocks we like better than AbbVie Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
FDA udělila dvě označení průlomové terapie přípravku Temab-A od AbbVie: jedno pro použití v kombinaci s bevacizumabem u dospělých s refrakterním metastatickým kolorektálním karcinomem a druhé pro monoterapii u dospělých s lokálně pokročilým nebo metastatickým nemalobuněčným karcinomem plic divokého typu EGFR exprimujícím protein c-Met.
Key Takeaways AbbVie's Temab-A earns two FDA Breakthrough Therapy designations for CRC and NSCLC.Temab-A is being studied as a c-Met-directed ADC with a topoisomerase 1 inhibitor payload.AbbVie is also evaluating Temab-A in head and neck, pancreatic, ovarian and other cancers. AbbVie (ABBV - Free Report) announced that the FDA has granted two Breakthrough Therapy designations (BTDs) to its investigational next-generation antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A; ABBV-400), for two different types of cancer indications – colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
One BTD covers Temab-A in combination with bevacizumab for treating adults with refractory, metastatic CRC who were previously treated with fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF monoclonal antibody (mAb), and, if indicated, anti-EGFR mAb therapy.
The second BTD is for Temab-A as a monotherapy for treating adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous NSCLC who previously received platinum-based chemotherapy and an anti-PD-(L)1 antibody therapy.
The two new designations from the FDA mark the first BTDs for Temab-A.
ABBV’s Price PerformanceYear to date, shares of AbbVie have rallied 21.6% compared with the industry’s increase of 11.7%.
Image Source: Zacks Investment Research
Both the above designations for Temab-A were based on data from the first-in-human M21-404 study. Temab-A is being evaluated as a c-Met-directed ADC with a topoisomerase 1 inhibitor payload across several advanced solid tumors, including CRC and NSCLC.
Besides CRC and NSCLC, AbbVie is evaluating Temab-A in other advanced solid tumors, including head and neck squamous cell carcinoma, gastroesophageal adenocarcinoma, pancreatic ductal adenocarcinoma and ovarian cancer. The development program includes several phase III and phase II/III studies evaluating the drug as a monotherapy and in combination with other therapies.
Strong Pipeline Expands ABBV’s Growth OpportunitiesAbbVie boasts a robust pipeline. The company recently announced positive top-line data from the phase III CERVINO study on etentamig for treating third-line-plus multiple myeloma. The study met both its primary goals, showing that treatment with etentamig significantly improved the objective response rate and progression-free survival compared with standard available therapies.
AbbVie is strengthening its portfolio of oncology medicines with the addition of ADCs, which are being considered a disruptive innovation in the pharmaceutical industry. ADCs will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
AbbVie expects pivotal data readouts for some other key pipeline candidates, including Temab-A in metastatic CRC and lutikizumab in hidradenitis suppurativa. The company is also developing ABBV-706, an ADC for treating relapsed/refractory small-cell lung cancer, as well as some other candidates that are in early-stage development.
ABBV’s Zacks Rank & Stocks to ConsiderAbbVie currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Actuate Therapeutics, Inc. (ACTU - Free Report) , Bristol Myers Squibb (BMY - Free Report) and CRISPR Therapeutics (CRSP - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for Actuate Therapeutics’ 2026 loss per share have narrowed from 86 cents to 73 cents, while loss per share estimates for 2027 have declined from 78 cents to 59 cents during the same time. ACTU’s shares have plunged 88.2% year to date.
Actuate Therapeutics’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 8.21%.
Over the past 60 days, estimates for Bristol Myers’ 2026 earnings per share have risen from $6.81 to $6.91, while estimates for 2027 have increased from $6.42 to $6.46 during the same time. BMY’s shares have risen 15.6% year to date.
Bristol Myers’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 14.43%.
Over the past 60 days, estimates for CRISPR Therapeutics’ 2026 loss per share have narrowed from $4.53 to $4.47, while loss per share estimates for 2027 have declined from $3.63 to $3.61 during the same time. CRSP’s shares have lost 0.1% year to date.
CRISPR Therapeutics’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average negative surprise being 1.38%.
On Sept. 10, HSBC analyst Rajesh Kumar maintained his "buy" rating on AbbVie (ABBV +0.74%), raising his price target on the pharmaceutical company's shares from $300 to $315 per share. Recently, other sell-side firms, such as Wolfe Research, have raised their price targets above $300 per share.
However, with AbbVie changing hands for around $262 per share, this price target nonetheless appears aggressive compared to other major pharmaceutical stocks. Even so, the rationale for it remains reasonable. It all has to do with two of the company's latest successful drug products: Skyrizi and Rinvoq.
Image source: Getty Images.
AbbVie, HSBC, and the $315 per share bull case HSBC analyst Rajesh Kumar's bull case for AbbVie is based on the growing approved indications for Skyrizi and Rinvoq. These pending expanded use cases include the use of Rinvoq to treat vitiligo and the release of a more convenient subcutaneous induction option for Skyrizi to treat Crohn's disease.
Kumar believes that these pending pipeline readouts will enable the company to raise peak sales guidance for both products, which could shift AbbVie's expected earnings growth rate "from the low mid-single digits" to the "high mid-single digits," a level of growth acceleration that will likely lead to a rerating for shares.
Adjusting for the one-time impact of recent pipeline drug purchases, AbbVie trades at around 16 times forward earnings. This suggests that, as the growth catalyst plays out, Kumar believes that AbbVie could rerate to a forward price-to-earnings multiple in the high-teens to low-20s range. Better yet, while Kumar's bull case focuses primarily on this catalyst, another factor could positively affect AbbVie's performance in the coming years.
Alongside the prospect of label expansion for these two drugs, AbbVie is further pivoting into immunology, notably through its recent $10.9 billion acquisition of Apogee Therapeutics. This is the aforementioned pipeline deal that will temporarily affect earnings this year, but could drive earnings growth in the years ahead.
Premium Feature
Moneyball Superscore
80/100
Today's Change
(
0.74
%) $
1.97
Current Price
$
267.73
Here's another way AbbVie could surge in the long run The "known unknown" regarding whether Skyrizi and Rinvoq sales could offset the loss of Humira's patent exclusivity has been more or less resolved. Last quarter, Skyrizi generated $5.5 billion in sales, while Rinvoq generated $2.5 billion in sales. Considering that Humira generated just $756 million in sales last quarter, AbbVie's new flagship products are generating 10 times as much revenue as its former legacy flagship drug.
Now, with label expansion for these two drugs, coupled with the further build-out of AbbVie's pipeline, there is far less uncertainty around AbbVie shares. Yet while all of this is a strong setup for a strong run in the years ahead, it may not play out exactly as Kumar envisioned in his recent research note. While AbbVie's shares could surge further on stronger-than-expected long-term sales growth, note that the stock, at around 16 times forward earnings, already trades at a premium to the low- to mid-teen valuations of many other pharmaceutical stocks.
In other words, it would be easier to see AbbVie rerated from 12 to 16 times earnings on the expanded label, but not necessarily a rerating from 16 to 20 times forward earnings. That said, even if price appreciation doesn't arrive as rapidly as Kumar anticipates, other strengths could pave the way for strong long-term returns for shares.
Besides appreciation potential, don't forget AbbVie's status as one of the blue chip dividend stocks. With a 2.6% forward dividend yield, AbbVie has raised its dividend for 13 consecutive years, ever since its spinoff from Abbott Laboratories, itself one of the Dividend Kings, in 2013. Dividend Kings are stocks that have increased their dividend payouts for at least 50 consecutive years.
Over the past three years, dividend growth has averaged between 5% and 6%. Considering these additional strengths, keep in mind that AbbVie shares could still perform well, even if Kumar's bull case doesn't go off without a hitch.
AbbVie snížila výhled upraveného zisku na akcii (EPS) pro 3. čtvrtletí 2026 na 3,73 až 3,77 USD, což je pod konsensem 3,85 USD, kvůli nákladům ve výši 216 milionů USD.
AbbVie (NYSE:ABBV – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.730-3.770 for the period, compared to the consensus EPS estimate of 3.850. The company issued revenue guidance of -.
Wall Street Analyst Weigh In A number of equities research analysts have issued reports on the company. HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Canaccord Genuity Group increased their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Oppenheimer lifted their price target on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Royal Bank Of Canada upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a report on Friday, July 10th. Finally, Barclays increased their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $272.39.
View Our Latest Stock Analysis on ABBV
AbbVie Stock Up 1.2% Shares of AbbVie stock opened at $265.93 on Tuesday. The stock has a market capitalization of $469.84 billion, a P/E ratio of 75.12, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24. The company has a 50-day simple moving average of $258.05 and a 200 day simple moving average of $235.01. AbbVie has a 12-month low of $190.75 and a 12-month high of $269.39. AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie will post 14.05 earnings per share for the current year.
AbbVie Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.
Insider Buying and Selling at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.
AbbVie News Roundup Here are the key news stories impacting AbbVie this week:
Positive Sentiment: AbbVie and partner Genmab reported positive Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The treatment produced a statistically significant and clinically meaningful improvement in progression-free survival versus R-CHOP alone, potentially expanding epcoritamab into frontline treatment and supporting future regulatory filings. AbbVie and Genmab lymphoma trial announcement Positive Sentiment: The lymphoma result strengthens AbbVie’s bispecific-antibody strategy and could add a new growth opportunity as the company seeks to diversify beyond its mature immunology portfolio. Reports indicated the combination reduced the risk of progression or death by approximately 51%. AbbVie lymphoma trial risk reduction report Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s treatment, described as the first approved selective D1/D5 drug, adding another commercial product to the company’s neuroscience franchise. AbbVie Parkinson’s treatment approval Neutral Sentiment: AbbVie joined a federal 340B rebate pilot program ahead of its planned 2027 launch. The impact is uncertain, but the program could influence future pricing and reimbursement for participating medicines. AbbVie 340B rebate pilot Negative Sentiment: AbbVie lowered third-quarter 2026 adjusted EPS guidance to $3.73–$3.77, below the approximately $3.85 analyst consensus, after including $216 million of acquired in-process research and development and milestone expenses. Full-year adjusted EPS guidance was reduced to $13.76–$13.96 from $13.87–$14.07. AbbVie updated earnings guidance About AbbVie (Get Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
Featured Articles Five stocks we like better than AbbVie NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Kombinace epcoritamabu s R-CHOP ve studii fáze III snížila u nově diagnostikovaného DLBCL riziko progrese onemocnění nebo úmrtí o 51 % oproti samotnému R-CHOP.
Key Takeaways AbbVie's epcoritamab plus R-CHOP significantly improved PFS versus R-CHOP alone in frontline DLBCL.The combination reduced the risk of disease progression or death by 51% in the phase III study.Epcoritamab plus R-CHOP was generally well tolerated, with a safety profile consistent with prior reports. AbbVie (ABBV - Free Report) , along with Genmab (GMAB - Free Report) , announced positive top-line data from the phase III EPCORE DLBCL-2 study, which evaluated epcoritamab in combination with standard-of-care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), with an International Prognostic Index (IPI) score of two to five.
Year to date, shares of AbbVie have rallied 19.1% compared with the industry’s increase of 11.4%.
Image Source: Zacks Investment Research
What Did ABBV’s EPCORE DLBCL-2 Study Results Show?The open-label, multicenter, randomized EPCORE DLBCL-2 study evaluated the efficacy of fixed treatment duration,epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with R-CHOP versus R-CHOP alone in the given patient population.
The study met its primary endpoint, wherein treatment with epcoritamab plus R-CHOP demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with R-CHOP alone. The combo of epcoritamab + R-CHOP reduced the risk of disease progression or death by 51%.
Per the company, this is the first phase III study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in PFS in frontline DLBCL.
The results were based on the first planned efficacy interim analysis. Following the significant benefit observed, the Independent Data Monitoring Committee recommended unblinding the study.
The safety profile of epcoritamab in combination with R-CHOP was generally well tolerated and similar to previously reported safety profiles of the individual treatments.
AbbVie and Genmab plan to engage with global regulatory bodies to determine the next steps of development for the investigational combination of epcoritamab plus R-CHOP.
More on ABBV’s Epcoritamab Development ProgramAbbVie currently markets epcoritamab under the brand name Epkinly in the United States and Japan, and as Tepkinly in the European Union.
Epkinly/Tepkinly is already approved as monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory follicular lymphoma (R/R FL) after two or more lines of systemic therapy.
In July 2026, the EC approved Tepkinly in combination with rituximab and lenalidomide (Tepkinly+R2) for adult patients with R/R FL after at least one line of systemic therapy.
The FDA approved Epkinly in combination with rituximab and lenalidomide for a similar indication in the United States in November 2025.
AbbVie has partnered with Denmark-based Genmab to jointly develop epcoritamab under the companies' oncology collaboration agreement. While both companies share commercialization rights in the United States and Japan, AbbVie is responsible for commercialization in other global markets.
AbbVie and Genmab continue to advance their global development and regulatory expansion while evaluating the therapy as a monotherapy and in combination regimens across multiple hematologic malignancies through several late-stage clinical studies.
ABBV’s Zacks Rank & Stock to ConsiderAbbVie currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the large-cap pharma sector is Pfizer (PFE - Free Report) , currently holding a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for Pfizer’s 2026 earnings per share have risen from $2.95 to $2.98, while estimates for 2027 have increased from $2.85 to $2.95 during the same time. PFE’s shares have surged 15.8% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.62%.
Nákup akcií AbbVie po schválení přípravku Rinvoq v roce 2019 přinesl celkový výnos 449,39 %, oproti 356,86 % po schválení přípravku Skyrizi, protože akcie po oznámení akvizice společnosti Allergan zlevnily.
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Every recent milestone entry point in AbbVie (NYSE:ABBV | ABBV Price Prediction) made money. What separates them is the size of the gain. In 2019, the better entry came during a period of pessimism. Buying on the Rinvoq approval, after the Allergan selloff, beat buying on the earlier Skyrizi approval. The good news turned out to be the more expensive time to buy.
Each return shown below is calculated from the milestone’s closing price to the $265.76 close on October 5, 2026. Returns are adjusted for splits and dividends; total return is the full gain measured on that basis.
Spinoff Day Started the Hunt for Humira’s Successor AbbVie began trading on its own on January 2, 2013, after separating from Abbott Laboratories (NYSE:ABT). It launched with one main product, Humira, and its story since then has been about finding a replacement for Humira.
Adjusted entry price: $20.38 $1,000 is now worth: $13,038.50 Total return: 1,203.85% Skyrizi’s Approval Was Good News at a Higher Price Skyrizi, approved April 23, 2019, was the first immunology drug built to succeed Humira. Second-quarter 2026 sales reached $5.51 billion, up 24.4%.
Adjusted entry price: $58.17 $1,000 is now worth: $4,568.60 Total return: 356.86% Rinvoq Arrived After the Allergan Selloff Rinvoq, approved August 16, 2019, was the second Humira replacement. Between the two approvals, AbbVie announced its $63 billion Allergan deal and the stock fell, creating the best entry of 2019. Second-quarter 2026 Rinvoq sales were $2.53 billion, up 24.5%.
Adjusted entry price: $48.37 $1,000 is now worth: $5,493.90 Total return: 449.39% Allergan Closed Ahead of the Revenue Cliff The Allergan deal closed May 8, 2020, moving AbbVie into aesthetics and neuroscience before Humira sales declined. Neuroscience revenue grew 20.3% to $3.23 billion in the second quarter of 2026.
Adjusted entry price: $65.74 $1,000 is now worth: $4,042.59 Total return: 304.26% First U.S. Humira Biosimilar Marked the Cliff’s Arrival The first U.S. Humira biosimilar reached the market January 31, 2023. Humira sales fell 35.9% to $756 million in the second quarter of 2026.
Adjusted entry price: $130.47 $1,000 is now worth: $2,036.94 Total return: 103.69% ImmunoGen Added an Oncology Pipeline The ImmunoGen acquisition, completed February 12, 2024, added cancer drugs, while Imbruvica, AbbVie’s older cancer drug, declined 29.4% in second-quarter 2026.
Adjusted entry price: $158.99 $1,000 is now worth: $1,671.50 Total return: 67.15% AbbVie Beat the S&P 500 Over Every Trailing Window AbbVie versus the price-only SPDR S&P 500 ETF Trust (NYSEARCA:SPY):
AbbVie SPY Year to date 19.1% 13.6% One year 17.2% 15.8% Five years 192.3% 78.2% Ten years 536.9% 260.3% Milestone Headlines Report Moves That Have Already Been Made The Rinvoq buyer held the stock for about four months less than the Skyrizi buyer yet earned more. Entry price mattered more than holding period. Watch the rollout of an injectable form of Skyrizi for Crohn’s disease, which management expects to boost sales beginning in early 2027. Also watch the 2026 adjusted EPS guidance range of $13.76 to $13.96.
Contact [email protected] for any questions or corrections.
AbbVie zveřejní 30. října výsledky za třetí čtvrtletí poté, co její čisté tržby vzrostly v prvním čtvrtletí 2026 o více než 12 % a ve druhém čtvrtletí 2026 o více než 10 %.
AbbVie (ABBV -1.60%) is a top healthcare company that's been doing well this year, rising by 17% in value, which is better than the S&P 500 and its gains of around 14%. It's been beating the market, and what could send its shares even higher is a strong earnings report for the third quarter.
In a few weeks, on Oct. 30, AbbVie will release its Q3 numbers. Here's why investors may want to consider buying the healthcare stock before then.
Image source: Getty Images.
The results are likely to be strong, againIn the past two quarters, AbbVie has generated strong growth, with its net revenue rising by more than 12% in the first quarter of 2026 and then by over 10% in the second quarter. The company's top-selling drugs, Rinvoq and Skyrizi, have also been obtaining more approvals from regulators, particularly in Europe, which could lead to stronger growth ahead.
The business has been doing extremely well, and yet there's still room for improvement in its oncology and aesthetics segments, which experienced modest declines in the second quarter.
With a broad and diverse business, AbbVie is in an excellent position to grow in both the short term and over the long run. Another period of double-digit growth could give investors an incentive to pile more money into this relatively safe healthcare stock, especially given how cheap it looks right now.
Premium Feature
Moneyball Superscore
80/100
Today's Change
(
-1.60
%) $
-4.26
Current Price
$
261.50
AbbVie's low valuation makes the stock a great buy right nowAcquisitions have bolstered AbbVie's business over the years, but one-time charges have also weighed down its financials in the process, which is why the stock may look expensive, with its price-to-earnings (P/E) multiple being a hefty 75. But based on its estimated future profits, its forward P/E multiple is just 16. By comparison, the average stock on the S&P 500 trades at close to 20 times its future profits.
And if its valuation wasn't enough of a reason to buy the stock, then the dividend could make AbbVie a no-brainer buy. At 2.6%, it’s a solid payout from a company that has an excellent track record of growing its dividend over the years.
For investors looking for a relatively safe stock to invest in, AbbVie is an attractive option for its modest valuation and excellent overall fundamentals. This is a stock that can be an excellent pillar to build a portfolio around and to simply hang on to for the long haul.
AbbVie se připojí k pilotnímu programu americké vlády, který od 1. ledna 2027 testuje nový systém rabatů na léky s nízkou cenou v rámci 340B. Program se bude týkat Imbruvica, Linzess a Vraylar.
US drugmaker AbbVie (ABBV.N) said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
Here are some details:
The pilot will begin on January 1, 2027, under the government's 340B program, which helps hospitals and clinics serving low-income patients buy medicines at a discount.
Under the new model, eligible healthcare providers will submit claims through a platform called Beacon to obtain 340B pricing on AbbVie's cancer drug Imbruvica, irritable bowel syndrome treatment Linzess and antipsychotic drug Vraylar.
AbbVie said it would provide healthcare groups with free access to the system, as well as customer service and special assistance for providers facing operational difficulties.
The rebate test will help improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect, the company said.
AbbVie said it plans to work closely with federal health regulators and healthcare providers throughout the rollout.
Besides AbbVie, Amgen (AMGN.O), AstraZeneca (AZN.L), Pfizer (PFE.N) and Bristol Myers Squibb (BMY.N) are among the companies approved for the federal pilot.
AbbVie získala od FDA schválení pro Juvmo, lék užívaný jednou denně na Parkinsonovu chorobu, s plánovaným uvedením na trh v říjnu 2026. Spolu s Vyalev a Duopa má cílit na více než 5 miliard USD vrcholových tržeb.
Key Takeaways AbbVie adds Juvmo to its Parkinson's portfolio, offering standalone and combination treatment options.Juvmo is the first selective D1/D5 dopamine receptor agonist approved for Parkinson's disease.AbbVie expects its three Parkinson's therapies to represent a peak-sales opportunity above $5 billion. AbbVie (ABBV - Free Report) continues to expand its neuroscience franchise. The company recently secured FDA approval for Juvmo, a once-daily oral treatment for Parkinson’s disease (PD). A commercial launch is targeted for October 2026.
Juvmo Expands AbbVie’s Neuroscience PortfolioJuvmo is a potentially important addition to AbbVie’s PD portfolio, given its differentiated mechanism and broad treatment positioning. The drug is the first selective D1/D5 dopamine receptor agonist that can be used both as a standalone treatment and in combination with levodopa, the current standard of care for PD symptoms. This provides physicians another option for managing motor symptoms as the disease progresses and could help address the limitations associated with increasing reliance on levodopa.
Juvmo’s approval further expands AbbVie’s PD portfolio, which already includes Vyalev and Duopa. PD has emerged as a new pillar of the company’s neuroscience franchise, with management expecting the three therapies to collectively represent a peak-sales opportunity of more than $5 billion.
The neuroscience segment is one of AbbVie’s fastest-growing therapeutic areas. It now accounts for nearly a fifth of the company’s overall topline and generated $6.1 billion in revenues in the first half of 2026. Revenues from neuroscience drugs rose 22% year over year, driven by broad-based growth across the marketed portfolio. The company currently expects to record approximately $12.7 billion in neuroscience revenues in 2026.
The approval could also provide a commercial payoff from AbbVie’s acquisition of Cerevel Therapeutics for approximately $8.7 billion in 2024. The deal came under pressure after emraclidine, one of its key assets, failed in two registration-enabling phase II studies in schizophrenia, prompting AbbVie to record a $3.5 billion impairment charge. With Juvmo now approved, its commercial performance could become an important part of the value story behind the Cerevel acquisition.
ABBV’s Competition in the Neuroscience SpaceOther bigger players in the neuroscience space include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
JNJ's neuroscience business is anchored by the depression therapy Spravato and the long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
Five dividend payers across four sectors promise to keep raising payouts through the next downturn, but one of them carries a GAAP payout ratio above 100% and a negative book value that would alarm most income investors at first glance.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
An income portfolio built inside one sector carries one set of risks. This basket spreads five dividend payers across four sectors: consumer staples with Coca-Cola (NYSE:KO | KO Price Prediction) and PepsiCo (NASDAQ:PEP), financials with JPMorgan Chase (NYSE:JPM), real estate with Realty Income (NYSE:O) and healthcare with AbbVie (NYSE:ABBV). The sections run by sector because the goal is diversity in a single basket, and each name is judged on the payout measure that fits its business. What ties them together is cash flow that keeps funding raises, and the latest proof arrived when JPMorgan declared a quarterly dividend of $1.65, up from $1.50, on September 15, 2026.
Company Sector Dividend Yield Forward Annual Dividend Coverage Metric Used Coca-Cola Consumer Staples 2.34% $2.12 Free cash flow PepsiCo Consumer Staples 4.35% $5.92 Free cash flow conversion JPMorgan Chase Financials 1.77% $6.6 Earnings and capital Realty Income Real Estate 5.58% $3.258 AFFO AbbVie Healthcare 2.58% $6.92 Adjusted (cash) earnings Coca-Cola: Consumer Staples Quality Anchor Coca-Cola yields 2.34%, the second-lowest payout in this group. Its job in the basket is stability, and the cash math supports it. Management raised its 2026 free cash flow guidance to about $12.4 billion from $12.2 billion, built on roughly $14.6 billion of operating cash flow less about $2.2 billion of capital spending. The forward dividend of $2.12 per share falls well inside trailing EPS of $3.33.
The quarterly dividend rose to $0.53 in 2026 from $0.51 in 2025. The verified payment record shows a higher quarterly amount in every year from $0.28 in 2013 through today, with regular quarterly payments running back to 1999. Coca-Cola’s longer streak is part of its reputation, but the exact consecutive-year count falls outside the history verified for this piece, so the 13-plus years of documented raises is the claim that holds up here. Cash of $12.9 billion and a debt-to-equity ratio of 1.47 add buffer.
Bull case: Coca-Cola is compounding faster than a mature staple should. Second-quarter revenue rose 6.7% to $13.38 billion, adjusted EPS of $0.97 beat the $0.93 estimate, and global unit case volume grew 5% with Coca-Cola Zero Sugar up 16%. Management guides comparable EPS growth of 9-10% for 2026, and FIFA World Cup activation across 180+ markets gives volume another boost. Investors have noticed: shares are up 27.14% year to date at $87.18, against an analyst target of $94.7.
Risk: Valuation. At 26 times trailing earnings, investors pay a premium for a yield near 2%. If volume growth cools after the World Cup lift, the multiple has room to compress, and Asia Pacific price/mix already fell 9%. The fourth quarter also carries six fewer days than a year ago, along with the pending African bottler sale and ongoing IRS tax litigation.
PepsiCo: Staples Yield With a Verified Dividend King Streak PepsiCo is the high-yield staple of the pair at 4.35%. The 4% hike that took effect with the June 2026 payment was, in management’s words, the 54th consecutive annual increase, which puts PepsiCo in Dividend King territory. The payment record supports the pattern: the quarterly dividend moved from $1.355 to $1.4225 to $1.48 over the last three raises, and it climbed from $0.13 in 1999 along the way.
Coverage is lower than Coca-Cola’s but still intact. The forward dividend of $5.92 compares with trailing EPS of $7.63. PepsiCo targets free cash flow conversion of at least 80% of net income with capex below 5% of net revenue, and it plans about $8.9 billion in 2026 cash returns, roughly $7.9 billion in dividends and $1.0 billion in buybacks. Leverage is the heavier of the two staples at a debt-to-equity ratio of 2.45, offset by $10.25 billion in cash.
Bull case: Shares are priced for disappointment while the business grinds higher. Shares are down 7.74% year to date and 7.93% over the past month at $128.5, trading at 15 times forward earnings. Meanwhile second-quarter revenue rose 6.4% to $24.18 billion, LatAm Foods grew 15% and EMEA grew 10%. Full-year guidance for 2-4% organic revenue growth and 4-6% core constant-currency EPS growth was confirmed. If North American snacks stabilize, the analyst target of $153.86 becomes a realistic re-rating path, and investors collect a 4%-plus yield while waiting.
Risk: Pricing pushback. PepsiCo plans to raise prices on sodas, chips and dip, and Wall Street is worried about the volume response. Frito-Lay North America revenue already fell 2% on weaker pricing and core operating margin contracted 40 bps. If shoppers trade down again, earnings growth slows and the dividend raise pace could shrink toward token increases.
JPMorgan Chase: Financials Payer With the Most Room to Raise JPMorgan yields 1.77%, the lowest here, and that is the point. A low payout relative to earnings is what funds fast raises. Trailing dividends of $6 per share are a small portion of trailing EPS of $23.33. The newly declared $1.65 quarterly payment goes ex-dividend on October 6 and pays on October 31. The quarterly dividend stood at $1.05 in early 2024, so the bank has made five increases in under three years.
Capital is fortress-grade. The CET1 ratio stands at 14.3%, supports by $1.5 trillion in cash and marketable securities and a latest $50 billion buyback authorization effective July 1, 2026. One caveat on track record: JPMorgan cut its dividend during the 2009 financial crisis, so it carries no Aristocrat label. The growth rate since then is the income story.
Bull case: JPMorgan posted record revenue across every line of business in the second quarter. EPS of $7.70 beat the $5.80 consensus, and even stripping out a one-time equity-stake gain and other equity gains, adjusted EPS of $6.14 rose 13% with ROTCE of 23%. Investment banking fees rose 30%, loans grew 10% and deposits grew 7%. The asset management arm added a $20 billion strategic partnership with QIA on September 21. At 15 times trailing earnings and $336.75 per share, the stock trades below the $375.43 analyst target after a 4.39% slide over the past week.
Risk: Credit and cost creep. Card net charge-offs run at 3.33%, the total allowance for credit losses rose 12% to $31.4 billion, and noninterest expense climbed 15%. Dimon has flagged sticky inflation, geopolitical tensions and high asset prices. If a downturn hits trading and credit at the same time, buybacks slow first, and the dividend raise pace likely follows.
Realty Income: Real Estate Monthly Payer Judged on AFFO Realty Income yields 5.58%, the highest payout in the basket and clearly high-yield, though still below a 6% threshold. Dividends arrive monthly. On September 8, it declared its 136th monthly dividend increase, lifting the monthly payment to $0.2715 from $0.271. That follows 115 consecutive quarterly increases and 670 consecutive monthly dividends as of its first-quarter report.
Earnings payout ratios mislead for REITs because depreciation on buildings drags GAAP net income well below the cash a landlord actually collects. That is why the trailing P/E of 41 looks extended. AFFO adds back that noncash depreciation and deducts recurring capital needs, making it the right yardstick. Realty Income raised 2026 AFFO guidance to $4.44-$4.45 per share, well clear of the forward annualized dividend of $3.258. Second-quarter AFFO of $1.09 rose 3.8%, and Fitch assigned an “A” issuer default rating, marking the outlook stable.
Bull case: A recent selloff made the income cheaper without breaking the business. Shares fell 10.3% over the past month to $55.36, well below the $67.26 analyst target, while occupancy holds at 98.8% and re-leased properties recapture 102.7% of prior rent. Management lifted 2026 investment guidance to $10 billion at a 7.3% initial cash yield, formed a $6 billion hyperscale data-center joint venture, and on September 14 announced a euro-denominated joint venture to grow its private capital platform. Investment spreads that wide keep AFFO rising, and rising AFFO keeps the monthly raises coming.
Risk: Leverage and tenant quality. Net debt to adjusted EBITDAre rose to 5.4x from 5.2x, and 65.7% of annualized base rent is tied to tenants below investment grade. If rates stay high, refinancing costs eat into those investment spreads and the stock stays rate-sensitive. Second-quarter GAAP EPS of $0.37 also missed expectations of $0.42 on impairments. Shares go ex-dividend on September 30, with payment on October 15.
AbbVie: Healthcare Cash Machine Behind a Misleading GAAP Number AbbVie yields 2.58%. It declared its next quarterly dividend of $1.73 on September 10, payable November 16. The quarterly payout climbed from $1.55 in 2024 to $1.64 in 2025 to $1.73 in 2026, and from $0.40 in 2013, its first year as a standalone company.
Here is where GAAP and cash split. Trailing GAAP EPS is just $3.55, below trailing dividends of $6.83, and the trailing P/E reads 74. Read literally, that looks like a dividend in danger. GAAP earnings include large noncash charges, mainly amortization of acquired drug intangibles plus acquired R&D write-offs such as the $744 million IPR&D charge that cost $0.41 of first-quarter EPS. None of that reduces the cash available for dividends. The cash-based view is what counts: 2026 adjusted EPS guidance of $13.87-$14.07 falls far above the forward dividend of $6.92, and forward P/E drops to 16. Second-quarter operating income rose 31% to $6.43 billion.
Bull case: The transition past Humira is working. Skyrizi revenue rose 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion, while neuroscience grew 20.3% to $3.23 billion. Total second-quarter revenue rose 10.2% to $16.99 billion. The pipeline keeps delivering: the FDA approved JUVMO for Parkinson’s disease on September 28, and the $10.9 billion Apogee acquisition closed on September 3. Shares are up 19.29% year to date at $266.47, with an analyst target of $278.61.
Risk: Patent erosion and deal costs. Humira sales fell 35.9% and Imbruvica fell 29.4% in the second quarter. The Apogee deal carries $0.14 of near-term EPS dilution, and AbbVie runs with a negative book value of -3.359 per share. If drug-pricing or tariff policy tightens while Skyrizi and Rinvoq growth slows, the raise pace would narrow toward the low single digits.
One Basket, Four Sectors, One Common Thread Each of these five names covers its dividend on the metric that matters for its business: free cash flow for the staples, earnings and capital for JPMorgan, AFFO for Realty Income and cash earnings for AbbVie. Spreading income across staples, banking, real estate and pharma means a shock to one sector leaves most of the paycheck intact. PepsiCo and Realty Income carry the yield, JPMorgan and AbbVie carry the dividend growth, and Coca-Cola supports the whole basket. That mix is built to keep raising payouts through whatever the next cycle brings (if you want to go deeper on the longest-running raisers, we ranked ten of them by today’s valuations in a free Dividend Kings report).
Contact [email protected] for any questions or corrections.
AbbVie uvedla, že RINVOQ ve studiích fáze 3 dál zvyšoval repigmentaci u nonsegmentálního vitiliga až do 76. týdne. V kombinaci s fototerapií NB-UVB byly výsledky číselně vyšší než u samotného RINVOQ. RINVOQ je v Evropské unii schválen pro léčbu dospělých i dospívajících od 12 let s nonsegmentálním vitiligem, kteří jsou kandidáty systémové léčby.
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy Phase 3 Viti-Up-1 and Viti-Up-2 studies show that among patients continuing RINVOQ, the proportions who achieved facial (F-VASI 75) and total body (T-VASI 50) repigmentation continued to increase through week 76 Findings from a phototherapy substudy show numerically higher responses with RINVOQ in combination with narrowband ultraviolet B (NB-UVB) phototherapy than with RINVOQ alone Data are being shared in a late-breaking oral presentation at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.
Presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, data also include week-28 findings from a phototherapy substudy, in which treatment groups receiving RINVOQ plus whole-body narrowband ultraviolet B (NB-UVB) phototherapy showed numerically higher repigmentation responses than groups receiving RINVOQ alone.
"Vitiligo is a chronic, unpredictable disease that can affect skin across the body, underscoring the need for systemic treatment options that go beyond addressing individual areas," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. "These late-breaking data support that RINVOQ can provide meaningful long-term repigmentation for patients with vitiligo and provide an early foundation for further research into its combination with NB-UVB phototherapy."
Continued Repigmentation with RINVOQ Through 76 Weeks
Following the 48-week placebo-controlled period (Period A) in the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies, patients either entered an open-label extension (OLE) and received RINVOQ 15 mg once daily or entered a phototherapy substudy.
In patients who continued on RINVOQ 15 mg once daily in the OLE, proportions of patients achieving F-VASI 75 and T-VASI 50 continued to increase from week 48 through week 76. Results for F-VASI 75 and T-VASI 50 in both studies are shown in the tables below.
Viti-Up-1 & Viti-Up-2 Observed-Case Analyses
Viti-Up-1
Viti-Up-2
RINVOQ 15 mg
once daily at Week 48
(N=130)
Continued
RINVOQ 15 mg
once daily at Week 76
(N=127)
RINVOQ 15 mg
once daily at Week 48
(N=145)
Continued
RINVOQ 15 mg
once daily at Week 76
(N=137)
F-VASI 75*
33.1 %
55.1 %
27.6 %
47.4 %
T-VASI 50*
29.2 %
42.5 %
26.2 %
40.1 %
*F-VASI 75 = ≥75% reduction from baseline in Facial Vitiligo Area Scoring Index; T-VASI 50 = ≥50% reduction from baseline in Total Vitiligo Area Scoring Index
Findings With RINVOQ and NB-UVB Phototherapy
Following completion of Period A in Viti-Up-1 or Viti-Up-2, 84 adults who failed to achieve T-VASI 90 at week 48 and met additional eligibility criteria were re-randomized to receive RINVOQ 15 mg once daily alone or in combination with whole-body NB-UVB phototherapy twice weekly for 28 weeks.
All groups showed improvement in facial and total body repigmentation from baseline, with numerically higher response rates observed in the RINVOQ + NB-UVB phototherapy combination groups than in the RINVOQ monotherapy groups. Detailed F-VASI 75 and T-VASI 50 results are shown in the table below.
Efficacy at Week 28 (NRI*)
Viti-Up-1/2 Period A Treatment (Tx): Placebo
Phototherapy Substudy Tx:
RINVOQ
(N=15)
RINVOQ + NB-UVB
(N=15)
F-VASI 75
40.0 %
46.7 %
T-VASI 50
20.0 %
33.3 %
Viti-Up-1/2 Period A Tx: RINVOQ
Phototherapy Substudy Tx:
RINVOQ
(N=27)
RINVOQ + NB-UVB
(N=27)
F-VASI 75
37.0 %
59.3 %
T-VASI 50
33.3 %
63.0 %
*NRI = Non-responder Imputation
"These findings are important for physicians treating people with vitiligo because they extend our understanding of repigmentation with continued RINVOQ treatment and provide the first data on combining NB-UVB with an approved systemic JAK inhibitor," said Julien Seneschal, M.D., Ph.D., professor of dermatology at the National Reference Center for Rare Skin Diseases, University of Bordeaux, France. "This research opens an important path for further investigation into how combination approaches could evolve to support patient care in non-segmental vitiligo."
Safety results for week 76 in Viti-Up-1 and Viti-Up-2 and for week 28 in the phototherapy substudy were consistent with the known safety profile of upadacitinib and with the profile observed during the 48-week Period A; no new safety signals were reported.
RINVOQ is the first and only systemic medication approved in the European Union for the treatment of adult and adolescent patients 12 years and older with NSV who are candidates for systemic therapy. The approval was based on results from the Phase 3 Viti-Up clinical program at week 48 versus placebo. The use of RINVOQ in non-segmental vitiligo is under regulatory review by the U.S. FDA.
About Viti-Up Clinical Trials
Viti-Up (upadacitinib M19-044) consists of two ongoing replicate Phase 3 studies (Viti-Up-1 and Viti-Up-2) conducted under a single protocol, with independent randomization, investigative sites, data collection, analysis and reporting for each study. The trials evaluate the efficacy, safety and tolerability of upadacitinib in adult and adolescent patients (ages 12 and older) with non-segmental vitiligo (NSV) who are candidates for systemic therapy. In Period A of both studies, participants were randomized in a 2:1 ratio to receive either upadacitinib 15 mg once daily or placebo for 48 weeks. Participants who completed Period A were eligible to enter Period B, an 112-week open-label extension in which all patients, including those initially randomized to placebo, received upadacitinib 15-mg once daily; together, Periods A and B span 160 weeks. The two studies randomized 614 participants with NSV across 90 sites worldwide. Following completion of Period A in Viti-Up-1 or Viti-Up-2, 84 adults who failed to achieve T-VASI 90 at week 48 and met additional eligibility criteria were re-randomized to receive RINVOQ 15 mg once daily alone or in combination with whole-body NB-UVB phototherapy twice weekly for 28 weeks.
More information on these trials can be found at www.clinicaltrials.gov (NCT06118411).
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,2 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1
Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.
EU Indications and Important Safety Information about RINVOQ® (upadacitinib)1
Indications
Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.
Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Important Safety Information
Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.
Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:
- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)
Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.
Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.
Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.
Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.
Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.
Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.
Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.
Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.
Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.
Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.
Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.
Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.
Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.
Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.
Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.
Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.
Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.
Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.
Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.
The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.
The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.
The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.
The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.
The most common serious adverse reactions were serious infections.
The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.
RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.
This is not a complete summary of all safety information.
See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu
Globally, prescribing information varies; refer to the individual country product label for complete information.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
RINVOQ. Summary of product characteristics. AbbVie; 2026. Pipeline. AbbVie. 2026. Accessed September 8, 2026. https://www.abbvie.com/our-science/pipeline.html ALL-RNQD-260137
Článek uvádí, že pět dividendových titulů prochází testem krytí dividend; největší rezervu mají Johnson & Johnson a Gaming and Leisure Properties. Tři z nich navíc vyplácejí více než 10letý Treasury s výnosem 5,18 %.
With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The 10-year Treasury now pays 5.18%, its highest reading of the past year as of Sept. 24. That raises the bar for every income stock. A dividend payer yielding less than a risk-free bond has to earn its place through growth, and one yielding more has to prove the payout is funded by real cash. This basket runs five names through the coverage metric that fits each business: free cash flow for the drugmakers, adjusted funds from operations (AFFO) for the REITs, and distributable cash flow for the pipeline partnership. Three of the five out-yield Treasuries. All five pass, and the margins of safety vary more than the yields suggest.
Gaming and Leisure Properties: An 8.32% Yield With the Most Room Among Ultra-High Yielders Gaming and Leisure Properties (NASDAQ:GLPI) yields 8.32%, which clears the ultra-high-yield threshold and tops the 10-year Treasury well. The quarterly dividend stands at 82 cents, or $3.28 on an annualized forward basis.
Dividend safety read: AFFO is the right metric for a triple-net REIT because it strips out non-cash depreciation that distorts GAAP earnings. Second-quarter AFFO came in at $304 million, or $1.03 per diluted share, up 10.1% year over year, with full-year 2026 AFFO guidance raised to $4.10 to $4.12 per share. Set that against a $3.28 annualized dividend and the cushion is wide. Leverage sits at 4.8x net debt to adjusted EBITDA, below the company’s 5x to 5.5x target range, giving it the ability to fund its pipeline without issuing new equity. The dividend history shows steady steps higher: 76 cents through 2024, 78 cents through 2025 and a 5.1% raise to 82 cents in the second quarter of 2026.
Bull case: Growth is already contracted. A $2.02 billion development pipeline carries a blended 8.77% cap rate, and management projects per-share AFFO growth of through 2027 and into 2028. Second-quarter adjusted EBITDA rose 12.2% to $405.5 million, and the vast majority of tenant rent coverage sits above 1.8x. The shares trade with a 50-day moving average of $42.79, below the 200-day average of $45.26 and well under the $52.39 analyst target. Sentiment leans positive, with 6 Strong Buy and 10 Buy ratings against 7 Holds and 1 Strong Sell.
Risk: Tenant concentration. A few of regional casino operators generate most of the rent, and the weakest master lease covers rent at only 1.59x. Construction on a Chicago casino project adds execution risk. If a major tenant hits a gaming downturn, lease coverage compresses first, and that is where investors should look before the dividend ever feels pressure.
Western Midstream: An 8.33% Distribution Backed by Guided Cash Flow Western Midstream (NYSE:WES | WES Price Prediction) yields 8.33%, the second ultra-high yielder in the group. The quarterly distribution is 93 cents per unit, or $3.72 annualized, with $3.68 paid over the trailing 12 months. As a master limited partnership, it issues a K-1 at tax time.
Distribution safety read: Distributable cash flow is the correct test for an MLP, and 2026 guidance calls for $1.85B to $2.05B, or $4.59 to $5.08 per unit. Even the low end sits well above the $3.72 annualized payout, and management expects results toward the high end of its ranges. First-quarter adjusted EBITDA hit a record $683.1M, up 15% year over year. The partnership holds an investment-grade balance sheet with roughly $2.0 billion of liquidity, and fee-based contracts with minimum-volume commitments protect cash flow when volumes wobble. The track record deserves a clear-eyed read: The quarterly payout climbed from 57 cents in early 2024 to 87 cents later that year and to 93 cents today, but it was cut from 62 cents to 31 cents in 2020.
Bull case: The $1.6 billion Brazos Delaware II acquisition adds roughly $100 million of additional EBITDA in 2026, and the Aris Water integration has captured about 85% of a $40 million synergy target. At 11 times forward earnings, the units price in modest expectations for a business guiding toward the top of its range.
Risk: Growth spending is eating into the cushion. Second-quarter capital expenditures of $741.791 million exceeded operating cash flow of $524.847 million, and free cash flow after distributions was -$137.4 million in the first quarter. If producers pull back drilling plans while capex stays elevated, the partnership leans harder on its balance sheet to hold the payout.
Realty Income: 5.93% Monthly Income With AFFO Coverage Intact Realty Income (NYSE:O) yields 5.93%. That is high-yield territory rather than ultra-high-yield, and it sits only slightly above the 5.18% Treasury, the thinnest premium among the three names that beat the risk-free rate. The next ex-dividend date is September 30, 2026.
Dividend safety read: Second-quarter AFFO rose 3.8% to $1.09 per share, while monthly dividends paid in the quarter totaled to 81 cents per share. Full-year AFFO guidance moved up to $4.44 to $4.45, well clear of the annualized dividend of $3.252 as of June 30. The company reported its 115th consecutive quarterly dividend increase and 670 monthly dividend announcements in a row. Fitch rates it ‘A’ with a Stable Outlook, and occupancy stands at 98.8%.
Bull case: The acquisition engine is accelerating. Realty Income invested $2.6 billion in the second quarter at a 7.3% initial cash yield and raised 2026 investment guidance to $10 billion. A $6 billion large-scale data center joint venture and a management platform with $3.5 billion of third-party assets open new growth opportunities beyond retail. A free cash flow yield of 7.35% supports continued raises.
Risk: Leverage is moving the wrong way. Net debt to annualized pro forma adjusted EBITDAre rose to 5.4x from 5.2x in the first quarter, and 65.7% of annualized base rent is tied to tenants below investment grade. With the 10-year yield up 0.54% in a month, higher refinancing costs pinch the spread between what Realty Income earns on new deals and what it pays to fund them. Analysts reflect that caution, with 15 Hold ratings.
AbbVie: Why Free Cash Flow Tells the Real Dividend Story AbbVie (NYSE:ABBV) yields 2.62% at a share price of $264.28. That trails the Treasury, so AbbVie earns its spot through coverage strength and payout growth rather than raw yield.
Dividend safety read: On paper, the payout looks extended. Trailing GAAP earnings per share of $3.55 sit below the $6.83 dividend per share, which puts the GAAP payout ratio above 100%. That figure misleads because GAAP earnings include huge non-cash charges tied to past acquisitions. In 2025, AbbVie booked net income of $4.226 billion but recorded $8.139 billion in depreciation and amortization, an expense that uses no cash. Free cash flow shows what actually funds the check: operating cash flow of $19.03 billion, less capital expenditures of $1.214 billion, still exceeds the $11.657 billion paid in dividends by a wide margin. Adjusted EPS guidance of $13.87 to $14.07 for 2026 tells the same story.
Bull case: The post-Humira transition is working. Skyrizi grew 24.4% to $5.505B and Rinvoq rose 24.5% to $2.525 billion in the second quarter, more than offsetting a 35.9% Humira decline. Adjusted EPS of $3.65 beat the $3.08 consensus on revenue of $16.99 billion, up 10.2%. Chief executive Robert A. Michael said “AbbVie delivered another excellent quarter… long-term outlook remains very strong.” The stock trades at 16x forward earnings after an 14.97% year-to-date gain.
Risk: The quarterly cushion narrowed in 2026. Second-quarter operating cash flow of $3.436 billion only slightly exceeded the $3.07 billion dividend payment, and the roughly $10.9 billion Apogee Therapeutics acquisition adds dilution and integration demands. Should Skyrizi and Rinvoq growth slow while Imbruvica keeps sliding (down 29.4%), the dividend growth rate is the first thing to give.
Johnson & Johnson: AAA Credit Behind a Payout Ratio That Is Creeping Higher Johnson & Johnson (NYSE:JNJ) yields 2%, the lowest in the group and well under the Treasury. Its case rests on balance-sheet quality: It is one of only two U.S.-based companies with a AAA credit rating.
Dividend safety read: The direction of the payout ratio is the key tell. In the second quarter of 2025, J&J earned net income of $5.537 billion and paid $3.129 billion in dividends. A year later, net income was essentially flat at $5.534 billion while dividends rose to $3.227 billion. Quarterly earnings growth of -0.9% against a dividend raise from $1.30 to $1.34 per share (3.1%) means the payout ratio edged up over the trailing year. The starting point remains conservative: trailing EPS of $8.62 against a $5.24 dividend per share, and 2025 free cash flow of $19.7B against $12.381 billion in dividends. In absolute dollars, no name here has more room.
Bull case: Newer drugs are carrying the load. First-quarter sales of DARZALEX rose 22.5% to $3.96 billion, TREMFYA jumped 68.3% to $1.61 billion and CARVYKTI climbed 62.1% to $597 million. Guidance calls for 2026 revenue of $100.3 billion to $101.3 billion and adjusted EPS of $11.45 to $11.65, which would pull the adjusted payout ratio back in the right direction.
Risk: STELARA biosimilars. Sales fell 59.7% in the first quarter, a roughly 920bps drag on Innovative Medicine, and litigation charges added $330 million. First-quarter operating cash flow of $2.514 billion came in below the $3.131 billion dividend, a reminder that quarterly cash is lumpy. If the planned Orthopaedics separation or patent cliffs slow earnings growth further, the payout ratio keeps drifting up.
Coverage Scorecard: Who Passes With the Most Room Johnson & Johnson and Gaming and Leisure Properties pass with the widest cushions, one on AAA-rated free cash flow and the other on AFFO guidance paired with leverage below target. Western Midstream and AbbVie clear their correct metrics well, though growth spending and a big acquisition trim their near-term margin. Realty Income passes on AFFO with the smallest balance-sheet room as leverage climbs. With the 10-year Treasury at 5.18%, only GLPI, WES and O pay more than the risk-free rate, and coverage is what separates the yields worth owning from the ones that merely look generous (we listed the seven warning signs that a fat yield is about to be cut, available here: Dividend Traps).
Contact [email protected] for any questions or corrections.
AbbVie uvedla, že ABBV-295 v 1. fázi vykázal poločas 10,7–12,3 dne a významné snížení hmotnosti, což podporuje další testování ve 2. fázi. Léčba byla obecně dobře snášena.
Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens ABBV-295 showed meaningful body weight reduction and a favorable tolerability profile at all evaluated dose levels, with topline results announced earlier this year Findings support advancement of ABBV-295 — a non-incretin, amylin-based mechanism — into Phase 2 development for chronic weight management , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting (Milan, Italy; September 28 – October 2). The study evaluated the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, an investigational long-acting amylin analog, in adults with a mean body mass index (BMI) of less than 30 kg/m2.
These detailed results being presented are from the 60 participants in Part 2B/2C of the MAD study, who were randomized to receive ABBV-295 (n = 45) or placebo (n = 15). Participants had a mean age of 41.5 years and a mean BMI of 29.3 kg/m2, and 88% were male. ABBV-295 was dose-escalated to 4, 6, or 14 mg once weekly, 14 mg every other week, or 8 mg monthly, and administered for 12 or 13 weeks.1 ABBV-295 is an investigational therapy that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists.1,2
"As the obesity treatment landscape evolves, we remain focused on bringing forth differentiated approaches that help expand available therapeutic options for people living with this complex disease," said Primal Kaur, M.D., senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie. "These detailed results showed meaningful weight loss alongside a half-life that could support dosing less frequently than once weekly, and they reinforce the scientific rationale for targeting the amylin pathway. We look forward to advancing ABBV-295 into Phase 2 development."
Key highlights from the short oral presentation include:
Pharmacokinetic profile supports evaluation of dosing intervals beyond weekly administration: ABBV-295 demonstrated dose-proportional increases in plasma exposure across cohorts. Median Tmax ranged from 24.0 to 48.1 hours, and the mean half-life ranged from 10.7 to 12.3 days, a profile that supported the once-weekly, every-other-week, and monthly regimens evaluated in the study.1 Gastrointestinal (GI) safety findings: GI adverse events (AEs) were predominantly mild and occurred primarily during the first six weeks of treatment. Among participants who reported a GI AE, 92% reported mild events as the highest severity. Nausea was reported in 33.3% of participants receiving ABBV-295 compared with 20.0% receiving placebo. Diarrhea was reported in 20.0% of participants receiving ABBV-295 compared with 0.0% receiving placebo. No severe GI AEs were reported, and discontinuations due to GI AEs were infrequent overall (4.4% vs. 0.0%, all active vs. placebo).1 Tolerability: No serious treatment-emergent adverse events (TEAEs) were reported, and most events were mild. The most commonly reported adverse events (AEs) >20% were decreased appetite, fatigue, headache, nausea, and diarrhea.1 Meaningful weight loss observed across weekly, every-other-week, and monthly regimens: ABBV-295 demonstrated dose-dependent reductions in body weight over a 12- to 13-week treatment period. Least-squares (LS) mean body weight reductions ranged from -7.8% to -9.8% at Week 12 for the once-weekly dosing cohorts and were -9.7% for the every-other-week cohort and -7.9% for the monthly cohort at Week 13, compared with approximately -0.3% for placebo.1 "Obesity is a chronic disease that requires long-term treatment, and the practical realities of therapy, such as how often someone has to take medication and how they feel while doing it, matter a great deal for patients to stay on treatment," said Juan Pablo Frías, M.D., Medical Director and Primary Investigator at Los Angeles Institute for Metabolic Research and study author. "In this Phase 1 study, ABBV-295 demonstrated meaningful weight loss across multiple dosing regimens and a pharmacokinetic profile supportive of further evaluation of extended dosing intervals. Together, these findings support continued development of this investigational therapy for patients."
EASD Presentation Details:
Abstract Title
Date/Time
Session
Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog for the treatment of obesity
Wednesday, September 30, 2026; 11:45 AM–12:45 PM CEST
LBA SO 07 Trials of tomorrow: new therapeutic horizons
Session C
ABBV-295 is an investigational asset and has not been approved for use by global regulatory authorities.
About ABBV-295
ABBV-295 is an investigational, long-acting amylin analog being developed for the treatment of obesity. Amylin, a satiety hormone, has been identified as a potential therapeutic target for the treatment of obesity given its role in activating signals to the brain that result in appetite suppression and the reduction of food intake, while also acting as an inhibitory signal to delay gastric emptying. ABBV-295 has not been approved by any health regulatory authority worldwide. The safety and efficacy of ABBV-295 have not been established.
About the Phase 1 GUC17-01 Study3
The Phase 1 clinical trial is a two-part, single-center, double-blind (within cohorts), randomized, placebo-controlled, single (Part 1) and multiple (Part 2) ascending dose study of subcutaneous ABBV-295. A total of 76 healthy adult participants were enrolled in the MAD study. In Parts 2B and 2C, participants had a BMI of 27.0 to 35.0 kg/m2. The primary objective is to assess the safety and tolerability of ABBV-295. Key secondary objectives are to characterize pharmacokinetics (PK) and to investigate pharmacodynamic effects. More information on this trial can be found at https://clinicaltrials.gov/ (NCT06144684).
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
Leaback R, Chowdhury E, Ferguson WG, et al. Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog for the treatment of obesity. Presentation ID LBA 87. Presented at: European Association for the Study of Diabetes Annual Meeting, 2026. Milan, Italy. Roth JD, Erickson MR, Chen S, Parkes DG. GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. British Journal of Pharmacology. 2012;166(1):121-136. doi:10.1111/j.1476-5381.2011.01537.x. A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06144684?intr=GUB014295&rank=1#participation-criteria. Accessed September 24, 2026. Media:
Bank of America zvýšila cílovou cenu AbbVie na 289 USD a J&J na 278 USD; u AbbVie ponechala doporučení Buy, u J&J Neutral. AbbVie má podle banky silnější růstový výhled díky pipeline.
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
BofA raised its price target on AbbVie (NYSE:ABBV | ABBV Price Prediction) to $289 from $282 and kept its Buy rating. It also lifted its Johnson & Johnson (NYSE:JNJ) target to $278 from $263 and kept a Neutral rating.
Both targets went up, but the firm’s conviction clearly leans toward AbbVie stock. For dividend-focused investors, the moves point to growing confidence that big pharma can grow through its patent cliffs.
Ticker Company Firm Action Old Rating New Rating Old Target New Target ABBV AbbVie BofA Price Target Raised Buy Buy $282 $289 JNJ Johnson & Johnson BofA Price Target Raised Neutral Neutral $263 $278 BofA’s Case: Patent Flexibility and a Bigger Icotyde Forecast Analyst Tim Anderson says AbbVie is well positioned for its next decade of growth. In his view, a “favorable” loss of exclusivity profile (the timeline on which patents expire) gives the company room to invest in potentially transformative programs in immunology, antibody-drug conjugates (ADCs) and neuroscience.
He adds that recent M&A has strengthened the late-stage pipeline. The pending Apogee acquisition, valued at about $10.9B, brings in an anti-IL-13 candidate for atopic dermatitis.
The J&J revision came after a physician dermatology survey. BofA raised its peak psoriasis sales forecast for Icotyde to $4.5B on 18% share, up from $2.4B on 10% share. Early demand supports that view. On the second-quarter call, management reported “over 18,000 prescriptions have been written for a total of now 11,000 patients”.
Company Snapshot: Two Pharma Giants Growing Through Patent Losses J&J’s second-quarter worldwide sales reached $25.3 billion, with operational growth of 5.6%. Tremfya generated $2 billion in sales, helping offset a 55.7% drop in Stelara. The company has raised its dividend for 64 consecutive years, putting it firmly in the rare club we ranked by valuation in a free Dividend Kings report.
AbbVie’s second-quarter revenue grew 10.2% to $16.99B. Adjusted EPS of $3.65 beat the $3.6084 consensus. Skyrizi rose 24.4% to $5.51B and Rinvoq climbed 24.5%, more than offsetting Humira’s slide to $756M.
Why the Move Matters Now for Pharma Investors Valuations help explain why BofA rates the two stocks differently. AbbVie trades at 16 times forward earnings, compared with 21 times for J&J. J&J stock has also run harder this year, up 31.14% year to date to $267.10. AbbVie is up 18.1% to $263.61.
Several catalysts are coming up. J&J holds an Enterprise Business Review on Dec 8, 2026 while it works on separating its Orthopaedics business. AbbVie expects a U.S. decision this fall on subcutaneous Skyrizi induction dosing in Crohn’s disease.
What It Means for Your Retirement Portfolio Both companies pay meaningful dividends. J&J pays $5.24 per share a year and AbbVie pays $6.83. Their revenue mixes keep moving away from older blockbusters. Still, biosimilar erosion continues, and AbbVie’s 2026 guidance of $13.87 to $14.07 includes $0.14 of dilution from the Apogee deal.
BofA’s revised outlook is worth a closer look for long-term investors. AbbVie gets the firm’s stronger endorsement. J&J’s Neutral rating suggests much of the Icotyde optimism may already be reflected in the stock.
Contact [email protected] for any questions or corrections.
AbbVie na kongresu EADV představí 60 abstraktů a prezentací z dermatologie, včetně nových dat pro SKYRIZI, RINVOQ i kandidáty lutikizumab a zumilokibart. Zaměří se na alopecii, atopickou dermatitidu, hidradenitis suppurativa, vitiligo, psoriázu a psoriatickou artritidu.
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic arthritis New data for risankizumab and upadacitinib provide further evidence supporting efficacy and safety across diverse patient populations Data evaluating investigational compounds lutikizumab and zumilokibart will also be presented, highlighting AbbVie's ongoing research in additional mechanisms of action , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapies, SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib).
"At EADV, we are excited to share new data that further strengthen the growing evidence base across our dermatology portfolio, including SKYRIZI, RINVOQ and investigational therapies," said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. "These findings underscore our ongoing research in advancing scientific understanding and delivering innovative treatment options that have the potential to meaningfully improve outcomes for patients across a broad spectrum of immune-mediated skin diseases."
Key data to be presented across the following therapeutic areas include:
Alopecia Areata (AA): 52-week data on the long-term efficacy and safety of upadacitinib from the Phase 3 UP-AA trials, alongside new analyses evaluating improvements in patients' quality of life following upadacitinib treatment. Atopic Dermatitis (AD): Late-breaking presentation of the primary 16-week results from the Phase 2 APEX Part B dose-regimen-finding study evaluating the efficacy and safety of zumilokibart in moderate to severe AD. Results from the Phase 2 APEX Part A study evaluating maintenance and improvement of response with zumilokibart through 52 weeks, as well as efficacy in patients with AD and evidence of type 2 inflammatory comorbidities. Data from both real-world registries and clinical trial settings evaluating the efficacy of upadacitinib in specific patient populations, including those with moderate disease, hand eczema or an itch-dominant phenotype. Hidradenitis Suppurativa (HS): Late-breaking presentation showing how lutikizumab targets neutrophilic inflammation and fibroblast activation in HS. Results from a Phase 2 study evaluating the impact of lutikizumab on symptom burden, disease burden and quality of life in patients with moderate-to-severe HS. An additional analysis of this Phase 2 study will assess the impact on disease severity according to the International Hidradenitis Suppurativa Severity Score System (IHS4) with lutikizumab. Non-segmental Vitiligo (NSV): Analyses from two Phase 3 trials (Viti-Up 1 and 2) of upadacitinib in adults and adolescents with NSV, evaluating patient-reported outcomes, disease stabilization and repigmentation, week 48 efficacy and safety data as well as week 76 continued repigmentation response. Findings from a phototherapy substudy evaluating the efficacy and safety of RINVOQ in combination with narrow band ultraviolet (NB-UVB) phototherapy and RINVOQ monotherapy after 28 weeks. Psoriasis (PsO): Efficacy and safety results from several real-world and clinical studies of risankizumab in patients with moderate to severe PsO, including adults with high-impact area involvement and Week 52 data in pediatric patients. Other key data include results from a head-to-head trial evaluating risankizumab vs. deucravacitinib in moderate psoriasis patients, and a retrospective, real-world study evaluating the association of risankizumab and other targeted immunomodulators on risk of developing psoriatic arthritis in adults with PsO. Psoriatic Arthritis (PsA): A post-hoc analysis of the Phase 3 KEEPsAKE-1 trial will evaluate radiographic progression in patients with active PsA treated with risankizumab according to their risk of joint erosive disease. The 2026 EADV Congress program is available here, including the late-breaking sessions. Select abstracts and oral presentations from AbbVie include:
Abstract Title
Session Details
Alopecia Areata
Impact of Upadacitinib on Clinician- and Patient-Reported Outcomes Assessing Visible Hair Loss at Key Sites in Patients With Severe Alopecia Areata: Results From Two Replicate Phase 3 Trials
Thursday, 1 October
16:40 – 16:50
FC04: Free Communication 4: Hair and nail disorders
Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Efficacy, Safety, and Tolerability Results from Week 52 of the Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Trial Program (UP-AA)
Thursday, 1 October
17:10 – 17:20
FC04: Free Communication 4: Hair and nail disorders
Atopic Dermatitis
Efficacy and Safety of Zumilokibart, a Half-Life-Extended Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis: Primary Results From the Phase 2 APEX Part B Dose-Regimen-Finding Study
Wednesday, 30 September
16:15 – 16:30
Session: D1T01.2 - Late-Breaking News
Room: Hall A
Upadacitinib Targets Multiple Disease-Relevant Inflammatory Pathways and Restores Skin Barrier in Atopic Dermatitis Lesions: Extending Beyond Type 2 Responses
Thursday, 1 October
09:50 – 10:00
FC01: Free Communication 1: Atopic dermatitis/Eczema
Efficacy of Upadacitinib in Patients With Itch-Dominant Atopic Dermatitis: A Post-Hoc Analysis From the Phase 3 Measure Up 1 and Measure Up 2 Trials
Digital e-poster
P1558
Real-World Impact of Achieving Optimal Versus Moderate Treatment Targets on Patient Outcomes: Analysis of the PPD CorEvitas Atopic Dermatitis Registry
Digital e-poster
P1556
Zumilokibart Provides Robust, Progressive Improvement in the Signs and Symptoms of Atopic Dermatitis: 52-Week Results from the Phase 2 APEX Part A Study
Digital e-poster
P1603
Responders to Zumilokibart Show Durable Maintenance and Deepening of Response Beyond Week 16: Results from the Phase 2 APEX Part A Study in Atopic Dermatitis
Digital e-poster
P2785
Efficacy of Zumilokibart in Patients with Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities: Results from the Phase 2 APEX Part A Study
Digital e-poster
P0151
Hidradenitis Suppurativa
Lutikizumab Targets Neutrophilic Inflammation and Fibroblast Activation to Drive Response in Hidradenitis Suppurativa
Wednesday, 30 September
16:00 – 16:15
Session: D1T01.2 - Late Breaking News
Room: Hall A
Patient-Reported Quality of Life and Disease Burden in Biologic-Naive Adults With Moderate-to-Severe Hidradenitis Suppurativa Treated With Lutikizumab: A Single-Arm, Open-Label, Phase 2 Study
Digital e-poster
P1448
Impact of Lutikizumab on Symptom Burden in Biologic-Naive Patients With Moderate-to-Severe Hidradenitis Suppurativa: Results From a Phase 2, Multicenter, Single-Arm, Open-Label Study
Digital e-poster
P1337
Characterization of the IHS4 Response to Lutikizumab Treatment in Biologic-Naïve Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Single-Arm, Open-Label Phase 2 Study
Digital e-poster
P1799
Non-Segmental Vitiligo
Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo at Week 76 and in Combination With NB-UVB Therapy
Thursday, 1 October
16:00 – 16:15
Session: D2T01.4 - Late Breaking News
Room: Hall A
Patient-Reported Outcomes With Upadacitinib in Adults and Adolescents With Nonsegmental Vitiligo: Pooled Results From Two Phase 3 Trials (Viti-Up 1&2) Through Week 48
Friday, 2 October
09:40 – 09:50
FC04: Free Communication 5: Psoriasis
Psoriasis
Real-World Effectiveness of Risankizumab Versus Other Biologic Therapies After 3 Years of Treatment in Adults With Moderate-To-Severe Plaque Psoriasis With High-Impact Area Involvement
Digital e-poster
P2617
Efficacy of Risankizumab in Patients With Scalp Psoriasis: A Subgroup Analysis by Affected Body Surface Area
Digital e-poster
P1110
Risankizumab Versus Deucravacitinib in Adult Patients With Moderate Plaque Psoriasis: 52-Week Results From IMMpactful, a Phase 4 Multicenter, Randomized Study
Digital e-poster
P2589
Risankizumab Treatment Is Associated With Lower Risk of Developing Psoriatic Arthritis in Patients With Psoriasis Compared to Other Targeted Immunomodulators
Digital e-poster
P1107
Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis in the OptIMMize-1 Phase 3 Study: Results Through 52 Weeks
Digital e-poster
P1010
Psoriatic Arthritis
Efficacy of Risankizumab in Prevention of Radiographic Progression in Patients With PsA at Low and High Risk of Joint Erosive Disease: 5-Year Data From the KEEPsAKE 1 Phase 3 Trial
Digital e-poster
P0359
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,2 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1
Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.
EU Indications and Important Safety Information about RINVOQ® (upadacitinib)1 Indications
Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.
Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Important Safety Information
Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.
Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:
- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)
Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.
Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.
Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.
Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.
Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.
Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.
Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.
Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.
Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.
Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.
Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.
Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.
Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.
Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.
Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.
Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.
Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.
Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.
Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.
The most commonly reported adverse reactions in AD trials (≥2% of patients) with
RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.
The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.
The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.
The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.
The most common serious adverse reactions were serious infections.
The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.
RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.
This is not a complete summary of all safety information.
See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu
Globally, prescribing information varies; refer to the individual country product label for complete information.
About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.3 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.3,4
EU Indications and Important Safety Information about SKYRIZI® (risankizumab)3
Indications
Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Important Safety Information
Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).
Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution.
Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.
Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.
Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.
The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).
Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.
This is not a complete summary of all safety information.
See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu
Globally, prescribing information varies; refer to the individual country product label for complete information.
About lutikizumab
Lutikizumab is a dual-variable-domain interleukin (IL) 1α/1β antagonist being investigated in several immune-mediated diseases, including HS and ulcerative colitis. Studies have shown IL 1α and 1β are elevated in HS lesions.5,6 Lutikizumab is an investigational agent and is not approved by regulatory authorities. Safety and efficacy have not been established.
About zumilokibart
Zumilokibart is a novel, high-affinity humanized IgG1 monoclonal antibody targeting interleukin-13 (IL-13) preventing the formation of the IL-13Rα1-IL4Rα heterodimer being investigated in AD. Zumilokibart is engineered for extended half-life, with clinical data demonstrating a half-life of approximately 77 days in humans.7 Zumilokibart is an investigational agent and is not approved by regulatory authorities. Safety and efficacy have not been established.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
RINVOQ. Summary of product characteristics. AbbVie; 2026. Pipeline. AbbVie. 2026. Accessed September 8, 2026. https://www.abbvie.com/our-science/pipeline.html Skyrizi. Summary of product characteristics. AbbVie; 2026. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292-1298. doi:10.1111/j.1365-2133.2011.10254.x Kanni T, Tzanetakou V, Savva A, et al. Compartmentalized Cytokine Responses in Hidradenitis Suppurativa. PLoS One. 2015;10(6):e0130522. doi:10.1371/journal.pone.0130522 Lim XQ, Winter E, Nograles K, et al. A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers. Clin Transl Sci. 2025;18(12):e70456. doi:10.1111/cts.70456 SOURCE AbbVie
AbbVie uvedla, že všechny tři dávky zumilokibartu ve 2. fázi u atopické dermatitidy splnily primární cíl a výrazně překonaly placebo v 16. týdnu. Pro 3. fázi vybrala střední dávku.
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates versus placebo at Week 16 1 The mid-dose regimen was selected for Phase 3 development, supporting further evaluation of the efficacy, safety and dosing profile of zumilokibart 1 Zumilokibart is a half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis 1 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis (AD) will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Sept. 30 – Oct. 3.
APEX Part B is an ongoing randomized, double-blinded, placebo-controlled, Phase 2 dose-finding study in adults with moderate-to-severe AD. For this analysis, 346 participants were randomized 1:1:1:1 and received a low-, mid-, high-dose zumilokibart regimen or placebo during the 16-week induction period. The primary endpoint was the proportion of participants achieving at least a 75% improvement from baseline in EASI (EASI-75) at Week 16. The mid-dose regimen was identical to the induction regimen evaluated in APEX Part A. 1,2
At 16 weeks, all doses of zumilokibart demonstrated statistically significant improvements compared to placebo in skin lesions based on EASI 90/100 and itch based on I-NRS4:
The mid- and high-dose regimens showed significantly greater improvement than placebo across key secondary endpoints, including near-complete or complete skin clearance based on EASI 90/100 and itch improvement based on I-NRS4. The mid-dose regimen achieved greater percent reductions versus placebo in skin severity (EASI) at Week 1 and in itch (I-NRS) at Week 2. The most common treatment-emergent adverse events through Week 16 (≥5% in any treatment group) were nasopharyngitis, headache, noninfective conjunctivitis, upper respiratory tract infection, atopic dermatitis, and urinary tract infection. "Despite significant advances in atopic dermatitis, there remains an unmet need for therapies that provide meaningful disease control with greater convenience for patients," said Kori Wallace, M.D., vice president, global head of immunology clinical development, AbbVie. "These results support the potential of zumilokibart to rapidly improve both skin and itch. Advancing the mid-dose regimen into Phase 3 and evaluating extended dosing intervals marks an important step in exploring a differentiated option for people living with AD."
"Atopic dermatitis is a chronic disease, and the frequency of administration can be an important consideration when selecting a long-term therapy," said Melinda Gooderham, M.D., FRCPC, SKiN Centre for Dermatology and Queen's University, Ontario, Canada. "At Week 16, zumilokibart demonstrated improvements in skin clearance and itch. These findings support the further evaluation of zumilokibart as a long-term treatment for atopic dermatitis."
Eczema Area and Severity Index (EASI) is a validated score that measures the severity of atopic dermatitis, ranging from 0 or clear skin to 72, indicating severe disease. EASI-75 at Week 16 is defined as achieving at least 75% improvement in lesion extent and severity from baseline on the EASI. Itch Numeric Rating Scale (I-NRS) is a patient reported outcome, rating itch on a 0 (no itch) to 10 (worst itch) scale.
Additional information about the program can be found on clinicaltrials.gov under the identifier NCT07003425.
EADV Presentation Details:
Abstract Title
Date/Time
Session
Efficacy and Safety of Zumilokibart (APG777), a Half-Life-Extended Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis: Primary Results From the Phase 2 APEX Part B Dose-Regimen-Finding Study
Wednesday, September 30, 2026; 4:15 p.m. CEST
Late breaker, Hall A
About Zumilokibart
Zumilokibart is a novel, high-affinity humanized IgG1 monoclonal antibody targeting interleukin-13 (IL-13) preventing the formation of the IL-13Rα1-IL4Rα heterodimer being investigated in AD. Zumilokibart is engineered for extended half-life, with clinical data demonstrating a half-life of approximately 77 days in humans. Zumilokibart is an investigational agent and is not approved by regulatory authorities. Safety and efficacy have not been established.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
AbbVie. Data on file ABVRRTI84044 A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT07003425. Accessed September 24, 2026 SOURCE AbbVie
AbbVie oznámila, že FDA schválila JUVMO (tavapadon) pro dospělé s Parkinsonovou chorobou. Jde o první a jediný selektivní agonista receptorů D1/D5 pro tuto indikaci.
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated approach to motor symptom control across the Parkinson's disease continuum Approval is supported by the Phase 3 TEMPO program demonstrating significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.
JUVMO Is a New Kind of Treatment for Parkinson's Disease
"The approval of JUVMO marks the first dopaminergic breakthrough for Parkinson's disease in decades," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "People living with Parkinson's and the clinicians who care for them have long faced difficult tradeoffs between motor control, treatment burden and tolerability. Clinicians now have a new treatment option that targets dopamine pathways differently and reduces the difficult tradeoffs associated with D2/D3 selective dopamine agonists."
Needed Innovation in the Parkinson's Disease Treatment Landscape
For people living with Parkinson's disease, maintaining consistent control of motor symptoms becomes increasingly challenging as the disease progresses. Oral levodopa remains the foundation of treatment and is often effective at controlling symptoms, but many patients require higher and more frequent doses over time. These adjustments can help restore symptom control yet may also contribute to treatment-related complications such as dyskinesia. About 70% of people living with Parkinson's disease have their oral levodopa dose increased within the first year of therapy.2
These challenges highlight the need for new treatment approaches that can help address the evolving needs of people living with Parkinson's disease. After 85 weeks on JUVMO, 93% of clinical trial participants had not increased their oral levodopa dose and 94% of participants with early Parkinson's disease had not started oral levodopa.3
Dopamine agonists have long been used to help manage symptoms and reduce reliance on oral levodopa escalation. However, currently available dopamine agonists primarily target D2/D3 receptors and their use may be limited by tolerability concerns. JUVMO introduces a different approach, selectively targeting D1/D5 receptors to provide health care providers and patients with a new option for managing motor symptoms across the Parkinson's disease continuum.
Why the Approval of JUVMO Matters for People across the Spectrum of the Disease
"Parkinson's disease treatment has long required health care providers to balance the need for dependable motor symptom control with considerations around treatment tolerability," said Hubert Fernandez, M.D., professor of neurology at the Cleveland Clinic Lerner College of Medicine and global principal TEMPO trial investigator. "Now we have a novel therapy that selectively targets D1/D5 receptors, which addresses a longstanding need for innovation and provides health care providers with greater flexibility to tailor treatment to individual patient needs."
Perspective from the Parkinson's Community
"For people with Parkinson's and their families, progress means having treatment options that deliver meaningful benefit in everyday life," said Brian Fiske, PhD, chief scientist of The Michael J. Fox Foundation for Parkinson's Research. "Each therapy approval is an important milestone in building a diverse treatment pipeline needed to meet the full range of unmet needs across the Parkinson's community."
AbbVie expects to make JUVMO available to patients in the U.S. in October 2026.
FDA Approval Was Supported by Phase 3 TEMPO Clinical Trial Data
Phase 3 data from the TEMPO clinical trial program demonstrated the efficacy and safety of JUVMO in people with early Parkinson's disease who were not taking oral levodopa (TEMPO-1 and 2) and as an adjunct to oral levodopa in people with Parkinson's disease experiencing motor fluctuations (TEMPO-3).1
In TEMPO-1 at week 26, JUVMO significantly improved activities of daily living scores versus placebo, as measured by MDS-UPDRS Part II, which includes everyday tasks like dressing, eating and personal hygiene (placebo: +0.9; 5 mg: -1.6; 15 mg: -1.7; p <0.0001 each dose versus placebo).1 Compared to baseline, JUVMO improved activities of daily living scores by 22-23% whereas the placebo group worsened by 12%. Additionally, JUVMO significantly improved activities of daily living and motor skills, as measured by MDS-UPDRS Part II + III combined scores, versus placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2; p <0.0001 each dose versus placebo) at week 26.4 JUVMO also significantly improved MDS-UPDRS Part II scores versus placebo in TEMPO-2 at week 26 (placebo: 0.0; 5-15 mg: -1.5; p =0.0007).1 JUVMO also significantly improved MDS-UPDRS Part II + III combined scores versus placebo in TEMPO-2 at week 26 (placebo: -1.2; 5-15mg: -10.3; p <0.0001).5 In TEMPO-3 at week 26, JUVMO 5-15 mg + oral levodopa significantly increased total daily "on" time without troublesome dyskinesia versus placebo + oral levodopa (1.7 hours versus 0.6 hours, p <0.0001).1 Total daily "off" time decreased by 1.9 hours with JUVMO + oral levodopa, compared to a decrease of 0.9 hours with placebo + oral levodopa (p =0.0006). Sustained efficacy was observed out to 85 weeks for those who continued in the open-label extension period (TEMPO-4).3 Of those on JUVMO + oral levodopa for 85 weeks, 93% did not increase their oral levodopa dose (96/103). Of those on JUVMO without levodopa, 94% did not initiate levodopa (257/273).3 The majority of treatment-emergent adverse events (TEAEs) were non-serious and mild or moderate in severity.1 The most common TEAEs for JUVMO without oral levodopa, reported in ≥5% of patients, were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth and anxiety. For JUVMO + oral levodopa, the most common TEAEs, reported in ≥5% of patients, were nausea, dyskinesia, dizziness, headache, hallucinations and orthostatic hypotension. About Parkinson's Disease
More than 11 million people worldwide are living with Parkinson's disease,6 a progressive and chronic neurological disorder characterized by tremor, muscle rigidity, slowness of movement and difficulty with balance.7
The motor symptoms of Parkinson's disease begin when approximately 60-80% of the dopamine-producing cells in the brain are lost and symptoms continue to worsen slowly over the course of time.8
As Parkinson's disease progresses, patients may experience complications, including motor and non-motor fluctuations and dyskinesia. Patients report switching from an "on" state (when symptoms are generally well controlled) to an "off" state, during which symptoms such as tremor and stiffness may reappear and patients may have more difficulty moving.9 Patients with later-stage Parkinson's disease may also experience dyskinesia (involuntary movements), which can significantly hinder daily activities.9
USE
JUVMO is a prescription medicine used for the treatment of Parkinson's disease in adults. It is not known if JUVMO is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Tell your healthcare provider about all your medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, as JUVMO (tavapadon) and certain other medicines may affect each other and how they work.
JUVMO may cause serious side effects. Talk to your healthcare provider before starting JUVMO and while on JUVMO if you have had or have any of the following:
Low blood pressure. This is a common side effect and may be serious. JUVMO can lower your blood pressure and make you feel dizzy, especially when you stand up (orthostatic hypotension). Do not get up too fast from sitting or after lying down. You may be more likely to feel dizzy after starting JUVMO or when your dose is increased. Unusual urges. Some people taking medicines for Parkinson's disease, including JUVMO, have had unusual urges. This may include gambling, compulsive eating, compulsive shopping, and increased sex drive. Seeing, hearing, or feeling things that are not real (hallucinations). This is a common side effect and may be serious. Tell your healthcare provider if you have a mental health problem such as hallucinations. Uncontrolled sudden movements (dyskinesia). This is a common side effect and may be serious. If you have new dyskinesia or your dyskinesia gets worse, tell your healthcare provider. This may be a sign that your dose of JUVMO or other Parkinson's medicines may need to be adjusted. The most common side effects of JUVMO include nausea, headache, change in taste, feeling tired (fatigue), vomiting, dry mouth, and anxiety.
These are not all the possible side effects of JUVMO. For more information, ask your healthcare provider or pharmacist.
JUVMO tablet for oral use is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.
Please see the full Prescribing Information, including Patient Information. Talk to your healthcare provider if you have questions.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.
About AbbVie in Neuroscience
At AbbVie, we believe people and their care partners living with difficult-to-treat nervous system disorders deserve more, and that purpose fuels our relentless drive to discover breakthrough science and deliver innovative medicines. We are helping to shape the future of neuroscience with a diverse portfolio of approved and investigational treatments designed to address some of the greatest burdens and unmet needs across psychiatry, migraine and pain, movement disorders and neurodegeneration. Our neuroscience therapies are making a meaningful impact for people around the world today, and our continued research reflects our commitment to exploring new approaches that have the potential to advance standards of care and create possibilities for patients living with these challenging conditions. Discover more at https://www.abbvie.com/science/areas-of-focus/neuroscience.html.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
JUVMO [package insert]. North Chicago, IL: AbbVie Inc. AbbVie. Data on file: H26.DoF.043. AbbVie. Data on file: ABVRRTI83605. Pahwa R, Moro E, Espay AJ, et al. Fixed-dose tavapadon for early Parkinson disease: a randomized clinical trial. JAMA Neurol. 2026;83(5):452-460. doi:10.1001/jamaneurol.2026.0590 Fernandez HH, Bhatia P, Cloud L, et al. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2026;25(8):721-730. doi:10.1016/S1474-4422(26)00215-2 Luo Y, et al. Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Frontiers in Aging Neuroscience. 2025 Jan 10;16:1498756. About Parkinson's: Parkinson's 101. The Michael J. Fox Foundation for Parkinson's Research. Available at: https://www.michaeljfox.org/understanding-parkinsons/i-have-got-what.php. Accessed June 17, 2026. Parkinson's Disease: Hope Through Research. National Institute of Neurological Disorders and Stroke. Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research. Accessed June 17, 2026. Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. Semin Neurol. 2017 Apr;37(2):147-157. doi: 10.1055/s-0037-1602423 SOURCE AbbVie
Americká FDA schválila lék AbbVie tavapadon na Parkinsonovu chorobu u dospělých, prodávaný jako Juvmo. Léčba je jednou denně a vychází z pozitivních dat z pozdní fáze klinického programu.
The US Food and Drug Administration has approved AbbVie's (ABBV.N) treatment for Parkinson's disease in adults, the health regulator's website showed on Friday.
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill.
It will be sold under the brand name Juvmo, according to the FDA's website.
Parkinson's is a long-term brain condition that gradually damages movement control, often causing tremors, stiffness and balance issues. More than 11 million people live with the disease worldwide, according to AbbVie.
Juvmo works by mimicking dopamine, a vital brain chemical that naturally decreases in people with Parkinson's.
The regulator's nod was based on data from AbbVie's late-stage trial program which showed the drug improved symptoms in patients with the disease. Common side effects reported in the trials included nausea, dizziness and headache.
AbbVie did not respond to a Reuters request for comment on the drug's launch and pricing.
Citi analysts had previously said the launch was expected in the third quarter of 2026, but that uptake was likely to be gradual as negotiations progressed on the drug's Medicare coverage.
AbbVie continued to target more than $5 billion in combined Parkinson's disease sales, Citi added.
AbbVie Inc. (NYSE:ABBV – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $268.41 and last traded at $266.4530, with a volume of 189319 shares traded. The stock had previously closed at $265.21.
Trending Headlines about AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: EPKINLY expands in follicular lymphoma: Health Canada issued a Notice of Compliance for EPKINLY, in combination with lenalidomide and rituximab, for adults with relapsed or refractory follicular lymphoma. The approval broadens the drug’s commercial opportunity and supports AbbVie’s oncology strategy. AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY Positive Sentiment: AI drug-discovery partnership: AbbVie and Iambic will collaborate on AI-enabled discovery programs in immunology, neuroscience and oncology. The partnership could improve research productivity and strengthen AbbVie’s long-term pipeline, though financial benefits are likely to take time. AbbVie and Iambic AI Drug Discovery Partnership Positive Sentiment: Rinvoq continues to gain indications: European approval for Rinvoq in children aged two and older with active polyarticular juvenile idiopathic arthritis adds to the drug’s international label and reinforces its role as a key growth driver. AbbVie Wins EU Approval for Rinvoq in Pediatric Arthritis Neutral Sentiment: Analyst comparisons are mixed: Reviews comparing AbbVie with Pfizer and Eli Lilly highlight its dividend record, pipeline investment and newer-drug growth, but also emphasize patent challenges and the need to replace aging products. Pfizer or AbbVie Comparison Negative Sentiment: Valuation and earnings concerns: A bearish analysis argues that revenue pressure and weakening earnings support a “sell” view. With ABBV trading at an elevated earnings multiple, investors may require continued strong execution from Rinvoq, Skyrizi, EPKINLY and the broader pipeline. AbbVie Revenue Pressure and Weakening Earnings Analyst Upgrades and Downgrades A number of research firms recently weighed in on ABBV. Cantor Fitzgerald restated an “overweight” rating on shares of AbbVie in a research note on Wednesday, September 16th. Guggenheim raised their price target on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Bank of America restated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. BMO Capital Markets upped their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, BNP Paribas Exane increased their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $276.64.
View Our Latest Analysis on ABBV AbbVie Stock Down 0.0% The stock has a market capitalization of $468.25 billion, a P/E ratio of 74.87, a PEG ratio of 1.20 and a beta of 0.29. The company has a fifty day moving average price of $256.95 and a 200-day moving average price of $233.05.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
Insider Activity at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by insiders.
Institutional Inflows and Outflows Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Burk Holdings LLC purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC lifted its position in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the last quarter. Abound Financial LLC purchased a new position in AbbVie during the fourth quarter worth $32,000. Principia Wealth Advisory LLC boosted its stake in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC bought a new position in AbbVie during the first quarter valued at $34,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie Company Profile (Get Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
Featured Articles Five stocks we like better than AbbVie Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Paychex Plunges, Providing the Entry Investors Have Been Waiting For The Case for Buying High-Yield General Mills Just Strengthened SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
AbbVie v 1. pololetí 2026 zvýšila tržby o 9,9 % na zhruba 32 miliard USD, ale tržby z onkologie klesly o 2,8 % na 3,28 miliardy USD kvůli Imbruvice, která klesla o 27,1 % na 1,09 miliardy USD. Růst Venclexty o 9,6 % na 1,54 miliardy USD, Elahere o 19,3 % na 409 milionů USD, Epkinly o 52,2 % na 186 milionů USD a Emrelis však propad částečně tlumí.
Key Takeaways Venclexta growth and newer therapies like Elahere and Epkinly are cushioning Imbruvica's decline.AbbVie added Decnupaz and is advancing ADC candidates across blood cancers and solid tumors.ABBV is broadening oncology through bispecifics, T-cell engagers and a PD-1/VEGF-targeted therapy. AbbVie (ABBV - Free Report) entered the second half of 2026 with its broader business continuing to grow, but oncology remained one of the weaker parts of the portfolio. While the company’s total revenues increased 9.9% year over year on an operational basis to roughly $32 billion during the first half of 2026, oncology sales that account for more than 10% of the figure moved in the opposite direction.
The company generated oncology revenues of $3.28 billion, down 2.8% year over year. Much of the weakness can be traced to Imbruvica, which declined 27.1% to $1.09 billion. The decline reflects the continued competitive pressure and IRA-driven pricing changes that took effect at the start of this year.
The more important part of the story, however, lies elsewhere. AbbVie has steadily added scale to a group of newer oncology therapies while also expanding its development pipeline across different cancer targets and treatment approaches. The progress so far raises the question of whether these products can eventually form a broader oncology portfolio capable of reducing the franchise's dependence on Imbruvica.
Venclexta & Newer Assets Help ABBV Cushion the Imbruvica DeclineVenclexta remains an important growth driver for AbbVie’s oncology business. The drug generated $1.54 billion in sales during the first half of 2026, up 9.6% year over year on an operational basis. Growth has been supported by continued demand in chronic lymphocytic leukemia (CLL), with Venclexta increasingly being used alongside BTK inhibitors as a fixed-duration treatment.
Beyond Venclexta, AbbVie’s newer oncology products are also gaining momentum. Management noted that double-digit sales growth from ovarian cancer therapy Elahere, lymphoma drug Epkinly and lung cancer therapy Emrelis helped partially offset the decline in Imbruvica. While Elahere sales rose 19.3% year over year to $409 million, Epkinly sales increased 52.2% to $186 million.
The portfolio received another addition in May with the FDA approval of Decnupaz for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Decnupaz marks AbbVie’s third marketed antibody-drug conjugate (ADC) and its first ADC approved for a blood cancer, further expanding the company’s oncology portfolio.
AbbVie Advances a Diversified Oncology PipelineThe company is increasingly broadening its oncology pipeline across multiple therapeutic approaches, with ADC emerging as a key area of focus. This drug class is widely viewed as one of the most promising innovations in cancer treatment due to its ability to selectively deliver cancer-killing agents to tumor cells.
AbbVie is advancing several ADC candidates targeting different cancer indications across different stages of clinical development. One such candidate, Temab-A, is in late-stage development for colorectal cancer and is also being studied in several mid-stage studies for other indications. The company is also evaluating Decnupaz for a second indication, acute myeloid leukemia, in a phase II study. Beyond these programs, AbbVie has other early-stage assets in development, reflecting its ambition to build a broader ADC platform across both hematologic malignancies and solid tumors.
However, AbbVie is not putting all its eggs in one basket. The company is also expanding its portfolio of T-cell engagers and bispecific antibodies. Etentamig is being evaluated as a BCMA×CD3 bispecific T-cell engager for multiple myeloma in a late-stage study. The company also added ABBV-2001, a CD38×BCMA×CD3 trispecific T-cell engager, to its pipeline through an exclusive licensing agreement with Ichnos Glenmark Innovation across North America, Europe, Japan and Greater China.
AbbVie has also added another approach in solid tumors through its partnership with RemeGen, under which it holds an exclusive license outside Greater China for ABBV-1480, a PD-1/VEGF-targeted bispecific antibody. The addition gives the company exposure to another mechanism as it continues to diversify its oncology pipeline beyond its existing portfolio of cancer therapies.
ABBV’s Competition in the Oncology SpaceOther bigger players in the oncology space include AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
For AstraZeneca, oncology sales now account for 46% of total revenues. Sales in its oncology segment rose 15% year over year in the first half of 2026, driven by the strong performance of medicines such as Tagrisso, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicine is its PD-L1 inhibitor Keytruda. The drug, approved for several types of cancer, alone accounted for 48% of MRK’s total revenues in first-half 2026.
Pfizer’s oncology revenues grew 2% in the first half of 2026, driven by drugs like Padcev, Lorbrena and the Braftovi-Mektovi combination. The segment now accounts for nearly 28% of its total revenues.
ABBV’s Price Performance, Valuation & EstimatesShares of AbbVie have gained 16% so far this year compared with the industry’s 12% growth, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price-to-earnings (P/E) ratio, the company’s shares currently trade at 17.01 times forward earnings, below the industry average of 18.08.
Image Source: Zacks Investment Research
ABBV’s EPS estimates for 2026 and 2027 have declined during the past 60 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie získala v EU schválení RINVOQ pro léčbu aktivní polyartikulární juvenilní idiopatické artritidy u dětí od 2 let. Nově je k dispozici i perorální roztok.
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs1 Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis1,2 A new oral solution of RINVOQ was approved for use in patients with pJIA1 RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases1 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.1
"The European Commission's approval of RINVOQ for pJIA expands the treatment options available to pediatric patients and their families, offering the potential for remission, improvements in pain and physical function," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "RINVOQ's new indication continues to build on our differentiated immunology portfolio with breadth and depth across therapeutic areas and patient populations."
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and is estimated to impact approximately 126,000 children in Europe.3 pJIA is a subtype of JIA and is characterized by inflammation in five or more joints – including the small joints of the hands and feet and large joints like the knees, hips and ankles – that persists for at least six weeks in children and adolescents.4,5 This disease can be painful and debilitating and, if left untreated, may lead to joint damage.3,6 Ongoing disease activity in pJIA is common, with persistent symptoms or flares affecting many patients into adulthood.6-8
Data Supporting the EC Approval
The EC approval of RINVOQ for pJIA is supported by the SELECT-YOUTH study and data from adult patients with rheumatoid arthritis. The SELECT-YOUTH study is a single-arm, open-label, global, Phase 1 study evaluating the pharmacokinetics, efficacy, safety and tolerability of RINVOQ in patients ages 2 to <18 years.1,2
RINVOQ demonstrated efficacy as early as week 12, with response rates improving through week 48, as shown below.1,2 The efficacy observed in children with pJIA was generally consistent with responses in adult patients with rheumatoid arthritis.1
SELECT-YOUTH Clinical Response1
Efficacy Measure
Week 12
RINVOQ*
(N=122)
Week 48
RINVOQ*
(N=122)
70% improvement of disease activity
(ACR pediatric 70 response), NRI1
66.4%
79.5%
Remission (JADAS27-CRP ≤1), NRI1
23.0%
43.4%
*All patients received RINVOQ 15 mg tablet or oral solution weight-based equivalent.
ACR=American College of Rheumatology; CRP=C-reactive protein; JADAS=Juvenile Arthritis Disease Activity Score; NRI=nonresponder imputation.
Functional ability, as measured by C-HAQ, improved, with a mean change from baseline of −0.46 (n=115) at week 12 and −0.64 (n=108) at week 48. Pain scores also improved, with a mean change from baseline of −26.2 (n=116) at week 12 and −30.8 (n=109) at week 48. C-HAQ and pain data are reported as observed.2
In the study, no new safety risks were identified.9 The rate of treatment-emergent adverse events (TEAEs) was 499.6 events per 100 patient-years (E/100 PY). The rate of serious adverse events was 10.2 E/100 PY. The rate of TEAEs that led to discontinuation of the study drug was 2.7 E/100 PY. No cases of major cardiovascular or thrombotic events, malignancies or deaths were reported during the study period.2 No negative impact on growth or development was observed.9
"The SELECT-YOUTH results underscore that clinical remission for children with pJIA is not a rare hope but a critical and achievable outcome that helps reduce the risk of permanent joint damage in some of our youngest, most vulnerable patients," said Prof. Dr. Gerd Horneff, head of the Department of General Pediatrics, Asklepios Clinic, Sankt Augustin, Germany. "The approval of RINVOQ in active pJIA provides a new oral systemic treatment option for patients suffering from this often-debilitating condition."
RINVOQ is also approved in the European Union for the treatment of adults and adolescents with atopic dermatitis, non-segmental vitiligo and alopecia areata and for adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease and giant cell arteritis.1
About the SELECT-YOUTH Study
The SELECT-YOUTH (M15-340) study is a single-arm, open-label, global, Phase 1 study to evaluate the pharmacokinetics, efficacy, safety and tolerability of upadacitinib in patients with polyarticular course juvenile idiopathic arthritis (pcJIA), ages 2 to <18 years. This study consists of three parts: Part 1 consisted of a seven-day multiple-dose pharmacokinetic evaluation, after which patients in Parts 2 and 3 of the trial received a low dose of upadacitinib (equivalent to 15 mg) by using either a twice-daily oral solution or once-daily extended-release tablet based on their body weight and ability to swallow tablets. For more detailed information on this study, please visit clinicaltrials.gov (NCT03725007).
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,10 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1
Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.
EU Indications and Important Safety Information about RINVOQ® (upadacitinib)1
Indications
Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.
Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Important Safety Information
Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.
Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:
- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)
Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.
Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.
Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.
Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.
Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.
Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.
Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.
Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.
Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.
Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.
Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.
Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.
Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.
Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.
Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.
Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.
Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.
Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.
Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.
The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.
The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in pediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.
The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.
The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.
The most common serious adverse reactions were serious infections.
The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.
RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.
This is not a complete summary of all safety information.
See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu
Globally, prescribing information varies; refer to the individual country product label for complete information.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
RINVOQ. Summary of product characteristics. AbbVie; 2026. AbbVie. Data on file: ABVRRTI83601. Garner AJ, Saatchi R, Ward O, Hawley DP. Juvenile idiopathic arthritis: a review of novel diagnostic and monitoring technologies. Healthcare (Basel). 2021;9(12):1683. doi:10.3390/healthcare9121683 Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol. 2009;5(11):616-626. doi:10.1038/nrrheum.2009.209 Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294(13):1671-1684. doi:10.1001/jama.294.13.1671 Glerup M, Rypdal V, Arnstad ED, et al. Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken). 2020;72(4):507-516. doi:10.1002/acr.23853 Balay-Dustrude E, Weiss NS, Sutton A, Shenoi S. Predictors of disease activity in patients with juvenile idiopathic arthritis at 12 and 24 months after diagnosis. ACR Open Rheumatol. 2024;6(8):489-496. doi:10.1002/acr2.11701 AbbVie. Data on file: ABVRRTI83825. Pipeline. AbbVie. 2026. Accessed July 8, 2026. https://www.abbvie.com/our-science/pipeline.html SOURCE AbbVie
AbbVie a Iambic uzavřely víceletou spolupráci na urychlení objevování malých molekulárních léčiv pomocí AI v imunologii, neurologii a onkologii. Iambic získá zálohu a může dostat milníkové platby i licenční poplatky z čistých výnosů.
Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise , /PRNewswire/ -- AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology. The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates.
"We are excited about the purpose-built AI capabilities Iambic is bringing to our Discovery scientists," said Nicholas Donoghoe, M.D., executive vice president and chief business and strategy officer, AbbVie. "We believe AI will be a powerful catalyst for scientific innovation across AbbVie. By equipping our teams with fit-for-purpose AI solutions, we can accelerate discovery, expand what is possible in R&D and significantly advance our commitment to making a remarkable impact for patients."
"Combining Iambic's platform with the drug-hunting expertise of AbbVie scientists can help us make more precise decisions about the molecules we pursue," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success, ultimately to deliver breakthrough medicines for patients sooner."
In traditional small molecule discovery, scientists evaluate dozens of properties for each candidate individually. Iambic's molecular superintelligence platform is powered by Enchant and NeuralPLexer, technologies designed to optimize the full range of candidate properties simultaneously, increasing the chance of making better molecules while reducing drug discovery timelines.
The collaboration will utilize Enchant v3, Iambic's next-generation multimodal transformer model that combines biomedical data modalities from across the drug discovery process and enables many drug design hypotheses to be tested in parallel and at scale. Enchant v3 is designed to achieve industry-leading prediction accuracy across drug discovery and development and is trained on over 6,000 molecular properties.
"Iambic's mission is to make better technology for better medicines — in our own hands and with partners," said Tom Miller, Ph.D., Co-Founder and CEO, Iambic. "We are eager to bring Iambic's molecular superintelligence platform to bear alongside AbbVie's world-class team to address unmet patient need. We anticipate an impactful collaboration — for Iambic, for AbbVie, and for the patients we serve."
Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.
About AI@AbbVie
AI@AbbVie is AbbVie's enterprise approach to using artificial intelligence (AI) to advance scientific innovation, strengthen business outcomes and improve how medicines are discovered, developed and delivered to patients. AI is an important enabler of our mission, helping employees enhance productivity, strengthen decision-making and accelerate progress across R&D, operations and other core business functions. Guided by human expertise, responsible governance and a commitment to meaningful impact, we are embedding AI across the enterprise to accelerate innovation and help improve patients' lives.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About Iambic Therapeutics, Inc.
Iambic's mission is to make better technology for better medicines. By utilizing molecular superintelligence — integrating proprietary AI with automated, scalable chemistry and biology experimentation — our platform is designed to address the totality of drug discovery and development. The utility of our platform has been demonstrated by the discovery of a novel drug candidate advanced to clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine. | iambic.ai
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
AbbVie oznámila, že Qulipta v klinické studii výrazně snížila počet migrenózních dní u menstruační migrény a splnila všechny sekundární cíle bez nových bezpečnostních signálů. To může otevřít cestu k rozšíření indikace.
AbbVie (ABBV -0.02%), a pharmaceutical giant, is best known for its work in immunology. Over the decade between 2013 (when it became a stand-alone publicly traded company) and 2023, the drugmaker's biggest growth driver was Humira, a medicine for several autoimmune disorders that was once the world's best-selling drug. Humira lost U.S. patent exclusivity in 2023, but since then, Skyrizi and Rinvoq, two other immunology medicines, have become AbbVie's growth pillars.
However, the healthcare leader does have products in other areas that are performing well. One of them is Qulipta, a migraine treatment. And recently, Qulipta achieved a meaningful clinical win that could help boost its sales over the medium term. What does this mean for AbbVie's prospects? Let's find out.
Image source: The Motley Fool.
A milestone in sight Qulipta was first approved in the U.S. in 2021 for the preventive treatment of migraine and later earned a label expansion to treat chronic migraine in adults. AbbVie recently announced top-line results from a Phase 3 clinical trial for the medicine in patients with menstrual migraine. During the study, Qulipta led to a meaningful reduction in migraine days compared with a placebo during the perimenstrual period. That was the primary endpoint. Qulipta also hit all secondary endpoints during the trial (including acute medication use and functional disability) while introducing no new safety signals.
The medicine seems likely to earn a label expansion in this indication, given these results. But how large an opportunity is it? As AbbVie notes, there are no medicines approved specifically for menstrual migraine. According to some estimates, around 12% of Americans experience migraines, and at least 60% of those who menstruate and experience migraines say that they happen around the time of their menstrual cycle. Assuming an even split among migraine patients between people who menstruate and people who don't, we could be looking at a total market opportunity of more than nine million adult patients for Qulipta in this indication in the U.S. Of course, there are some complications.
Even if Qulipta becomes the first medicine approved in this narrow niche, it won't achieve anything close to 100% penetration. Its eventual sales in this market will depend on factors such as health insurance coverage, physician adoption, and how many patients believe their menstrual migraines are severe enough to warrant pharmaceutical management. This subset might be far lower than the total number who experience menstrual migraine. Patients who want treatment might also choose alternatives; there may not be medicines approved specifically for menstrual migraines, but other treatments can help. Still, this clinical win should have a meaningful impact on Qulipta's performance.
Premium Feature
Moneyball Superscore
79/100
Today's Change
(
-0.02
%) $
-0.06
Current Price
$
263.96
Is the stock a buy? But how much will Qulipta truly contribute from here on out? In the second quarter, the medicine posted $350 million in sales, up 31% year over year. Some analysts expect the therapy to eventually generate peak sales of over $2 billion. And for context, it generated $1 billion in revenue last year. But AbbVie's total revenue in the second quarter alone grew 10% year over year to $17 billion.
In other words, although Qulipta can contribute, AbbVie's most important growth opportunities lie elsewhere. The company's Skyrizi and Rinvoq should remain its biggest growth drivers for the foreseeable future. These immunology drugs have exceeded expectations. Management expects more than $31 billion in combined revenue for the two of them this year. It had initially predicted they would reach that milestone in 2027. That 2027 target itself had been raised by $4 billion from an earlier forecast.
AbbVie should also expand its immunology lineup. The company recently closed the $10.9 billion acquisition of Apogee Therapeutics, granting it access to zumilokibart, a promising late-stage immunology asset. Zumilokibart is being developed for eczema and several other indications. And according to some analysts, it could achieve peak sales of $5.2 billion in eczema alone. This drug might become one of the heirs to AbbVie's current growth pillars. And the company has a pipeline full of other promising candidates, even beyond its core therapeutic area.
Expect consistent financial results from AbbVie over the long run. Lastly, the drugmaker is an excellent dividend stock. AbbVie is a Dividend King: A company that has raised its payouts for at least 50 straight years. All these factors make AbbVie an excellent stock to buy and hold, especially for income-seeking investors.
AbbVie na IMS 2026 představí výsledky fáze 3 CERVINO pro etentamig, který u relabujícího/refrakterního mnohočetného myelomu splnil oba primární cíle: ORR i PFS.
Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs , /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings.
Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie's strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma.
"Despite meaningful progress in multiple myeloma, the disease remains incurable and patients continue to face challenges related to treatment resistance, disease heterogeneity, tolerability and durable disease control," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie. "Our presence at IMS reflects the depth and momentum of our multiple myeloma strategy as we advance our scientifically differentiated portfolio, spanning T-cell engagers, targeted therapies and rational combinations designed to address distinct disease mechanisms and evolving patient needs, with the goal of delivering more precise, durable and accessible treatment options."
The full list of AbbVie presentations at IMS includes:
Note: All presentation times are listed in local Glasgow time.
Abstract Title
Date/Time
Session
Abstract Number
Real-World (RW)
Characteristics, Treatment
Patterns, and Outcomes
in Triple-Class Exposed
(TCE)
Relapsed/Refractory
Multiple Myeloma
(RRMM) in Europe:
Results from the
HARMONY Big
Data Platform
Wednesday,
September 23, 2026
12:00–1:00 PM
Poster Presentation
PA-386
Etentamig in Patients with
Relapsed/Refractory
Multiple Myeloma (RRMM)
with Prior Exposure to B-
Cell Maturation Antigen
(BCMA)-Targeted
Therapy
Thursday, September
24, 2026
12:00–1:00 PM
Poster Presentation
PA-181
A Phase 1/2, Open-Label,
Platform Study to
Evaluate the Safety and
Efficacy of Etentamig
Monotherapy or
Combination Therapy in
Patients with Multiple
Myeloma
Friday, September 25,
2026
12:00–1:00 PM
Poster Presentation
PA-008
Phase 1/2, Open-Label,
Platform Study of
Surzetoclax with
Etentamig in Biomarker-
Selected Patients with
Relapsed/Refractory
Multiple Myeloma (RRMM)
Friday, September 25,
2026
12:00–1:00 PM
Poster Presentation
PA-346
Real-World (RW)
Infection-Related
Healthcare Resource
Utilization (HCRU) and
Costs in Patients (pts)
with Multiple Myeloma
(MM) Receiving
T-cell Redirecting
Therapies (TCRTs)
Friday, September 25,
2026
12:00–1:00 PM
Poster Presentation
PA-387
CERVINO: Phase (Ph) 3
Results of Etentamig vs
Investigator's Choice of
Standard Available
Therapies (SAT) in
Patients (Pts) With Triple-
Class
Exposed Relapsed or
Refractory Multiple
Myeloma
(RRMM)
Friday, September 25,
2026
3:00–5:00 PM
Plenary Session
Hall 5
LBA-01
Etentamig Combined With
Pomalidomide Plus
Dexamethasone
(Pom+Dex) in Relapsed/
Refractory Multiple
Myeloma (RRMM) After
1–3
Prior Lines of Therapy: A
Phase 1b Dose-
Escalation and Safety
Expansion Study
Saturday, September
26, 2026
8:30–9:30 AM
Oral Presentation
Abstract Session 9
Hall 5
OA-24
AbbVie Advances ABBV-
2001/ISB 2001: A Unique,
Single-Molecule
Trispecific T-cell Engager
(TCE) Approach Toward
Robust Anti-Myeloma
Activity with Superior
Tumor Cytotoxicity
Saturday, September
26, 2026
9:30–10:20 AM
Oral Presentation
Future Targets and
New Modalities of
Therapy
Hall 5
N/A
Surzetoclax: A Potentially
Best-in-Class BCL-2
Inhibitor for the Treatment
of Multiple Myeloma
with t(11;14) Translocation
or High BCL-2
Expression
N/A
Poster Presentation
PA-468
More information about the IMS 2026 meeting, including AbbVie's presence, will be available here.
Additional information around AbbVie's ongoing clinical trials in multiple myeloma can be found at clinicaltrials.gov.
Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
AbbVie oznámila, že výnosy její neurologické divize v první polovině roku 2026 vzrostly o 21,8 % na 6,1 miliardy USD. Firma zároveň zvýšila celoroční výhled na výnosy této divize na zhruba 12,7 miliardy USD.
Key Takeaways ABBV's neuroscience revenues rose 21.8% to $6.1 billion in the first half of 2026.Vraylar, Botox Therapeutic, Ubrelvy and Qulipta delivered double-digit sales growth in the period.Vyalev is driving PD growth, while tavapadon could add another franchise pillar if approved. AbbVie (ABBV - Free Report) has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively concentrated business initially anchored by Vraylar and Botox Therapeutics into a broader, multi-franchise platform.
The company has expanded into migraine with Ubrelvy and Qulipta and established a Parkinson’s disease (PD) franchise with Vyalev, broadening its neuroscience presence beyond its traditional psychiatry and neurotoxin therapies. This expansion has not only diversified AbbVie’s revenue base but also created multiple avenues for sustained growth.
AbbVie’s Neuroscience Growth Remains Broad-BasedThe transformation is increasingly visible in the franchise’s financial performance. AbbVie’s neuroscience portfolio generated $6.1 billion in revenues in the first half of 2026, up 21.8% year over year on an operational basis, making it one of the company’s fastest-growing therapeutic areas. Importantly, growth was broad-based across its three key pillars — psychiatry, migraine and PD — rather than being driven by a single product.
Vraylar remains the cornerstone of AbbVie’s psychiatry franchise. The drug generated $1.98 billion in revenues in the first half of 2026, up 18.6% year over year, with AbbVie citing continued share gains in bipolar disorder and adjunctive major depressive disorder.
Migraine has emerged as a major pillar of AbbVie’s neuroscience portfolio. Alongside Botox Therapeutic, the company now markets the oral CGRPs Ubrelvy and Qulipta, creating a portfolio spanning both preventive and acute migraine treatment. In the first half of 2026, Botox Therapeutic generated $2.05 billion, while Ubrelvy and Qulipta generated $731 million and $646 million, respectively. Sales of all three products increased at double-digit rates from the year-ago period, with Qulipta leading growth at 39.2%, followed by Ubrelvy at 26.4%.
PD represents the newest pillar of AbbVie’s neuroscience franchise, with Vyalev emerging as a significant growth driver. The therapy generated $457 million in first-half 2026 sales, up sharply from the prior-year period, while second-quarter sales increased more than 27% sequentially. AbbVie said Vyalev is well on track to achieve blockbuster sales this year.
The strong performance has prompted AbbVie to raise its full-year outlook for the franchise. The company now expects 2026 neuroscience revenues of approximately $12.7 billion, $100 million above its previous forecast, including Vraylar sales approaching $4.1 billion and Botox Therapeutic sales expected to reach nearly $4.2 billion. AbbVie also raised its overall 2026 revenue outlook by $300 million to approximately $67.6 billion.
A Potential FDA Nod Could Add Another Growth Driver for ABBVBeyond the continued uptake of its marketed therapies, AbbVie could add another growth driver to its neuroscience portfolio with tavapadon, a once-daily oral therapy for PD. The drug is a selective D1/D5 dopamine agonist being developed as both a monotherapy and an add-on to standard of care, giving the company another mechanism to address PD.
AbbVie expects an FDA decision on tavapadon in the third quarter of 2026. If approved, the drug could launch later this year, expanding the company’s PD portfolio alongside Vyalev and Duopa. Management expects the three therapies to collectively represent a PD opportunity of more than $5 billion in peak sales.
AbbVie is also advancing a pipeline of neuroscience programs across several areas. It recently initiated a phase II study on GemibotulinumtoxinA, a next-generation toxin for essential tremor, and a phase Ib study of ABBV-1758, an amyloid-beta antibody for the treatment of Alzheimer’s disease. These programs broaden AbbVie’s neuroscience ambitions beyond its established products, providing additional opportunities to replenish and diversify the portfolio over the longer term.
ABBV’s Competition in the Neuroscience SpaceOther bigger players in the neuroscience space are Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the depression therapy Spravato and the long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and EstimatesShares of AbbVie have outperformed the industry year-to-date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.93 times forward earnings, lower than its industry’s average of 18.07.
Image Source: Zacks Investment Research
ABBV’s EPS estimates for 2026 and 2027 have declined over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie uvedla, že její výhled na rok 2026 má být téměř o 10 miliard USD nad vrcholem před ztrátou exkluzivity HUMIRA. Firma zároveň staví růst na imunologii, neurologii a akvizici Apogee Therapeutics.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItAbbVie NYSE: ABBV executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises.
Speaking at a Morgan Stanley event, Chairman and Chief Executive Officer Rob Michael said AbbVie’s 2026 guidance is expected to be nearly $10 billion above the company’s peak before HUMIRA’s loss of exclusivity. He said HUMIRA revenue has declined by $18 billion from its peak, while growth from AbbVie’s other platforms has totaled $28 billion, led by immunology and neuroscience.
Get AbbVie alerts:
MarketBeat Week in Review – 08/03 - 08/07Michael said the company sees a “clear line of sight” to growth into the next decade, supported by additional indications for RINVOQ, immunology combination treatments, assets acquired through business development, and newer programs in oncology and neuroscience.
Apogee deal expands immunology ambitions AbbVie highlighted its acquisition of Apogee Therapeutics as a key addition to its immunology strategy. Michael said the transaction provides a late-stage atopic dermatitis asset, referred to during the event as zumi, as well as an opportunity to enter asthma, an area AbbVie had previously identified as a growth target.
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad ExposureRoopal Thakkar, AbbVie’s head of research and development and chief scientific officer, said the company expects to begin enrolling patients in the registrational program for zumi this year, with a potential launch in the early part of 2030. AbbVie plans to conduct global studies and include adolescents, while also evaluating the asset in combination with a half-life-extended TSLP program in asthma.
Thakkar said the Phase 2b data generated by Apogee showed strong efficacy and that the company aims to replicate those results in larger studies. He noted that atopic dermatitis and asthma remain underpenetrated markets for advanced therapies and said both markets are growing at more than 15% annually.
Chief Commercial Officer Jeff Stewart said AbbVie is not particularly concerned about potential biosimilar competition for DUPIXENT, citing the company’s experience competing in markets affected by biosimilars to HUMIRA and STELARA. Stewart said atopic dermatitis biologic penetration is approximately 8% in the U.S. and lower internationally, leaving room for market expansion.
SKYRIZI, RINVOQ and combination programs Stewart said AbbVie continues to see strong patient capture rates for SKYRIZI and RINVOQ despite increasing competition. The company expects a fourth-quarter approval for subcutaneous induction of SKYRIZI in Crohn’s disease, followed by an estimated 60 to 90 days to secure broad payer access.
According to Stewart, the SKYRIZI subcutaneous induction data showed strong results across placebo-controlled endoscopic endpoints and clinical remission. AbbVie also expects additional RINVOQ catalysts from potential indications in giant cell arteritis, lupus, hidradenitis suppurativa, vitiligo and alopecia.
Michael said combination therapies represent the next stage of innovation in immunology. AbbVie has added or developed several mechanisms, including TL1A, TREM1 and alpha 4 beta 7, which it intends to study with SKYRIZI in inflammatory bowel disease.
Thakkar said early Phase 2a data for a SKYRIZI and alpha 4 beta 7 combination showed a doubling of endoscopic remission compared with SKYRIZI alone. AbbVie plans to evaluate multiple combinations in Crohn’s disease and ulcerative colitis, including combinations involving alpha 4 beta 7, TL1A and potentially TREM1. The company is also working on co-formulations designed to deliver combination treatments in a single injection.
Neuroscience and oncology updates In neuroscience, Michael said VYALEV has exceeded AbbVie’s expectations and is expected to reach global blockbuster status this year. He said the company also expects tavapadon to complement VYALEV in Parkinson’s disease and reiterated AbbVie’s view that its Parkinson’s franchise represents a $5 billion opportunity at peak.
Stewart said tavapadon could have a slower initial launch because AbbVie missed the Medicare reimbursement window for 2027. Still, he described its clinical profile as differentiated, citing data suggesting sustained control over 85 weeks without requiring escalation of oral levodopa and carbidopa.
Thakkar said AbbVie’s Alzheimer’s disease work includes an A-beta program acquired through Aliada Therapeutics that has entered Phase 1b, as well as an ADARx collaboration focused on siRNA approaches targeting tau. He said the company is also exploring neuroimmunology and disease-modifying opportunities in Parkinson’s disease.
In oncology, Thakkar highlighted etentamig, AbbVie’s next-generation BCMA T-cell engager for multiple myeloma. He said the company plans to present data later in September at the International Myeloma Society meeting and expects to submit the treatment for approval this year. Thakkar said the program is being developed with once-monthly dosing, a single step-up regimen, and an aim of improving convenience and safety compared with currently available therapies.
Policy and AI priorities Michael said AbbVie is monitoring policy issues involving U.S. biopharma competitiveness, international drug-pricing practices and the 340B drug discount program. He said the company supports the original intent of 340B but believes the program’s growth and patient definition have led to abuse that could divert investment from research and development.
He also said AbbVie will have three medicines participating in a rebate pilot program, which he described as an opportunity to increase transparency.
On artificial intelligence, Michael said AbbVie’s focus extends beyond individual functional applications. He said the company is training employees and deploying tools intended to improve decision-making across research, operations and commercial activities, including efforts to increase the probability of research success, reduce costs and support new patient starts.
About AbbVie (NYSE:ABBV)AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in AbbVie Right Now?Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Waverly Advisors zvýšila ve 2. čtvrtletí svůj podíl v akciích AbbVie o 43,6 % na 322 558 akcií v hodnotě 81,17 milionu USD. EVP Nicholas Donoghoe zároveň prodal 32 710 akcií.
Waverly Advisors LLC increased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 43.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 322,558 shares of the company’s stock after acquiring an additional 97,882 shares during the quarter. Waverly Advisors LLC’s holdings in AbbVie were worth $81,168,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Burk Holdings LLC bought a new position in shares of AbbVie during the 2nd quarter worth about $30,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie in the 4th quarter valued at about $31,000. Finally, Abound Financial LLC acquired a new stake in shares of AbbVie in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 70.23% of the company’s stock.
Insider Activity In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.
AbbVie Price Performance ABBV opened at $257.17 on Monday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a market capitalization of $454.36 billion, a PE ratio of 72.65, a P/E/G ratio of 1.16 and a beta of 0.29. The company’s 50-day moving average is $254.46 and its 200 day moving average is $230.95. AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s payout ratio is presently 195.48%.
Analyst Upgrades and Downgrades ABBV has been the topic of a number of research reports. JPMorgan Chase & Co. upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $276.64.
View Our Latest Report on ABBV
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Positive Phase 3 menstrual-migraine results: Atogepant met the primary and secondary endpoints in the LUNA late-stage study, demonstrating reductions in menstrual migraine days along with positive safety and efficacy results. The data could support regulatory expansion of Qulipta into an indication with no specifically approved targeted therapies, potentially broadening AbbVie’s migraine franchise. AbbVie’s Atogepant Meets Goal in Late-Stage Menstrual Migraine Study Positive Sentiment: Potentially more flexible treatment use: The results support intermittent preventive treatment around menstruation, which could expand Qulipta’s addressable market beyond continuous daily migraine prevention. Investors view the outcome as evidence of continued momentum in AbbVie’s migraine business. AbbVie Gains as Qulipta Opens a New Migraine Market Positive Sentiment: Additional pipeline catalyst: AbbVie completed its ECLIPSE migraine trial, setting up another potential data milestone for the company’s migraine portfolio. A favorable outcome could further strengthen its competitive position in the CGRP market. Neutral Sentiment: Dividend maintained: AbbVie declared a quarterly dividend of $1.73 per share, payable November 16 to shareholders of record October 15. The declaration reinforces the income appeal of ABBV but does not represent a new increase in the payout. Neutral Sentiment: Analyst confidence remains favorable: HSBC raised its price target to $315 from $300 while maintaining a Buy rating, reflecting optimism about AbbVie’s newer growth products and pipeline. Negative Sentiment: Ongoing concentration concerns: Investors continue to monitor AbbVie’s reliance on Skyrizi and Rinvoq to offset Humira’s patent-related decline. The stock’s elevated valuation also leaves less room for disappointment if pipeline launches or immunology growth slow. AbbVie Company Profile (Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
Featured Stories Five stocks we like better than AbbVie Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
NewEdge Advisors ve 2. čtvrtletí snížila podíl v AbbVie o 30,5 % a prodala 192 976 akcií. Po transakci držela 439 164 akcií v hodnotě 110,511 milionu USD.
NewEdge Advisors LLC cut its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 30.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 439,164 shares of the company’s stock after selling 192,976 shares during the quarter. NewEdge Advisors LLC’s holdings in AbbVie were worth $110,511,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Burk Holdings LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $30,000. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie during the fourth quarter worth $28,000. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. bought a new stake in AbbVie in the 4th quarter valued at $31,000. Finally, Marquette Asset Management LLC raised its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.
Insider Activity In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades A number of research firms have recently commented on ABBV. Piper Sandler raised their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Royal Bank Of Canada raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Guggenheim lifted their price objective on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Barclays upped their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company increased their target price on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $276.64. Check Out Our Latest Stock Report on AbbVie
AbbVie Stock Up 0.0% Shares of ABBV stock opened at $257.17 on Monday. The company has a market capitalization of $454.36 billion, a P/E ratio of 72.65, a P/E/G ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a 50-day moving average price of $254.46 and a 200 day moving average price of $230.95.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the firm posted $2.97 EPS. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current year.
AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Positive Phase 3 menstrual-migraine results: Atogepant met the primary and secondary endpoints in the LUNA late-stage study, demonstrating reductions in menstrual migraine days along with positive safety and efficacy results. The data could support regulatory expansion of Qulipta into an indication with no specifically approved targeted therapies, potentially broadening AbbVie’s migraine franchise. AbbVie’s Atogepant Meets Goal in Late-Stage Menstrual Migraine Study Positive Sentiment: Potentially more flexible treatment use: The results support intermittent preventive treatment around menstruation, which could expand Qulipta’s addressable market beyond continuous daily migraine prevention. Investors view the outcome as evidence of continued momentum in AbbVie’s migraine business. AbbVie Gains as Qulipta Opens a New Migraine Market Positive Sentiment: Additional pipeline catalyst: AbbVie completed its ECLIPSE migraine trial, setting up another potential data milestone for the company’s migraine portfolio. A favorable outcome could further strengthen its competitive position in the CGRP market. Neutral Sentiment: Dividend maintained: AbbVie declared a quarterly dividend of $1.73 per share, payable November 16 to shareholders of record October 15. The declaration reinforces the income appeal of ABBV but does not represent a new increase in the payout. Neutral Sentiment: Analyst confidence remains favorable: HSBC raised its price target to $315 from $300 while maintaining a Buy rating, reflecting optimism about AbbVie’s newer growth products and pipeline. Negative Sentiment: Ongoing concentration concerns: Investors continue to monitor AbbVie’s reliance on Skyrizi and Rinvoq to offset Humira’s patent-related decline. The stock’s elevated valuation also leaves less room for disappointment if pipeline launches or immunology growth slow. AbbVie Company Profile (Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
Further Reading Five stocks we like better than AbbVie Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Summit Financial Strategies Inc. cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 34.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,278 shares of the company’s stock after selling 4,873 shares during the period. Summit Financial Strategies Inc.’s holdings in AbbVie were worth $2,335,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $28,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares during the last quarter. Burk Holdings LLC purchased a new stake in AbbVie in the second quarter worth approximately $30,000. IFC & Insurance Marketing Inc. bought a new position in AbbVie during the fourth quarter valued at approximately $31,000. Finally, Abound Financial LLC bought a new position in AbbVie during the fourth quarter valued at approximately $32,000. Institutional investors own 70.23% of the company’s stock.
AbbVie Stock Up 0.0% Shares of NYSE ABBV opened at $257.17 on Monday. The firm’s fifty day moving average is $254.46 and its 200 day moving average is $230.95. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company has a market cap of $454.36 billion, a price-to-earnings ratio of 72.65, a PEG ratio of 1.16 and a beta of 0.29.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year. AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.
Analyst Ratings Changes ABBV has been the subject of a number of recent research reports. Citigroup boosted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Cantor Fitzgerald upped their price target on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $276.64.
Get Our Latest Stock Analysis on ABBV
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Positive Phase 3 menstrual-migraine results: Atogepant met the primary and secondary endpoints in the LUNA late-stage study, demonstrating reductions in menstrual migraine days along with positive safety and efficacy results. The data could support regulatory expansion of Qulipta into an indication with no specifically approved targeted therapies, potentially broadening AbbVie’s migraine franchise. AbbVie’s Atogepant Meets Goal in Late-Stage Menstrual Migraine Study Positive Sentiment: Potentially more flexible treatment use: The results support intermittent preventive treatment around menstruation, which could expand Qulipta’s addressable market beyond continuous daily migraine prevention. Investors view the outcome as evidence of continued momentum in AbbVie’s migraine business. AbbVie Gains as Qulipta Opens a New Migraine Market Positive Sentiment: Additional pipeline catalyst: AbbVie completed its ECLIPSE migraine trial, setting up another potential data milestone for the company’s migraine portfolio. A favorable outcome could further strengthen its competitive position in the CGRP market. Neutral Sentiment: Dividend maintained: AbbVie declared a quarterly dividend of $1.73 per share, payable November 16 to shareholders of record October 15. The declaration reinforces the income appeal of ABBV but does not represent a new increase in the payout. Neutral Sentiment: Analyst confidence remains favorable: HSBC raised its price target to $315 from $300 while maintaining a Buy rating, reflecting optimism about AbbVie’s newer growth products and pipeline. Negative Sentiment: Ongoing concentration concerns: Investors continue to monitor AbbVie’s reliance on Skyrizi and Rinvoq to offset Humira’s patent-related decline. The stock’s elevated valuation also leaves less room for disappointment if pipeline launches or immunology growth slow. Insider Transactions at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.
AbbVie Profile (Free Report)
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
Recommended Stories Five stocks we like better than AbbVie Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
